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2 Nomenclature, Glossary, Abbreviations 
2.1 Nomenclature of cytological and histological findings 
The following table provides an overview of the nomenclature of cytological and histological 
findings and their abbreviations [1].  
 
Table 1: Nomenclature of cytological and histological findings 
Bethesda System for the classification of 
cytological findings 
WHO nomenclature for histological analyses 
NILM Negative for intraepithelial 
lesions and malignancies 
 
ASC-US Atypical squamous cells of 
undetermined significance 
 
ASC-H Atypical squamous cells – 
cannot exclude HSIL 
 
LSIL Low-grade Squamous 
Intraepithelial Lesion 
CIN1 Cervical intraepithelial neoplasia 
mild dysplasia 
HSIL High-grade Squamous 
Intraepithelial Lesion 
CIN2 Cervical intraepithelial neoplasia 
Moderate dysplasia 
CIN3 Cervical intraepithelial neoplasia 
Severe dysplasia / carcinoma in situ 
 
In this thesis, the term “cytology negative” is often used instead of NILM. 
 
2.2 Glossary, Abbreviations 
 
Table 2: Glossary, Abbreviations 
Acronym Explanation 
AIS Adenocarcinoma in situ 
ARTISTIC UK Randomized Controlled Trial [2-4] 
ATHENA US “Addressing the Need for Advanced HPV Diagnostics” Study evaluating 
the clinical performance of cobas HPV assay with partial genotyping and 
different triage strategies for HPV-positive women [5] 
BAG Swiss Federal Office of Public Health (“Bundesamt für Gesundheit”) 
C Comparator 
CCCaST Canadian Cross Sectional Study [6] 
CHF Swiss Francs 
CI Confidence Interval 
CIN Cervical Intraepithelial Neoplasia 
CIR Cumulative Incidence Rate 
CIS Carcinoma in Situ 
Conization A treatment of precancerous lesions by removal of the affected area from 
the cervix. Different techniques of conization are available; one of these is 
LEEP (see below). 
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Cyt cytological testing 
EURONHEED European Network of Health Economic Evaluation Databases 
FPHT “Finnish Public Health Trial” [7-10] 
GDP Gross Domestic Product 
HPV Human Papilloma Virus 
hrHPV High risk Human Papilloma Viruses 
I Intervention 
ICER Incremental Cost Effectiveness Ratio 
ITT Intention to Treat 
KPNC Kaiser Permanente Cohort Study [11] 
LBC Liquid based cytology 
LEEP Loop Electrosurgical Excision Procedure, a treatment of precancerous 
lesions by removal of the affected area from the cervix 
LYG Life Years Gained 
M Month 
MeSH Medical Subjects Headings 
n.a. Not applicable 
Neg Negative 
neg cyt/ 
cyt neg 
Tested negative with a cytological test 
neg HPV/ 
HPV neg 
Tested negative with an HPV test 
NPV Negative predictive value 
NTCC Italian “New Technologies for Cervical Cancer (NTCC) screening study” 
[12-15] 
OECD Organization for Economic Co-operation and Development 
POBASCAM Dutch population-based randomized controlled trial for the implementation 
of high-risk HPV testing in cervical screening according to [16, 17] 
Pap Papanicolaou test 
pos cyt/ cyt 
pos 
Tested positive with a cytological test 
pos HPV/ 
HPV pos 
Tested positive with an HPV test 
PPP Purchasing Power Parity 
PPV Positive predictive value 
RCT Randomized Controlled Trial 
RR Rate Ratio 
Swedescreen Swedish Randomized Controlled Trial [18, 19] 
y Year(s) 
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3 Abstract 
 
In Switzerland 90 women die of cervical cancer every year and 240 fall ill with the disease. In 
the last 30 years both the incidence and mortality of cervical cancer have steadily declined. 
This is attributed mainly to screening with the Pap test, named after its inventor George 
Papanicolaou. However this test is now challenged for its low sensitivity and more and more 
countries are changing their cervical cancer screening strategies to Human Papilloma Virus 
(HPV) tests or are considering so. 
This thesis aims to make a recommendation for the future of cervical cancer screening in 
Switzerland based on a systematic review of the clinical and health economic evidence of 
other industrialized countries, and a transferability analysis of its results to the Swiss setting. 
The focus of this thesis is on unvaccinated women. 
The following research questions were pursued:  
 What is the best screening strategy with the highest clinical effectiveness to prevent 
cervical cancer at the lowest burden of follow up?  
 How does the optimal algorithm for screening with the HPV test compare to 
screening with the Pap test in terms of incremental cost effectiveness?  
 Are relevant barriers for the implementation of HPV based screening in Switzerland 
identified? 
For women of 30 years and older, 5 yearly HPV testing with cytology triage or 5 yearly 
HPV16/18 genotyping with direct referral to colposcopy and cytology triage for other hrHPV 
types seem to be the screening strategies with the best balance of benefits and harms. In 
health economic studies, these strategies were either cheaper than cytology based testing or 
more expensive at incremental cost effectiveness ratios (ICERs) below acceptability 
thresholds. These findings are likely transferable to the Swiss health system. Feasibility 
analysis shows that the adherence to screening algorithms should be controlled to avoid 
overdiagnosis and overtreatment as well as loss to follow up. Therefore HPV based testing 
should be implemented preferably in an organized screening setting. 
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4 Introduction 
4.1 Background and current status 
In Switzerland 90 women die every year of cervical cancer and 240 fall ill with the disease. 
Cervical cancer makes up only 1.4% of all cancers of women in Switzerland, however in 
contrast to many other cancers about half of the women with the disease are younger than 
50 years and a first peak in the incidence rate occurs between 35 and 39 years of age [20] 
(Figure 1). 
 
Figure 1 Cervical Cancer in Switzerland adapted from figures G4.6.1 and G4.6.2 of [20] 
  
 
In the last 30 years both the incidence and mortality of cervical cancer has steadily declined. 
This is attributed mainly to screening and early detection of precancerous and in situ 
cancerous stages with the help of the Pap test, named after its inventor George 
Papanicolaou. The test involves collection of cells from the cervix by a gynecologist and 
subsequent microscopic analysis for abnormal cells by a pathologist. The success of the 
screening is masking the comparatively high risk that cervical cancer is presenting to 
women’s health: If the incidence of invasive cancers and that of in situ carcinomas detected 
by screening are combined, then the risk of developing cervical cancer is comparable to that 
of lung cancer (23/100’000 vs 25/100’000) [21]. Worldwide, cervical cancer is the fourth most 
frequent cancer in women with an estimated 530 000 new cases in 2012 and estimated 
270’000 deaths representing 7.5% of all female cancer deaths. More than 85% of these 
cervical cancer related deaths occur in less developed regions [22]. 
 
In Switzerland regular screening for cervical cancer is recommended and the obligatory 
health insurance providers pay for a Pap test every 3 years. Even though screening with this 
assay is performed in Switzerland in an opportunistic manner and relies on the initiative of 
patients and gynecologists, approximately 50% of all women aged 25 to 55 who responded 
to the 2007 Swiss health survey declared to have undergone a Pap test within the last 12 
months. Weaknesses of the opportunistic nature of the Swiss screening program are 
reflected in the difference to which degree persons of different cantons, nationalities and 
socioeconomic backgrounds participate [21].  
 
The technological weakness of the Pap test is its low sensitivity. According to a US Study of 
833 invasive cervical cancer cases in women enrolled in health plans revealed that 32% had 
had a negative Pap test in the previous 3 years [23]. 
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In 2008 Harald zur Hausen received the Nobel Prize for the discovery that cervical cancer is 
caused by human papilloma viruses. Indeed HPV DNA is present in 99.7% of all cases of 
cervical squamous carcinomas [24]  
Twelve to 15 HPV types are considered carcinogenic with HPV types 16 and 18 being the 
most aggressive [25] [26].  
 
As a consequence of this discovery current prevention efforts are increasingly focused on 
the vaccination of young women against the HPV virus.  
 
In addition the value of HPV testing for screening is under investigation. Several randomized 
controlled clinical trials have been initiated using tests for HPV infection to identify women at 
risk of developing cervical cancer. The most important trials are NTCC in Italy [12], 
POBASCAM in the Netherlands [16], Swedescreen in Sweden [19] and ARTISTIC in 
England [27].  
 
Before HPV testing can be considered for screening programs a health technology 
assessment should be performed where potential clinical benefits and harms are weighed 
against each other, the optimal use of the technology is evaluated (e.g. frequency, 
combination with other technologies), and the cost-effectiveness of the new technology 
versus the current is calculated. The latter can be done as cost-effectiveness analysis (e.g. 
cost per life year saved, or cost utility analysis where costs per quality adjusted life years 
(QALYs) are calculated. Finally the feasibility of the alternatives needs to be assessed in the 
specific set up and technological and organizational resources available in a specific health 
system. (E.g. are both alternatives effective in an opportunistic versus organized screening 
program, and are all societal groups likely to benefit from the alternatives in the same way). 
 
While a Health Technology Assessment (HTA) for Switzerland on HPV testing for cervical 
cancer screening is missing, HTAs exist for other countries e.g. the UK [2], Belgium [28], 
Australia [29] and Germany [30]. Cost-effectiveness analyses have also been published, e.g. 
in the Netherlands [31], Norway [32], Canada [33, 34] and the USA [35-37]. 
 
This master thesis addresses the gap of a missing HTA on primary testing with HPV for 
cervical cancer screening for the Swiss Health Care System by performing a systematic 
review of HTAs and health economic assessments of other countries. It assesses whether 
findings from these studies can be transferred to the Swiss environment and whether 
recommendations can be derived for the future of the Swiss screening set up for cervical 
cancer. 
 
The conclusions of this thesis are expected to facilitate the discussion on the future of 
cervical cancer screening in Switzerland. 
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4.2 Hypotheses and Research Questions 
 
Hypothesis 1 
Cervical Cancer Screening can be improved both in terms of clinical effectiveness (due to 
better sensitivity of the HPV test, women at risk will be better managed and there will be 
fewer cases of advanced precancerous stages, fewer cases of invasive cancer and fewer 
deaths from cervical cancer), as well as in terms of cost effectiveness (due to longer 
possible intervals between screening visits for women testing negative), by using first line 
HPV testing instead of first line Pap testing.  
The optimal test method may differ with the age of the screened subpopulation as women 
under 30 years of age have more transient HPV infections and lower incidence rates of 
cervical cancer than older women and may therefore suffer from more overdiagnosis and 
overtreatment with first line HPV testing than older women. 
 
Research Question 1a 
What is the best test or combination of tests which results in the highest clinical 
effectiveness to prevent cervical cancer at the lowest burden of follow up? 
Research Question 1b 
What is the best age to start using HPV as primary screening test in terms of clinical 
effectiveness and cost effectiveness? 
Research Question 1c 
How does the optimal algorithm for first line screening with HPV compare to the current 
regimen of cytological tests in terms of ICERs expressed as cost per modelled life year 
gained (LYG) or cost per QALY? 
 
Hypothesis 2 
Implementation of screening with first line HPV testing is feasible.  
This aspect is important because a new screening technology may pose challenges with 
respect to organizational aspects, or acceptance by medical doctors and patients. It may 
create anxiety, increase inequalities by differential participation rates of social subgroups, or 
have side effects on other medical interventions or preventive actions by reducing the 
number of doctor’s visits etc. 
 
Research Question 2 
In the event that HPV testing is found to be clinically effective and cost effective, are any 
potential barriers to implementing screening based on HPV testing identified? If yes, which 
barriers are these? Are they relevant for the Swiss health care setting? 
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5 Methods 
 
Research questions 1a-c were addressed by a systematic review of the literature in the 
following steps.  
1. Systematic reviews and meta analyses of clinical evidence were identified to get an 
overview of currently available clinical evidence. HTAs and health economic studies 
were identified to get an overview of health economic evidence. 
2. Systematic reviews and meta analyses were analyzed for the research questions 
regarding evidence on clinical effectiveness of HPV testing. 
3. HTAs and health economic studies were analyzed for the research questions in terms of 
clinical effectiveness and cost effectiveness. If the research questions were answered by 
an HTA or health economic study, it was further analyzed for its quality by application of 
the EURONHEED checklist [38] 
4. and for its transferability of results to the Swiss health care system according to the 
criteria described below. 
5. For studies that were found transferable to the Swiss setting, economic results were 
converted to Swiss currency of the cost year 2015 by adaptation to purchasing power 
parities. 
 
Research question 2 was addressed as follows:  
6. Those studies that identify screening with HPV as clinically and cost effective were 
analyzed for information on the feasibility of the implementation of the identified 
approaches and any potential barriers to implementation. 
 
Synthesis: 
7. In the final step the answers to the research questions were synthesized and considered 
for relevance for the Swiss Health System. 
 
Details of these steps are described below. 
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5.1 Identification of relevant literature 
 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and the databases of the University of York 
Centre for Reviews and Dissemination (CRD) http://www.crd.york.ac.uk/CRDWeb/, which 
include the Cochrane database, were searched with algorithms covering the following 
populations (P), interventions (I), comparators (C) and outcomes (O) (PICO): 
 
P: Women undergoing cervical cancer screening. 
I: Screening for cervical cancer with first line HPV testing. 
C: Screening for cervical cancer with first line Pap test or Liquid Based Cytology (LBC). 
O: For clinical results: precancerous stages detected, cancers prevented, cancer deaths 
prevented, LYG, QALYs 
O: For health economic results: cost, ICER expressed as incremental cost per QALY gained 
or incremental cost per clinical effect parameter gained. 
 
The search algorithm in PubMed was developed by combining MeSH items (Medical 
Subjects Headings) with keywords for all elements of the PICO. Thereby both indexed as 
well as non-indexed publications containing the elements of the PICO were included in the 
outcome of the search.  
For the CRD database truncated keywords were used.  
It was verified that the results with the search algorithms included already known relevant 
publications. In addition, the most recent relevant publications identified through the search, 
were checked for relevant references that might have been missed by the algorithms. The 
algorithms were refined until they found all publications already known or identified through 
the reference checks.  
 
The full literature search algorithms are shown in Appendix 1: “Literature search algorithms” 
 
Resulting titles and abstracts were screened for relevance to the research questions and 
publications meeting criteria underwent full text analysis. Publications not meeting criteria 
were excluded from further analysis. 
 
The criteria for inclusion or exclusion of publications were the following: 
 Publications were required to meet the PICO criteria.  
 Only first line HPV screening was considered as intervention, e.g. studies that only 
assessed HPV testing as triage after positive Pap test were not considered. 
 Only cytology based screening strategies (either with the Pap test or LBC) were 
considered as comparator. 
 Only publications in English or German language were considered. 
 Only economic analyses for industrialized countries (e.g. Europe, North America, and 
Australia) were considered in the analysis, as the transferability of health economic data 
from developing countries is unlikely. 
 Only publications from 2008 and later were considered as the follow up of important 
randomized clinical studies such as NTCC [12], POBASCAM [16], Swedescreen [19] and 
ARTISTIC [27] ended in the years 2008 to 2012 [39]. Older publications are unlikely to 
reflect up to date current clinical effectiveness data. 
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 Only systematic reviews/ meta-analyses based on randomized controlled trials were 
used to assess clinical effectiveness. 
 
 Exclusion criteria for publications that met criteria above were the following: 
o Only HPV testing based on samples taken by a clinician were included into the 
compilation of quantitative clinical and economic evidence. Publications 
evaluating the use of self-sampling in HPV testing were not analyzed in detail. 
o Publications were also excluded if they did not meet basic quality criteria for 
systematic reviews (e.g. no description of literature analysis, comments only). 
 
 A four eyes principle was applied for the identification of relevant literature. In case of 
differences between the author of the thesis and the second person in the literature 
review process, the reasons for differences were discussed until agreement was reached 
for the selection or exclusion. The four eyes principle was only applied to the literature 
selection process. Extraction of answers to the research questions, evaluation of study 
quality and transferability were done by the author of this thesis alone. 
 
The Prisma 2009 Flow Diagram [40] was used to document the literature selection process.  
5.2 Analysis for evidence supporting research questions 1a-b  
5.2.1 Definition of benefits and harms of screening with HPV testing 
As a prerequisite for the evaluation of clinical effectiveness to prevent cervical cancer at the 
lowest burden of follow up, it is necessary to define the relevant indicators for clinical 
effectiveness (or benefits) versus burden from screening (or harms). 
5.2.1.1 Measures of benefit 
The most important measures of benefit are life years gained (LYG) or quality adjusted life 
years (QALYs) gained by a screening strategy. As surrogate markers the increased 
detection of precancerous stages in early screening rounds followed by decreased detection 
of those stages in subsequent screening rounds is considered a benefit.  
The absolute sensitivity and specificity to detect precancerous stages are relevant measures 
as they influence the detection rate and the number of false positive results. The last 
investigated benefit measure is the length of time that a negative screening test can predict 
the absence of cervical cancer. 
 
Cancer screening aims at the detection of cancer before symptoms arise. Earlier detection of 
cancer improves patient prognosis and can reduce mortality. Cervical cancer screening is 
especially attractive as precursor stages of cancer can be identified and treated which aims 
at the reduction of the incidence of cervical cancer [21]. 
Thus the ultimate benefits of cervical cancer screening are reduced morbidity and mortality 
from cervical cancer.  
The related measures of benefit reported in this thesis are in most cases the number of life 
years gained or QALYs. Depending on the availability of data in the publications, cancer 
incidence rates, number of cancer cases and reduction of cancer risk may be shown. The 
findings on these benefit measures are shown in results chapters 7.1.1, 7.2.1, 7.3.1 and 
Table 10 in Appendix 4: “Research question 1a-c – Excerpt of answers from HTAs and 
Health Economic Studies”. Numbers on avoided cancer deaths were not available. 
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As the incidence of cervical cancer in countries with existing screening programs is low, 
surrogate markers such as the detection of precancerous stages are used to assess new 
strategies in clinical studies. Table 1 gives an overview of the nomenclature used for 
cytological and histologic findings during screening. Cervical Intraepithelial Neoplasia (CIN) 
of grade 2 and 3 are typically eligible for treatment to avoid progression to cancer. CIN3+ 
(the number of cases with CIN3 or invasive cervical cancer) seems the best surrogate 
marker as the probability of CIN3 to develop to invasive cancer is higher than that of CIN2 
[41, 42]. 
 
Most meta analyses use the relative detection of CIN3+ and CIN2+ (the number of CIN2, 
CIN3 and invasive cancers) in a first screening round and reduced relative detection of 
CIN3+ and CIN2+ in a later screening round as markers of benefit [43-47]. The decreased 
detection in subsequent screening rounds is important as otherwise it could be argued that 
the additional precancerous lesions detected are predominantly those that would 
spontaneously regress if not detected and treated [12]. 
The relative detection (calculated as the ratio of detection of e.g. CIN3+ with HPV based 
testing versus cytology testing) is more independent of prevalence than positive predictive 
value (PPV) or negative predictive value (NPV) and thereby also better transferable to other 
countries with potentially different prevalence.  
 
Therefore the surrogate marker related measures of benefits reported in this thesis are the 
increased detection of precancerous stages in early screening rounds followed by decreased 
detection of those stages in subsequent screening rounds.  
Findings on the relative detection of CIN2+ and CIN3+ are described in the results chapter 
7.2.2. 
 
The last investigated benefit measure is the length of time that a negative screening test can 
predict the absence of cervical cancer. A screening test that allows longer reassurance 
against cancer will allow longer screening intervals and thus fewer screening events in a 
woman’s lifetime. Fewer screening events also reduce the number of false positive results 
and avoid unnecessary treatments [48]. 
Findings that address the question on the possible length of time between screening rounds 
are described in results chapter 7.2.3. 
5.2.1.2 Measures of harms 
The most often reported indicators of the burden of screening are the rate of colposcopies 
done in a screening algorithm and increased cumulative detection of early precancerous 
stages over several screening rounds. 
 
Harms from screening include anxiety from a positive screening result [49], inconvenience of 
more frequent and/or more intense follow up testing with colposcopies, as well as potential 
physical damage from biopsies taken during colposcopies and LEEP treatment of 
precancerous lesions [50] as cited in [51]. 
 
Depending on the clinical guidelines in different health systems CIN2 is treated by conization 
by Loop Electrosurgical Excision (LEEP) (e.g. in the US) [52] or rather observed for 
regression, persistence or progression (e.g. in Germany) [46]. In Switzerland the current 
expert letter on cervical cancer screening and follow-up [53] recommends treatment by 
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conization, except for pregnant women and for young nonparous (but screening compliant) 
women, where colposcopic surveillance every 6 months over 2 years is recommended.  
There are indications that LEEP treatments may result in an approximately two-fold increase 
in preterm delivery risk with risk increasing with the volume and numbers of excisions [54]. 
This association is currently challenged as the studies from which these data were retrieved 
involved comparatively large loop sizes and deep excisions [54] [28]. According to Bruinsma 
[55], the increased risk was observed only when women who underwent such procedures 
were compared with women with no history of abnormal cervical cytology or colposcopy 
results, while women with CIN may be at increased risk for preterm delivery even when 
untreated [54, 56]. Nevertheless, as long as this risk cannot be completely ruled out, special 
consideration needs to be taken to ensure that women of child bearing age are protected 
from these harms.  
In the absence of data on the numbers of LEEP treatments the detection rates of 
precancerous lesions that are eligible for LEEP treatment (CIN2 and CIN3) were analyzed 
as a marker of potential burden.  
 
While increased detection of CIN2+ and CIN3+ is a benefit if it occurs in earlier screening 
rounds and leads to lower occurrence of CIN3+ in later screening rounds, it may also 
indicate overdiagnosis. 
It is known that not all of these lesions will progress to invasive cervical cancer. In a study in 
New Zealand a subset of women with CIN3+ lesions were not treated. As a follow up the 
incidence of cervical cancer was observed after up to 30 years [42]. 30% of these women 
had developed cervical cancer during this time. For CIN2 it is estimated that 40% regress 
over a period of 2 years with lower likelihood of regression for HPV16-positive CIN2 [41]. 
 
Therefore increased relative cumulative detection of CIN2+ and CIN3+ over several 
screening rounds is discussed in systematic reviews and meta analyses as a potential 
marker of overdiagnosis and thus potential harm [43, 45]. The results on this point are 
described in chapter 7.2.2. 
 
In addition, the number of colposcopies can serve as surrogate marker for the potential 
burden of screening. This is the first more invasive screening activity and often involves 
biopsies. The number of colposcopies done in a screening program per woman screened, 
the relative rate of colposcopies between two screening strategies and the number of 
colposcopies done to detect one case of CIN3+ were frequently reported. Results on 
colposcopy rates of screening strategies are described in chapters 7.2.4 and 7.3.4. 
 
5.2.2 Extraction of answers from systematic reviews and meta analyses 
The information from systematic reviews and meta analyses on research questions 1a-b was 
extracted from the publications by making notes while reading each results chapter and by 
searching with key words per results chapter, e.g. “interval”, “year”, “length” for the chapter 
on evidence for the potential lengthening of screening intervals. 
 
Some systematic reviews and meta analyses had a wider scope than this thesis and were 
evaluating other uses of HPV tests such as triage after a positive cytological test or follow up 
after treatment. In this case only the data regarding the use of HPV testing as a primary 
screening test were analyzed. If systematic reviews and meta analyses had information on 
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both screening in developed/ high resource versus developing / middle and low resource 
countries, only the analysis for developed / high resource countries was taken into account. 
 
Results of the search were extracted and documented in Table 9 and Table 11. In addition a 
synthesis of all findings per result section was created by counting the systematic reviews, 
meta analyses, HTAs or health economic studies with similar findings (or no findings) and 
describing the key findings together with the references of the respective studies. 
 
Clinical evidence from clinical systematic reviews and meta analyses and evidence on 
clinical and economic evidence from cost effectiveness models were first evaluated 
separately and afterwards a synthesis of findings from both was created by explaining 
similarities and differences. 
 
5.2.3 Extraction of answers to research questions 1a-c from HTAs and health 
economic studies 
The information from HTAs and health economic studies on research questions 1a-c were 
extracted with the same method as for clinical publications and are represented in Table 10 
and Table 12 
 
Extracted elements in Table 10 include a study description, the goal of the study, the country 
for which the analysis was performed, a brief description of the model (population, screening 
strategies modelled), the perspective of the economic evaluation, the currency and price 
year and the applied discounting rates for costs and benefits.  
For research question 1a on the clinical effectiveness a short summary is provided stating 
how HPV based testing compared to cytology based testing in the model. In addition a 
tabular overview is provided of the clinical effectiveness data (life years or QALYs and if 
available % reduction of lifetime cancer risk or cancer incidence rate), for the most important 
strategies. (Typically all strategies that were on the cost effectiveness frontier are shown. In 
addition other strategies may be shown that are important for the comparison of different 
screening algorithms across studies). If available, data on the burden of screening (e.g. 
colposcopy rates) are shown. If not available a statement is made on the availability of these 
data.  
For research question 1b on the best age to start testing for HPV, a summary of the findings 
of the study is provided. If the research question was not addressed, this is documented. 
For research question 1c a summary statement is provided on the cost effectiveness of HPV 
based screening versus cytology based screening. Cost data were extracted in a table 
showing the costs and ICERs for the strategies. If no ICER values were provided in the 
studies, the dominant strategies were identified from the cost effectiveness plane in the 
study and the ICERs were calculated based on the LYG (or QALYs) and cost data provided. 
In this case some inaccuracy of the ICER values occurs due to rounding effects (as both 
costs and LYG will not be displayed in the publication with all available positions after the 
decimal point). In this case this is annotated in the applicable table.  
 
5.2.4 Terms used to characterize strategies from an economic perspective 
 
The term “dominant” is used for a strategy that was shown to be more effective and less 
costly than another. Vice versa a strategy is said to be “dominated” either because it was 
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less effective and more costly than another or when it was less costly than another, but had 
a higher incremental cost-effectiveness ratio (“weakly dominated”). 
Strategies that were not dominated by any other strategy are considered to be on the “cost-
effectiveness frontier”. Strategies are considered “cost-effective”, if they were on the cost-
effectiveness frontier and did not exceed an absolute country specific threshold for their 
incremental cost effectiveness ratio as discussed below. 
 
5.3 Evaluation of the quality of HTAs / health economic studies 
The analysis of the quality of studies can be supported by using checklists.  
The systematic review of Goeree et al [57] on the transferability of HTAs and economic 
evaluations compared different checklists for the evaluation of the quality and availability of 
transferability information of publications. Of these, the checklist of Boulenger was selected 
(hereafter called the EURONHEED checklist) [58], together with the guidelines to complete 
the list [38] to evaluate the publications for this thesis. The advantage of this checklist was 
that the general quality of the publication could be assessed in a systematic manner as well 
as the availability of data for the transferability analysis. 
 
The EURONHEED checklist [38] is shown in Table 13 and consists of 6 main sections:  
 Questions Q1–M2 aim at the quality of description of the research question, the PICO 
elements and the inputs of studies (samples) or models (e.g. detail of description, origin 
of model parameters).  
 Questions E1–E7 aim at the detail and quality of clinical effectiveness reporting.  
 Questions B1– B5 address the definition and valuation of benefits measures (e.g. 
QALYs).  
 Questions C1–C11 cover the level of detail on costs inputs.  
 Questions D1– D4 cover discounting aspects  
 Questions S1 and O1 address important aspects of the discussion by the authors.  
 
The full checklist contains 42 questions. 16 of these (shown in Table 13 in bold and blue 
background color), are specifically aimed at important data for the evaluation of 
transferability. 
For each question the following answers are possible and are assigned a score as indicated 
in ():  
 ‘yes’ (1),  
 ‘partially’ (P) (0.5),  
 ‘no or no information provided’ (No/NI) (0), or  
 ‘not applicable’ (N/A).  
 
To calculate the quality data score all 42 questions are used and for the calculation of the 
transferability data score only the subset of 16 questions are used.  
The scores are calculated with the formula:  
Σi Si /n–x. 
where n is the number of questions, x is the number of questions for which the response is 
N/A and S is the score of each question. 
 
The maximum score possible is 1 if all applicable questions are answered with a ‘yes’. 
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The value of the quality data score is indicative of the level of detail provided on all important 
aspects of a study. No weighting in the score of single different questions is applied. 
Therefore a “no” to a fundamental quality criterion such as HT1 and HT2 (description of 
intervention and comparator in sufficient detail), or E5 (adequate reporting on the 
effectiveness results), is weighted equally to ‘no’ in Q2 (justification of the alternative 
technologies used by the author). However the authors of the checklist state that weighting 
is applied in the checklist by having several detailed questions on important aspects of study 
quality [38], so that publications of minor quality still result in lower scores than studies of 
higher quality. 
 
In addition Goeree et al. recommend to define “knock-out” criteria for the quality of a 
publication, based on a subset of questions [57]. In the case of this thesis a “no” to the 
question E5 (adequate reporting on the effectiveness results) was considered a knock-out 
criterion from a quality perspective.  
 
The value of the transferability data score is indicative of how much detail is provided that 
can be used for the transferability analysis of a study (and thus is not indicative for the result 
of the transferability analysis). 
 
The results for all single questions of the checklist for the health economic studies are 
provided in Table 13. The quality data score for each study is also provided in Table 10. 
 
Wherever the checklist showed that relevant information is missing or incomplete and this 
might have influenced the results, this was made transparent when results of this study were 
reported in the results section. 
 
To evaluate whether results were influenced by the study quality, a comparison was done, 
whether certain screening strategies were only analyzed by studies with low or high quality 
data scores, or whether the quantitative effects (ICERs) correlated with the quality data 
scores. This was only done for studies that were found to be potentially transferable  
5.4 Evaluation of the transferability of health economic results to the 
Swiss health care system 
The transferability of answers to the research questions from each health economic study to 
the Swiss health care system was analyzed based on the following criteria (adapted from the 
approach Michael Drummond taught in the 2014 Lugano summer school on HTA 
Assessments): 
 Was a comparator used that is relevant to the current Swiss setting? Is the viewpoint of 
the analysis relevant to the Swiss setting? 
 Do treatment options used in the model compare to current clinical practice in 
Switzerland? 
 Is there any indication of a different base line risk of the populations? 
 Does the screening setting (organized or opportunistic) influence the result? 
 Can results of the sensitivity analyses be used to make assumptions for the Swiss 
setting? If any parameters are different in the Swiss setting, have they been analyzed in 
the sensitivity analysis? If yes, are the differences expected to influence the result of the 
research question and in what direction? 
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 Can costs and consequences be deduced for the Swiss setting (e.g. by putting Swiss 
units and costs into the calculation of the study or by adaptation to purchasing power)? 
 
After all aspects had been assessed a summary statement was created for the transferability 
of each study. 
The algorithm applied was:  
1. Studies with insufficient level of reporting were excluded from further transferability 
analysis based on a rating in the EURONHEED checklist with ‘No/NI’ of questions E5 
(adequate reporting on the effectiveness results). 
2. Studies not containing a comparator relevant for the Swiss health system were not 
considered transferable. 
3. All other studies were considered potentially transferable and any differences 
observed from the Swiss setting or the impact of study reporting weaknesses were 
assessed based on the detailed analyses according to the steps below.  
The exclusion criteria are in line with the knock-out criteria applied by Welte et al. in their 
transferability decision chart [59]. 
 
The results of this analysis are presented in Table 14. 
 
In order to analyze transferability, reference values for the Swiss Health System were 
identified as described in the following sections: 
5.4.1 Was a comparator used that is relevant to the current Swiss setting?  
A relevant comparator for the Swiss setting should be as close as possible to current 
practice in Switzerland. In the absence of data that systematically monitor the actual 
implementation of cervical cancer screening in Switzerland the recommendations of the 
Swiss Society for Gynecology and Obstetrics and the reimbursement rules of the obligatory 
health insurance system were assumed to be representative of current practice. 
 
The Swiss Society for Gynecology and Obstetrics recommends cervical cancer screening in 
Switzerland with a cytological test every 3 years for women aged 30-70 and every 2 years 
for women of 21-29 years in the “SGGG Expertenbrief 40“ [53]. The obligatory health 
insurance system grants reimbursement for the first two screening tests with a yearly 
frequency and afterwards for a test every three years. Both Pap test and liquid based 
cytology are used in Switzerland for cervical cancer screening [1]. After a cytological primary 
screening result of atypical squamous cells of undetermined significance (ASC-US), an HPV 
test is recommended (see 0 for details).  
Therefore the Swiss recommendations for screening algorithms are most similar to the 
strategies “cytology with HPV triage” used in health economic modelling studies with a 3-
yearly frequency. 
 
Another aspect of the comparability of the screening is the assumed sensitivity and 
specificity for the screening tests. Studies in Germany have shown that the sensitivity of Pap 
testing in Germany was much lower than in international studies, partly due to the practice of 
sampling by gynecologists [60]. No Swiss reference data are available for this aspect of the 
transferability analysis, as no published data on the actual sensitivity and specificity of 
cytological screening in Switzerland were found. Sensitivities and specificities in the 
transferability analysis are therefore described in Table 14 but not specifically discussed.  
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5.4.2 Is the viewpoint of the analysis relevant to the Swiss setting? 
The viewpoints taken in the different studies were typically the healthcare payers perspective 
and always included direct medical costs. Indirect medical costs (e.g. women’s travel cost to 
screening, diagnosis and treatment and productivity loss of women due to participation in 
screening, diagnosis and treatment for cancer and precancerous lesions) were sometimes 
also included. In countries with organized screening, costs for the organization of the 
screening program including invitations, reminders and registrations of screening results 
were also included.  
In this thesis all viewpoints in the different studies were considered potentially relevant for 
the Swiss setting. Even where costs of an organized screening program were included, this 
viewpoint may become relevant in the future should Switzerland decide to implement an 
organized screening program for cervical cancer. This is currently being discussed as part of 
the Swiss national strategy against cancer [61]. In this case it will be important to know how 
cost effective HPV based testing will be compared to cytology based testing under that 
setting. 
As the viewpoint and thus the included costs can influence the total cost of screening and 
thus the height of the ICER, for transparency and better comparability the viewpoint taken 
and included costs are described for each study in Table 14. 
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5.4.3 Do treatment options used in the model compare to current clinical practice in 
Switzerland? 
The Swiss Society for Gynecology and Obstetrics recommends the following algorithms of 
positive cytological and histological findings in the “SGGG Expertenbrief 40“ [53] (Table 3). 
 
Table 3: Recommended follow up and treatment of screening results in Switzerland 
Cytological screening 
test result 
follow up 
LSIL Colposcopy indicated. 
If negative repeat cytology after 6 and 12 months. 
HSIL Colposcopy, cytology and biopsy. 
Diagnostic conization if result is ambiguous (for women <30 
years postpone conization if compliance with follow up is high. In 
this case colposcopy and cytology after 6 and 12 months. 
ASC-US  HPV test.  
If HPV negative repeat cytology after 6 and 12 months. 
If HPV positive perform colposcopy, cytology and biopsy. 
ASC-H (atypical 
squamous cells) 
Colposcopy 
AGC (Atypical Glandular 
cells of Undetermined 
Significance) 
Colposcopy, endocervical curettage and HPV typing 
If all results negative, colposcopy every 4-6 months for 2 years. 
Histological Finding Follow up 
CIN 1 Cytology every 6 months.  
If CIN1 is persistent over 2 years or if cytology and histology are 
discrepant, conization or laser vaporization 
CIN 2-3 Conization if woman is not pregnant.  
In young nulliparous women who are compliant with follow up 
screening: colposcopy and cytology every 6 months for 2 years. 
If persistent after 2 years conization 
AIS (Adenocarcinoma in 
Situ) 
Deep conization with curettage of endocervix.  
 
In the transferability analysis treatment options described in the health economic models 
were compared to Swiss recommended treatments. If differences were observed these were 
discussed for their potential impact on the transferability of the results.  
5.4.4 Is there any indication of a different base line risk of the populations? 
A different base line risk of the population may be relevant for transferability as models are 
“calibrated” to a country specific cancer incidence rate and / or a HPV prevalence rate. 
Therefore all health economic studies were compared for the comparability of those rates. 
If differences were found, they are discussed for their potential relevance on the 
transferability of the results in Table 14. 
 
The epidemiology of cervical cancer in Switzerland was partly described in the introduction.  
Compared to other developed countries the age corrected incidence and mortality of cervical 
cancer is low. The latest published data from 2008-2012 of the Swiss National Institute for 
Cancer Epidemiology and Registration (NICER) (http://www.nicer.org/NicerReportFiles2015-
2/EN/report/atlas.html?&geog=0, last accessed Jan 05 2016), show an age standardized 
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incidence rate per 100’000 women of 5.4 (95% CI = 4.9-5.8) and an age standardized 
mortality rate per 100’000 women of 1.4 (95% CI = 1.2-1.5).  
 
Swiss HPV prevalence values were taken from de Vuyst et al [62] who compared age 
dependent prevalence of hrHPV between several European countries. Swiss prevalence 
values in women between 30 and 60 years were found slightly above mean prevalence 
(9.4% vs 8.1%). In younger women below 30 years Swiss prevalence values were lower 
than in most other analyzed countries. 
 
5.4.5 Does the screening setting influence the result? 
In this thesis it is assumed that the screening setting (e.g. organized or opportunistic) will 
mostly influence the attendance rates of women in primary screening and follow up. 
 
Therefore in the transferability analysis modelled attendance rates were extracted from the 
health economic studies and compared to attendance rates in Switzerland. 
If differences were observed they were discussed for their potential impact on transferability. 
 
The Swiss reference values for screening coverage and attendance rates can only be 
estimated. In Switzerland organization of cervical cancer screening is opportunistic and 
mostly depends on the recommendations of gynecologists and general practitioners. As 
there is no central organization and quality assurance of cervical cancer screening there is 
neither systematic monitoring nor control over the implementation of the screening 
recommendations.  
Estimations by the Swiss Federal Office of Public Health (BAG) indicate that there is 
overscreening in some women and other women are never or rarely screened [1].  
Both underscreening of a significant number of Swiss women as well as overscreening is 
further implied by the results of the Swiss Health Survey 2007 as portrayed in [21].  
79.6% of the women (20 years and older) reported that they had had a cervical cancer 
screening test at least once in their lifetime. These data indicate that 20% of the women in 
Switzerland never participate in cervical cancer screening. 
Overscreening compared to guidelines is indicated by the number of women reporting that 
they had a cervical smear within the last 12 months (42.5% across all age ranges), with the 
highest numbers reported by women between 30 and 49 (about 52%). If women of this age 
group were tested every three years according to guidelines, only 33% should have been 
tested within the last 12 months. Therefore these numbers indicate more frequent testing of 
a significant number of women. A cost effectiveness analysis of 2008 for the addition of HPV 
vaccination to cervical cancer screening in Switzerland [63] assumed a real life frequency of 
screening of every 2 years based on expert opinions. 
 
In addition to attendance of women, the compliance of physicians to recommended follow up 
procedures may be higher in organized screening programs than in an opportunistic setting.  
No recent data were found for Switzerland for compliance to cervical cancer screening follow 
up and treatment recommendations. Therefore baseline data for a comparison are not 
available and a discussion of this aspect impossible. 
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5.4.6 Can results of the sensitivity analyses be used to make assumptions for the 
Swiss setting? If any parameters are different in the Swiss setting, have they 
been analyzed in the sensitivity analysis? If yes, are the differences expected 
to influence the result of the research question and in what direction? 
If any differences were identified for aspects 5.4.1 to 5.4.5, it was checked if the aspect was 
addressed in the sensitivity analysis of the study and was found to have an impact on the 
results. This information contributed to the evaluation of the points 5.4.1 to 5.4.5 as 
described above. 
5.4.7 Can costs and consequences be deduced for the Swiss setting (e.g. by putting 
Swiss units and costs into the calculation of the study or by adaptation to 
purchasing power?) 
If the studies did not provide results in a manner that allowed putting Swiss units and costs 
into the calculation of the study, the costs and ICERs were deduced by adaptation to 
purchasing power parities was pursued. 
For studies which were found to be potentially transferable to the Swiss Health System it 
was analyzed how ICERs calculated in different local currencies for different cost years 
might translate into Swiss Francs (CHF) for the same cost year (2015). It is clear that such a 
translation will only lead to an approximation of the true costs in Switzerland. However this 
translation at least improves comparability of the different studies and gives an impression of 
where the ICERs would be in CHF/LYG or /QALY. 
 
A comprehensive method for conversion of cost factors from one country to another would 
involve adaptation to three factors: differences in resource utilization, differences in prices of 
healthcare services and changes in costs over time. (Personal communication of Matthias 
Schwenkglenks). However, for the research questions in this thesis an adaptation to 
resource utilization was not deemed applicable, as the different screening strategies used in 
the models have inherent fixed assumptions for resource utilizations. Adaptation to prices of 
healthcare services was done by applying purchasing power parities and changes in costs 
over time according to the description below. 
 
If costs were reported in the original currency of the country, the cost values were directly 
translated into CHF with the conversion factor for the Organization for Economic Co-
operation and Development (OECD) Purchasing Power Parity (PPP) values from 
http://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP last accessed March 20, 2016. 
Afterwards the value in CHF was inflated to 2015 by using the annual average Swiss 
consumer price index rates from 
http://www.bfs.admin.ch/bfs/portal/de/index/themen/05/02/blank/key/jahresdurchschnitte.htm
l; last accessed March 24, 2016.  
If costs were reported in another currency and the conversion factor to local currency was 
reported, the costs were reconverted with that factor to local currency before converting to 
CHF with PPPs.  
If costs were reported in another currency and no conversion factor was given, the costs 
were reconverted to local currency by using a conversion factor from the year the costs were 
reported. The conversion factor was taken from http://www.wallstreet-
online.de/waehrungsrechner for July 1st of the cost year. In this case the conversion factor is 
reported in the thesis. 
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5.4.7.1 Cost of screening tests in studies compared to Switzerland  
As the sensitivity analyses of studies showed that the assumed costs of the cytology and 
HPV assay influences the costs and ICERs within a study, the current costs of these tests in 
Switzerland have been investigated. 
According to 2012 Tarmed tax points and with the Canton of Zürich as example a Pap test is 
reimbursed with 20.30 CHF if negative, 40.20 CHF if ambiguous and 71.70 CHF if positive.  
HPV hybridization (which is one method of HPV triage of positive cytological tests), is 
reimbursed with 84.76 CHF.  
There is no price (tax point) fixed for hrHPV testing as a primary cervical cancer screening 
test, as this is not a reimbursed screening strategy. However, in the “Analysenliste” a 
maximum reimbursement of 180 CHF is given for HPV DNA Amplification and hrHPV typing.  
Should HPV testing become a primary screening test in Switzerland a new price will have to 
be fixed for this application. This price will likely be lower than the current value in the 
“Analysenliste” due to higher expected testing volumes.  
 
5.4.7.2 Accepted ICER threshold of a cost effective intervention in Switzerland 
There is no published accepted ICER threshold in Switzerland. The World Health 
Organization’s (WHO) Commission on Macroeconomics and Health recommends that an 
intervention be considered very cost-effective if the ICER is less than the country’s per 
capita gross domestic product. (World Health Organization, Macroeconomics and Health: 
investing in health for economic development: report of the commission on macroeconomics 
and health; 2001). 
 
The provisional per capita Gross Domestic Product (GDP) 2014 for Switzerland according to 
the Federal Office of Statistics is 78’432 CHF 
http://www.bfs.admin.ch/bfs/portal/de/index/themen/04/02/01/key/bip_einw.html last 
accessed 24 Jan 2016. 
In a decision of the Swiss Federal Court (BGE 136 V 395) a limit of 100‘000 CHF/ LYG was 
deemed an acceptable threshold. 
 
Therefore, in the discussion of the potential cost effectiveness in a Swiss setting, ICER 
values translated into 2015 CHF were compared to an acceptable threshold of 100’000 
CHF/LYG. In studies where only cost/ QALY were shown, an acceptable threshold of 
100’000 CHF/QALY was assumed. As cost per QALY is always the same or higher than cost 
per LYG within the same study, this seemed an acceptable simplification. 
 
5.4.8 Were QALYs evaluated likely to be the same in Switzerland? 
The original checklist of Drummond also contains the question whether QALYs evaluated in 
a study would likely be the same in the country of interest. However Swiss baseline data for 
QALYs of all aspects of cervical cancer screening are not available. Only some disutilities 
have been used for cervical cancer stages in a Swiss study on the cost effectiveness of HPV 
vaccination [63]. Therefore, this aspect was not taken into account for the decision whether a 
study was transferable or not. If QALYs were used in a study they are described in Table 10 
and Table 5. The effect of using different sets of disutilities for the creation of QALYs is 
discussed in chapter 7.3.4.3Error! Reference source not found.. 
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5.5 Extraction of answers to research question 2  
All clinical and economic studies were analyzed for information on the feasibility of the 
implementation of the identified approaches and any potential barriers to implementation. 
 
During the analysis of the publications for the other research questions notes were taken on 
contents addressing research question 2. In a second step, to ensure that a systematic 
approach was taken, all publications were searched with the terms “concern”, “feasib”, 
“barrier”, “implement” and “however”. Publications in German language were searched with 
the terms “bedenken”, “durchführ”, „einführ“, “möglich”, “machbar”, “hinder”, “implement”, 
“umsetz”, “trotzdem”, “hingegen”, “dennoch”, “allerdings”, “jedoch” und “aber”. By this 
method paragraphs containing concerns on the implementation of HPV based screening 
were identified that could have been missed in the first step. 
 
Answers were then classified into “concern categories” and focus areas identified based on 
the frequency that the different concerns were mentioned. All detailed information retrieved 
and the associated concern categories are displayed in Appendix 5: “Research question 2 – 
Excerpt of answers”. 
 
Relevance for the Swiss health system was assessed by comparing the concerns to 
available information on the Swiss cervical cancer screening set up. 
 
The areas of concern are described in results chapter 10.1 and the relevance for the Swiss 
health system is described in chapter 10.2. 
5.6 Conclusions for Swiss policy 
Based on the findings for Research Questions 1a, b and c and 2, hypotheses 1 and 2 are 
answered and a recommendation for Swiss policy is made.  
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6 Literature Search Results 
6.1 Literature search results Clinical Systematic Reviews and Meta 
Analyses 
 
Figure 2 shows the Prisma 2009 Flow Diagram for the literature selection of clinical 
systematic reviews or meta analyses. The last search of the databases was done on March 
12, 2016. After removal of duplicates 201 publications remained. The titles and abstracts of 
these publications were screened for relevance to the research questions and the exclusion 
criteria described in the methods chapter. Seventeen records were health economic studies 
and analyzed in the health economic evidence results. 179 records were excluded based on 
titles and abstract search. The remaining 22 publications underwent full text search and 
another 6 articles were excluded. Reasons for exclusion were in 43 cases that language or 
countries did not meet inclusion criteria, in 120 cases that publications did not address the 
research questions (many publications covered HPV vaccination instead of primary cervical 
cancer screening with HPV tests), and in 5 cases that publications were not systematic 
reviews or meta analyses (e.g. short comments or reviews that were explicitly identified as 
not being a systematic review).  
Sixteen systematic reviews and meta analyses remained that were further analyzed for this 
thesis [43-49, 51, 52, 54, 56, 64-68]. 
Seven of these were done from the perspective of the US health system [64] [54] [56] [51] 
[67] [52, 68], 2 from the perspective of the German health system [46, 65] (one being an 
update of the other), and 7 studies were done independent of a specific health system [43] 
[47] [66], [44] [48] [45] [49]. Analyses related to a specific health system were typically done 
to develop new clinical guidelines, while the other studies typically aimed at a comparison of 
the relative sensitivity and specificity of HPV based versus cytology based cervical cancer 
screening.  
 
Of three studies only qualitative results including the definition of benefits and harms of 
different cervical cancer strategies were derived [51, 52, 56]. 
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Figure 2 Prisma 2009 Flow Diagram [38] for search results for clinical systematic reviews or meta 
analyses 
Records identified through 
database searching in PubMed
(n =123) 12 Mar.2016
Records identified through 
database searching in Centre 
for Reviews and Dissemination 
of the University of York
(n =93) 12.Mar.2016
Records after duplicates 
removed
(n =201)
Records screened
(n =201)
Full-text articles assessed for 
eligibility
(n = 22)
Studies included in qualitative 
synthesis
(n = 16)
Studies included in 
quantitative synthesis 
(n =13 )
Records excluded
(n =(162+17) =179)
43 country / language
117 not research question
2 not systematic review
17 Records transferred to search 
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6.1.1 Evolution of Clinical Evidence - Relevant clinical studies 
The randomized controlled studies POBASCAM, Swedescreen, NTCC1, NTCC2 and 
ARTISTIC and their combined follow up, are considered the key randomized controlled 
studies in the evolution of clinical evidence about HPV based cervical cancer screening. 
In addition the cohort studies KPNC, VUSAscreen and ATHENA had relevant influence on 
the formation of new clinical guidance. 
 
To analyze the clinical evidence, systematic reviews and meta analyses from 2008 onwards 
were searched. As since 2008 several key clinical studies were still ongoing and more and 
more results were published, earlier reviews and meta analyses come partially to different 
conclusions than more recent publications, depending on the amount of information 
available at the time of writing. 
 
To illustrate how clinical information emerged within the last years a brief summary of the 
evolution of clinical evidence is provided below. An overview of study setup and results of 
individual studies included into systematic reviews and meta-analyses is provided in 
Appendix 2: “Description of Randomized Controlled Trials and Cohort Studies”. 
 
6.1.1.1 Background 
 
As cervical cancer screening with the Pap test has successfully reduced cancer incidence 
and mortality in countries where screening was established [49], researchers exploring the 
use of HPV testing in cervical cancer screening had to find a balance to gain data on 
potential benefits and harms for HPV testing without putting women in the intervention arm 
of the study at risk of higher cancer morbidity and mortality. 
First studies were therefore cross sectional and cohort studies to evaluate the statistical 
association of positive HPV and cytology tests and the prevalence and subsequent 
incidence of cervical cancer precursors and invasive cervical cancer cases as summarized 
in the systematic review of Cuzick from 2008 [49]. 
 
6.1.1.2 Studies with HPV and Cytology Cotesting in the Intervention Arm 
Based on the data from cross sectional studies and cohorts the first randomized controlled 
trials were performed in Europe which contained an intervention arm of cotesting of HPV and 
cytology tests. These studies are POBASCAM in the Netherlands (end results reported in 
2012 [16]), Swedescreen in Sweden (end results reported in 2009 [18], follow up results 
reported in 2014 [69]), ARTISTIC in the UK (end results published in 2009 [3], follow up until 
2014 included into the UK HTA of 2014 [2]), and NTCC 1 in Italy (end results published in 
2010 [12]).  
 
6.1.1.3 Studies with HPV testing only in the intervention arm 
Comparing data on women with both a negative HPV and negative cytology test with women 
with only a negative HPV test revealed, that an additional cytology test adds only little 
sensitivity and therefore allowed the first clinical studies in which women in the intervention 
arm received only a standalone HPV test in the first screening round (NTCC 2 in Italy) or 
HPV testing with cytology triage (FPHT in Finland). 
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One study frequently included into systematic reviews and meta-analyses even though not 
transferable to a European or US context, is a study done in rural India (“INDIA” [70]) where 
a previously unscreened population was either screened with one time HPV testing or one 
time cytological testing. The study showed that one time screening with HPV testing 
significantly reduced morbidity and mortality from cervical cancer compared to unscreened 
women, while one time screening with cytology screening did not. Some systematic reviews 
and meta-analyses [44, 46] included this study to compare relative detection rates of cervical 
cancer and precancerous stages in a first screening round. 
 
6.1.1.4 Cohort studies addressing HPV based testing with and without partial 
genotyping 
The women participating in the studies POBASCAM, Swedescreen, NTCC and ARTISTIC 
were followed up in a combined cohort study published in 2014 [39]. 
 
Other important cohort studies include VUSAscreen in the Netherlands(end results 
published 2012 [71]), and the huge US KPNC Study. In the latter the follow up of up to 1.4 
million American women screened by cotesting with HPV and cytology is analysed (end 
results published 2014 [11, 72, 73]. 
The most recent systematic review of Huh et al. [64] also included the industry sponsored 
ATHENA study which characterizes a new HPV test yielding results in one measurement for 
all hrHPV types and for HPV 16 and 18 thus allowing triage of HPV positive women by HPV 
subtyping (end results published 2015 [5]). 
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6.2 Literature Search Results HTAs and Health Economic Studies 
 
Figure 3 shows the Prisma 2009 Flow Diagram for the literature selection of HTAs and 
health economic studies. The last search of the databases was done on March 12, 2016. 
After removal of duplicates 310 publications remained. The titles and abstracts of these 
publications were screened for relevance to the research questions and the exclusion criteria 
described in the methods chapter. 289 records were excluded based on titles and abstract 
search. The remaining 21 publications underwent full text search and 1 other article was 
excluded [3] because it was superseded by a newer publication on the topic of the same 
authors [2]. 
Twenty studies were found that were included in the qualitative analysis [2, 28-37, 60, 74-
81].  
 
Six publications did not give results for the quantitative and/ or transferability analysis.  
The studies of Dillner and Mühlberger [74, 81] were reviews of primary health economic 
studies and did not yield quantitative results, however qualitative input was available e.g. on 
research question 2. Two studies did not report results in sufficient detail for quantitative 
analysis [77, 78]. The studies of Berkhof and van Rosmalen [31, 79] did not include or show 
results for a comparator of 3 yearly screening (the minimum frequency was 5 yearly), and 
therefore allowed no transferability analysis to the Swiss setting. 
 
The included publications are health technology assessments from Belgium [28], the UK [2], 
Germany [30, 60] and Australia [29] and health economic studies from the USA [35-37], 
Canada [33, 34], Italy [76], Norway [32] and Sweden [75]. 
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Figure 3 Prisma 2009 Flow Diagram [38] for Search Results for Health economic Studies 
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7 Results Research Question 1a “What is the best test or 
combination of tests which results in the highest clinical 
effectiveness to prevent cervical cancer at the lowest burden of 
follow up?” 
The results chapter starts with a summary of all key findings (7.1), then describes the details 
from clinical systematic reviews and meta analyses (7.2), followed by the details extracted 
from HTAs and health economic studies (7.3). A reference is given after the summary 
statements to the subsequent chapters where detailed results and references to publications 
can be found. 
 
7.1 Summary Results Research Question 1a 
7.1.1 Protection against cervical cancer 
Evidence from both clinical studies and health economic studies showed that HPV based 
cervical cancer screening is more effective than cytology based screening in preventing 
cervical cancer cases. (7.2.1, 7.3.1) 
7.1.2 Surrogate Markers CIN2+ and CIN3+ over 2 screening rounds 
Meta analyses of Randomized Clinical Trials (RCTs) showed that HPV based testing leads 
to increased detection of CIN2+ and CIN3+ in the first screening round and decreased 
detection in the second screening round (7.2.2). 
Comparison of CIN2+ and CIN3+ over 2 screening rounds from RCTs indicates that direct 
referral to colposcopy after a single HPV positive result leads to overdetection of CIN2 and 
CIN3 lesions that might otherwise regress without being detected.  
On the other hand strategies that used HPV testing with cytology triage and retesting to 
detect HPV persistence before colposcopy referral did not lead to increased CIN2+ or CIN3+ 
numbers over 2 screening rounds. This was interpreted by most systematic reviews as proof 
of earlier detection of precancerous lesions instead of overdetection of regressive lesions in 
the first screening round. One systematic review disagreed with this interpretation and 1 was 
not sure how to interpret this finding. 
Detection of precancerous lesions was not discussed in health economic studies. However 3 
studies used QALYs instead of life years as effectiveness markers and assigned disutilities 
to precancerous lesions. In these studies HPV based screening strategies were more 
effective in terms of QALYs than cytology based screening strategies (7.3.4.3). 
7.1.2.1 Sensitivity and specificity of HPV versus cytology based screening 
HPV testing was 24 to 40% more sensitive but 2-8 % less specific than cytology tests to 
detect precancerous lesions CIN2+ or CIN3+ as shown by a meta analysis based on RCTs 
and cross sectional studies (7.2.2.4). 
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7.1.3 HPV testing with direct referral to colposcopy 
HPV testing with direct referral to colposcopy showed higher clinical effectiveness than 
cytology based testing based on the RCT NTCC and health economic models (7.2.2.2, 
7.3.1). However HPV testing with direct referral to colposcopy seems also to increase the 
detection of lesions that might otherwise regress before detection. In addition both 
systematic reviews as well as health economic studies show that this strategy leads to 
approximately twofold increased colposcopy rates (7.2.2.3, 7.2.4.1, 7.3.4.1). 
7.1.4 HPV with cytology triage  
HPV with cytology triage showed higher clinical effectiveness than cytology based testing 
based on RCTs and all health economic models that were included into the analysis (7.2.2, 
7.2.4.1, 7.3.1, 7.3.4.1). 
Whether or not colposcopy rates are increased compared to cytology varied between studies. 
One systematic review found lower colposcopy rates with HPV versus cytology testing in the 
RCT FPHT and 10-20% higher colposcopy rates in POBASCAM and ARTISTIC. Another 
systematic review calculated colposcopy rates per detected CIN3+ and found elevated 
colposcopy numbers (5.4 vs 4) in ARTISTIC and NTCC1, however not in POBASCAM and 
FPTH. The combined follow up of POBASCAM, NTCC, ARTISTIC and Swedescreen 
showed that the number of women with biopsies were comparable in the strategies applying 
HPV with cytology triage algorithms (7.2.4.1).  
Colposcopy rates of HPV based screening were lower with HPV based testing when longer 
screening intervals were used:  
Three models cited in systematic reviews showed that colposcopy rates with 5 yearly HPV 
with cytology triage are lower than with 3 yearly cytology based testing (7.2.4.2). 
Four health economic studies modelled colposcopy rates for HPV with cytology triage and 
found that these rates were slightly lower or slightly higher than with cytology based 
screening (-4% to + 10%). In these studies screening frequencies of HPV based testing 
were closer to those of the cytology based screening (3 yearly in 2 of these studies and in 
the other 2 studies cytology based screening was done at 5 yearly intervals at the age of 50-
65 (7.3.4.1)).  
7.1.5 Cotesting 
Cotesting showed higher clinical effectiveness than cytology based testing based on RCTs 
and all health economic models that had modelled this screening strategy (7.2.1, 7.2.2, 
7.3.1).  
7.1.6 Cotesting compared to HPV with cytology triage 
When cotesting is compared with HPV with cytology triage, HPV with cytology triage was 
found similarly effective to detect CIN2+ or CIN3+ as cotesting in 6 systematic reviews and 
meta analyses. One systematic review found the evidence from RCTs too limited to 
recommend HPV with cytology triage instead of cotesting. One review had other concerns to 
switch from cotesting to HPV with cytology triage in the primary screening (7.2.2.1.1). 
Three of 5 health economic studies showed the same clinical effectiveness for cotesting as 
for HPV with cytology triage. In these cases the follow up algorithm after cotesting was 
similar as after HPV with cytology triage. In 2 health economic studies cotesting was more 
effective than HPV with cytology triage. In 1 of these studies every HPV result was directly 
followed up with colposcopy and in the other follow up after primary testing was not 
described (7.3.4). 
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7.1.7 HPV with genotyping for HPV 16/18 
Partial genotyping with HPV 16/18 identifies women with the highest risk for cervical cancer. 
According to cohort studies the risk to develop CIN3+ in the next 3 years is higher for 
HPV16/18 positive / cytology negative women than for other hrHPV positive / cytology 
positive women (7.2.4.1). Therefore a screening strategy with direct referral to colposcopy 
for HPV16/18 positive women and retesting for other hrHPV positive and cytology negative 
women was recommended by 3 systematic reviews. One non health economic modelling 
study came to the conclusion that this strategy had a lower number of cases of cervical 
cancer with fewer colposcopies (7.2.4.2). 
Four health economic studies modelled this strategy. In these genotyping for HPV16/18 
always had the highest clinical effectiveness of all strategies. This strategy showed higher 
colposcopy rates than HPV with cytology triage in 3 of the 4 studies. One study showed a 
modest absolute increase of colposcopies and the lowest colposcopy rate per detected 
CIN3+ compared to all other strategies (7.3.1, 7.3.4, 7.3.4.1). 
7.1.8 Longer Screening Intervals with HPV vs Cytology 
Screening intervals can be prolonged from 3 years with cytology to 5 years with HPV based 
testing. This was consistently shown by clinical systematic reviews and meta analyses as 
well as by health economic models (7.2.3, 7.3.3). 
 
7.1.9 Other potential harms and burden from HPV based testing 
A systematic review of the results of 3 out of 5 RCTs indicated that the number of positive 
primary screening test results that were subsequently not associated with CIN3+ (called 
“false positive” results), was higher with HPV than with cytology testing. The authors 
assumed this may be compensated over the lifetime of women by longer screening intervals 
(7.2.4.4). In one health economic study the number of false positive results was modelled. 
Cytology based screening had higher numbers of false positive results than HPV based 
screening of the same frequency. The term “false positive” was however not clearly defined 
in this study (7.3.4.2).  
 
Only limited data are available for psychosocial effects of positive primary screening results 
with HPV versus cytology. The main difference is that HPV has the connotation of a sexually 
transmitted disease which may be associated with stigma (7.2.4.5). No data are available on 
the amount of physical damage from biopsies taken and treatment of precancerous lesions 
(7.2.4.6). 
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7.2 Details on Clinical Evidence from Systematic Reviews and Meta 
Analysis 
7.2.1 Protection against cervical cancer 
HPV based screening resulted in significantly lower invasive cervical cancer numbers 
compared with cytology based screening in the combined follow up of 4 European RCTs. A 
trend towards lower cervical cancer incidence rates is reported in all systematic reviews or 
meta analyses that discussed this end point. 
 
The endpoint of invasive cervical cancer was addressed by 6 out of 15 systematic reviews or 
meta analyses. 
4 systematic reviews reported “indications” for lower cancer incidence rates in the second 
screening round and prolonged follow up of the RCTs NTCC and POBASCAM [45, 51, 67, 
68]. 
Quantitative results on the reduction of cervical cancer incidence were reported by IQWIG 
[46] based on their meta analysis of the results in the second screening round of NTCC, 
POBASCAM and Swedescreen (RR = 0.24, 95% CI = 0.10-0.60), and by Huh [64] based on 
the combined follow up of NTCC, POBASCAM, Swedescreen and ARTISTIC of Ronco et al. 
[39] (RR = 0.45, 95% CI= 0.25–0.81). 
 
The challenge in this end point is that the overall incidence of invasive cervical cancer in an 
already screened population is low. Therefore, most individual RCTs were not powered to 
detect a significant reduction in the incidence of cervical cancer cases [39]. 
Ronco et al [39] analyzed the combined follow up data of women enrolled in the studies 
ARTISTIC, POBASCAM, Swedescreen and NTCC. Thereby 176’464 women were followed 
up for a median of 6.5 years.  
The results of this combined follow up show that even though differences exist in the 
detailed algorithms used in the intervention groups (e.g. using cotesting versus HPV testing 
only as primary screening test and the follow up after a positive HPV results (direct referral 
to colposcopy versus retesting of HPV+/cyt- women after one year)), there was a common 
effect of protection against cervical cancer. 
Using HPV testing in cervical cancer screening resulted in a significantly lower number of 
cervical cancers with no significant heterogeneity between studies. The protective effect of 
HPV testing was more predominant against adenocarcinoma (RR 0.31 (0.14-0.69)), than for 
squamous-cell carcinoma (RR 0.78 (0.49-1.25)). This is due to the especially low sensitivity 
of cytology to detect adenocarcinoma. In women with a negative screening test at entry, the 
rate ratio for all invasive cervical cancer cases was 0.30 (0.15–0.60). From these numbers 
the authors of this study concluded that HPV based screening provides 60-70% greater 
protection against invasive cervical cancer compared with cytology [39]. 
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7.2.2 Surrogate markers CIN2+ and CIN3+ over 2 screening rounds 
7.2.2.1 Detection of CIN3+ and CIN2+ in round 1 
CIN2+ detection was significantly increased in all meta analyses and CIN3+ significantly 
increased in 3 meta analyses and non-significantly increased in 2 meta analyses in 
screening round 1 with HPV based testing versus cytology based testing. 
 
All 9 systematic reviews addressing this surrogate marker [49, 51, 52, 54, 56, 64, 66-68] 
confirmed that HPV based testing leads to increased detection of CIN2+/CIN3+ without 
giving quantitative results. These findings were based on the RCTs NTCC, POBASCAM, 
FPHT, HPV Focal, and ATHENA. 
One systematic review [48] did not address this surrogate marker, as its focus was on 
positive primary test results without subsequent CIN3+ confirmation.  
 
All 5 meta analyses addressing the surrogate markers CIN2+ and/ or CIN3+ came to the 
same conclusions on the relative detection of CIN2+ and similar conclusions on CIN3+ with 
HPV based screening versus cytology based screening [43-47].  
 
The quantitative results from the meta analyses are as described in the following 
paragraphs:  
 
In the most comprehensive meta-analysis from Arbyn [28, 44] (Figure 4), a good 
overview is given on the results of the RCTs NTCC1 (Ronco [15]), CCCaST (Mayrand [6]), 
Swedescreen (Naucler [19]), NTCC2 (Ronco [13]), FPHT (Leinonen [8]), POBASCAM 
(Rejkaart [16]) and ARTISTIC (Kitchener [3]). 
HPV based screening algorithms lead to significantly increased detection of CIN2+ and not 
significantly increased CIN3+ in the first screening round (analysis restricted to women older 
than 35 years).  
 
Figure 4 Detection of CIN2+ and CIN3+ in the first screening round with HPV testing versus cytology as 
taken from figures 4 and 5 of [28] 
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The ARTISTIC study (Kitchener [3]) is shown separately in this meta-analysis because of the 
high heterogeneity introduced by this study. It was discussed that the comparator used in 
this study was LBC, newly introduced in the UK with an unusually high proportion of cytology 
positive samples of up to 17%. The reason that HPV based testing did not detect more 
CIN2+ or CIN3+ cases might therefore be associated with an unusual high sensitivity 
threshold of LBC in this study. (It is important to note that in general authors of systematic 
reviews and meta-analyses did not distinguish between different cytological techniques as 
comparators to HPV testing and consider Pap test and LBC as equivalent e.g. [52]. In a 
meta-analysis LBC was found to be neither more sensitive not specific than the Pap test 
[82]. The main advantage of LBC over the Pap test is that the number of samples of 
insufficient quality can be reduced.1  
It was also discussed that in the ARTISTIC study follow up of HPV positive cytology negative 
women was incomplete. Only 62% of HPV positive women had repeat testing as per 
protocol and of those persistently positive only 66% underwent colposcopy.  
Even with inclusion of the ARTISTIC study the big picture remains that CIN2+ detection was 
significantly and CIN3+ detection non significantly increased in the first screening round. 
 
The biggest increase in CIN3+ detection by HPV testing was seen in the Italian NTCC1 and 
2 studies. These studies differs from others in that it had a comparatively more active follow 
up of HPV positive cytology negative women. In NTCC1 for women of 35 years and older 
and in NTCC2 for all women a positive HPV test led immediately to colposcopy while in 
other studies HPV positive and cytology negative women were invited for retesting after 12-
18 months and only women persistently positive for HPV were invited for colposcopy. 
 
The meta analysis by IQWIG [46] showed the same picture. It provided a forest plot of 
results of the relative detection of CIN3+ at round 1 from NTCC1 and 2, Swedescreen, 
POBASCAM and ARTISTIC and “FTPH” with pooled results for all age groups (including 
women younger than 30 years), for CIN3+ detection at round 1. Due to the high 
heterogeneity across studies it was decided to not calculate a common effect size. However 
from the graph it is obvious that only the NTCC2 study had a relevant and significant 
increase in CIN3+ detection in round 1. 
The study of CCCaST [6] was not included in this analysis as both intervention and control 
arms had HPV testing (in different order of sampling).  
 
The meta analysis by Bouchard-Fortier [43] came to the same conclusion that relative 
detection of CIN2+ is significantly increased and that of CIN3+ not significantly increased 
even though done across all age groups (including women younger than 30 years). This 
meta analysis focused on cotesting as intervention and therefore included only NTCC1, 
ARTISTIC, POBASCAM and Swedescreen.  
 
The meta analysis by Murphy [45] showed a significantly increased detection also of 
CIN3+ in round 1. It included NTCC 1 and 2 (pooled results over both phases), 
Swedescreen, POBASCAM and ARTISTIC for CIN2+ results, but excluded ARTISTIC for 
CIN3+ results due to the high heterogeneity introduced. The analysis included all women 
including those younger than 30 years.  
                                                          
 
1
 In Switzerland both methods are used  1. Untiet, S., et al., [Cervical cancer screening in Switzerland - current practice 
and future challenges]. Ther Umsch, 2013. 70(4): p. 223-30. 
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Both the meta-analyses of Bouchard-Fortier and Murphy did not include FPHT. For this 
study only results of the first round have been reported and the authors wanted to compare 
results of the first round with those of the second round and over both screening rounds. 
 
The meta analysis by Pileggi [47] also found a significantly increased CIN3+ detection rate 
of 1.48 (CI = 1.02-2.13). The difference between this study and the others is that it included 
the Finnish FPHT study and used results from all women of 25-65 years of age, while Arbyn 
[44] only used data from women older than 35 years. 
 
In summary: depending on the inclusion or exclusion criteria used, in round 1 CIN2+ 
detection was always significantly increased, while CIN3+ detection was increased non-
significantly or significantly. 
7.2.2.1.1 Comparison of HPV testing as primary screening with cotesting in round 1 
Testing with HPV alone is similarly effective to detect CIN2+ or CIN3+ than cotesting with 
HPV and cytology. This was a consistent finding across most systematic reviews and meta 
analyses that discussed this aspect, while some found the evidence limited. 
 
Only the meta analysis of Arbyn [44] compared in a quantitative manner cotesting with 
primary testing with HPV alone (with or without triage). The detailed results are shown in 
Figure 5. They show that no significant difference in the relative detection rate of CIN2+ or 
CIN3+ was observed in any of the single studies included in the meta-analysis if the 
numbers of CIN2+ or CIN3+ cases identified by HPV positive samples only were compared 
to additional cases found in HPV negative, cytology positive women [28, 44].  
 
Five systematic reviews [47, 52, 56, 64, 68] stated that HPV testing alone had similar 
sensitivity for the detection of CIN2+ and CIN3+ as cotesting without stating quantitative 
results. Evidence was taken from the RCTs included in the meta analysis of Arbyn and the 
cohort studies KPNC [73], ATHENA [5] and [39, 83]. Whitlock [68] even warned that 
cotesting might offer no additional CIN3+ detection above HPV screening alone, but may 
yield more false-positive results.  
 
Moyer [51] found the evidence on benefits and harms of HPV testing alone versus cotesting 
too limited yet to make a recommendation for it. 
 
Saslow [67] had a concern that with HPV testing alone, problems with sampling of the 
material for the test might go unnoticed and lead to false negative results, which would be 
recognized with a cytology sample taken at the same time. No data on the frequency of false 
negative HPV results were provided by Saslow. 
 
The question was not addressed in the other 7 systematic reviews or meta analyses [43, 46, 
48, 49, 52, 54, 66]. 
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Figure 5 Relative detection rate of CIN2+ and CIN3+ with HPV testing alone versus cotesting as taken 
from figure 6 in [28]. 
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7.2.2.2 Detection of CIN3+ and CIN2+ in round 2 
HPV based testing led to significantly fewer CIN3+ stages in the second screening round. 
This finding was consistent across all meta-analyses. In addition all single studies except 
NTCC1 showed this result. 
Also significantly fewer CIN2+ stages were found in the second screening round. This result 
is however only based on 2 meta-analyses, and single studies had higher heterogeneity. 
 
For screening round 2 the relative detection of CIN3+ in intervention arm versus control was 
analyzed in 4 meta analyses [43-46] (Figure 7) and CIN2+ in 2 meta analyses [43, 45] 
(Figure 6). They were based on the only 4 RCTs containing data for more than one 
screening round: POBASCAM, NTCC 1 and 2, Swedescreen and ARTISTIC.  
 
Significantly fewer CIN3+ stages were found in the second screening round in the 
intervention arm versus control. There was no heterogeneity between studies if the age of 
women was 35 years or older and higher heterogeneity when women of all ages were 
included. Heterogeneity was highest when NTCC rounds 1 and 2 were separately reported. 
The background is that in NTCC round 1, in younger women the relative detection rate of 
CIN3+ was not reduced in round 2, while the reduction in NTCC2 was much more 
prominent. The difference between NTCC1 and 2 is that in NTCC 1 cotesting was applied 
and young women positive for HPV but negative for cytology were retested within 12-18 
months. The authors commented that only 70% of the women returned for retesting. In 
contrast in NTCC2 only HPV testing was done and every positive HPV test was followed up 
with immediate colposcopy.  
The same findings were discussed in 3 systematic reviews [51, 56, 68] and were interpreted 
as a protective effect of HPV based testing in round 1. 
Six systematic reviews or meta analyses did not report detection of CIN3+/CIN2+ in 
screening round 2 [47, 48, 52, 54, 64, 67] 
 
Figure 6 Relative Detection of CIN2+ in the 2nd screening round with HPV versus cytology testing 
Meta-analysis Forest Plot (created after Plots in the respective publications) 
Murphy 
[45] 
 
All ages 
 
Pooled results from NTCC1 and 2 
POBASCAM interim results from 
Bulkmans [17] 
 
Bouchard-Fortier [43] 
 
All ages 
 
Only NTCC1, as only cotesting was 
analyzed as intervention 
 
POBASCAM final results based on 
Rijkaart [16] 
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Figure 7 Relative detection rate of CIN3+ in the 2
nd
 screening round with HPV versus cytology testing  
Meta-analysis Forest Plot (created after Plots in the respective 
publications) 
Arbyn  
[28, 44] 
 
women of ≥ 35  
 
pooled results from NTCC1 and 2 
 
IQWIG 
[46] 
 
All ages 
 
ARTISTIC was excluded from analysis 
of round 2 because more than 30% of 
the women of round 1 were lost to follow 
up in round 2.  
Due to the high heterogeneity no overall 
value was calculated 
 
Murphy 
[45] 
 
All ages 
 
Pooled results from NTCC1 and 2 
 
Bouchard-Fortier 
[43] 
 
All ages 
 
Only NTCC1, as only cotesting was 
analyzed as intervention 
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7.2.2.3 Detection of CIN3+ and CIN2+ over both screening rounds 
Detection of CIN3+ and CIN2+ was similar over 2 screening rounds with HPV versus 
cytology. This was shown in two meta-analyses. This was true for all individual studies but 
one (NTCC). This study showed elevated CIN3+ and CIN2+ values over 2 screening rounds 
indicating that immediate colposcopy after every positive HPV results without triage will lead 
to overdiagnosis of precancerous lesions while triage with cytology limits overdiagnosis. 
 
Two publications contained meta analyses on the relative detection of CIN2+ and CIN3+ 
with HPV based screening versus cytology only screening [43, 45] over two screening 
rounds (Figure 8). 
In these meta analyses the summary measure over all studies showed no significantly 
changed detection rates of CIN2+ or CIN3+.  
One single study showed increased detection of CIN2+ and CIN3+ over both screening 
rounds, i.e. NTCC2, where every positive HPV result was followed up with immediate 
colposcopy. CIN2+ was also significantly increased in NTCC1 where women of 30 years and 
older were followed up with immediate colposcopy and younger women were followed up 
with retesting after 12-18 months. 
The authors of the study concluded that HPV testing in younger women leads to 
overdiagnosis of CIN2 [12]. 
At the same time it is important to note that in NTCC1 and 2 also in older women relative 
cumulative detection rates over 2 screening rounds of CIN2 and CIN3 were significantly 
increased.  
Therefore it may be concluded that immediate referral to colposcopy of every HPV positive 
woman leads to overdiagnosis of precancerous lesions, a significant number of which would 
otherwise regress before being detected and treated.  
 
The systematic review of Patanwala [66] interpreted this differently. According to the authors 
HPV based testing was only more sensitive over 2 screening rounds than cytology based 
testing if followed by immediate colposcopy. 
 
The systematic review of Whitlock [68] also mentioned that cumulative detection rate of 
CIN3+ over 2 screening rounds was only elevated in NTCC2 (HPV only with direct referral to 
colposcopy for all ages), but not in NTCC1 (cotesting with direct referral to colposcopy for 
older women and retesting after 1 year for younger women). The authors were not sure how 
this result should be interpreted. 
 
The other systematic reviews and meta analyses did not address this indicator. 
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Figure 8 Relative Detection of CIN2+ and CIN3+ over both screening rounds in the intervention arm vs 
cytology only 
Meta-analysis Forest Plot (created after Plots in the respective 
publications) 
Murphy 
[45] 
 
All ages 
 
Pooled results from NTCC1 and 2 
 
Bouchard-Fortier  [43] 
 
All ages 
 
Only NTCC1, as only cotesting was of 
analyzed as intervention 
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7.2.2.4 Clinical evidence of sensitivity and specificity of cervical screening with HPV 
tests 
 
HPV tests are 24 to 40% more sensitive but 2 to 8% less specific than cytology tests to 
detect precancerous lesions CIN2+ or CIN3+. 
 
The absolute sensitivity of the HPV test to detect CIN3+ was most comprehensively shown 
by Arbyn [28] for the most studied assay HC2 (Hybrid Capture® 2), which was used, e.g. for 
the RCTs ARTISTIC and NTCC. 
In industrialized countries the sensitivity of this HPV assay to detect CIN3+ was consistently 
high at 0.98 (0.97-0.99). In an earlier meta-analysis the sensitivity of the HPV assay to 
detect CIN2+ was 0.96 (0.95-0.98) [44]. Arbyn [28] reported that the sensitivity of the HPV 
assay HC2 to detect CIN3+ was 24% to 40% higher than cytology depending on the disease 
threshold (CIN2+ or CIN3+), or on the cytological cutoff (ASC-US or Low-grade Squamous 
Intraepithelial Lesion (LSIL)). 
 
The relative specificity of HC2 for excluding CIN2+ was significantly lower than cytology: 
ratio of 0.98 (95% CI: 0.96-0.99) and 0.92 (95% CI: 0.90-0.94), considering the cutoffs ASC-
US+ or LSIL+, respectively ([28].  
 
Sensitivity and specificity for other HPV tests was also most extensively discussed by Arbyn 
[28] (Table 4). Of these the most relevant tests are GP5+6+ which was used in the RCTs 
POBASCAM and Swedescreen and the cobas HPV test which was used in the ATHENA 
study. 
As a summary, these tests showed high inter assay comparability for sensitivity and 
specificity to detect CIN2+ or CIN3+. 
 
Table 4: Relative accuracy of other HPV tests compared to HC2 to find underlying CIN2+ or CIN3+ in 
primary screening (taken from table 7 in [32]) 
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7.2.3 Longer Screening Intervals with HPV vs Cytology 
A negative HPV test result gives better and longer security against the development of 
CIN3+ and cancer than a negative cytology result. This was a consistent finding from all 
systematic reviews or meta analyses addressing this question. 
 
Screening intervals should be chosen based on the probability that disease progresses 
between intervals to a stage that is beyond the threshold that is considered for treatment. 
These probabilities are typically developed based on the data observed in cohort studies.  
The probability after a cytology negative result to develop CIN3+ or cervical cancer over the 
next 3 years was higher than after a hrHPV negative result over the next 5 years.  
 
This was reported by 7 systematic reviews or meta analyses based on the cohort studies 
KPNC [11, 72, 73], ATHENA [5] and [39, 83] and in 1 systematic review [68] also based on 
the RCTs POBASCAM, ARTISTIC, Swedescreen and FPHT. 
 
Longer screening intervals than with cytology without specifying the exact length of the 
interval were found indicated by Bouchard-Fortier [43] based on the results of the RCTs 
Swedescreen POBASCAM, ARTISTIC and NTCC. Moyer [51] found evidence from a cohort 
study in 2007 that instead of 2 yearly cytology testing, 3 yearly cotesting would be possible. 
According to Moyer the results from ARTISTIC [4] indicate a possible screening interval of 
even 6 years. Six years was also proposed by Cuzick [49] based on the results from 
POBASCAM and Swedescreen [17, 19]. Schiffman [52] interpreted the results of cohort 
studies [83, 84] that a negative HPV results gives 5-10 years of protection against cervical 
cancer.  
Four systematic reviews did not address this question [46-48, 66]. 
 
Some results from the above mentioned cohort studies are presented in the following 
paragraphs: 
 
The biggest cohort study was KPNC in which up to 2011 more than 300’000 women tested 
with cotesting were followed up for 4-6 years. They showed that the risk to develop CIN3+ in 
the next 5 years per 100’000 women for HPV negative women was 0.16% when they were 
also cytology negative, and 0.86% when cytology positive. Cytology negative women who 
were HPV positive results had a 5.9% risk to develop CIN 3+. 
 
In the ATHENA study 347 cases of CIN3+ were identified over 3 years. 47.3% occurred in 
baseline cytology negative women and 9.8% in baseline HPV negative women (p<0.001) [5]. 
 
In the combined follow up of the European RCTs POBASCAM, ARTISTIC, Swedescreen 
and NTCC, the authors concluded from the cumulative incidence rates of invasive cervical 
carcinoma that 5 yearly testing with HPV is more protective than 3 yearly cytological testing 
[39]: 
The Cumulative Incidence Rates (CIR) (95% confidence interval) of invasive cervical 
carcinoma per 100’000 women were significantly lower after 5.5 years with a HPV negative 
result than after 3.5 years with a cytology negative result. 
 After 3.5 years After 5.5 years 
I=HPV negative women 4.6 (1.1-12.1) 8.7 (3.3-18.6) 
C=cytology negative women 15.4 (7.9-27.0) 36.0 (23.2-53.5) 
.  
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7.2.4 Quantitative results on the burden of HPV based screening 
Direct referral to colposcopy after an HPV result leads to highly increased colposcopy rates, 
while HPV testing with cytology triage does not (shown from data of RCTs). Based on 
models 5 yearly HPV based screening with cytology triage will lead to fewer colposcopies / 
1000 women than 3 yearly cytology based screening. In addition partial genotyping for HPV 
16/18 to triage women for immediate colposcopy was recommended based on data from 
cohort studies. 
The number of positive primary screening test results per screening round is higher with 
HPV than with cytology testing. This may be compensated over the lifetime of women by 
longer screening intervals. 
Only limited data are available for psychosocial effects of positive primary screening results 
with HPV versus cytology. No data are available on the inconvenience of more frequent 
testing, or the amount of physical damage from biopsies taken and treatment of 
precancerous lesions. 
 
7.2.4.1 Colposcopy Rates from RCTs and cohort studies 
 
Several systematic reviews and meta analyses stated that RCTs were deficient in the 
reporting of follow up events such as colposcopies, biopsies, treatments and adverse events 
[43, 44, 46, 65, 67, 68]. Some analysis was possible however to estimate the burden of 
screening with HPV compared to cytology: 
 
In NTCC with direct referral to colposcopy after every positive HPV result 3 systematic 
reviews [45, 66, 68] reported that colposcopy rates were much higher in the intervention than 
in the control group. 
Schiffman [52] judged that based on the data from the KPNC cohort direct referral to 
colposcopy would double the colposcopy rate from current practice. (Current practice in the 
US with 5 yearly cotesting refers HPV positive / cytology negative women to retesting after 
one year). Massad [54] argued that based on KPNC, direct referral to colposcopy for these 
women is not necessary as the risk to develop CIN3+ over 5 years is lower than 5%. 
Therefore Massad agrees that retesting of HPV positive/ cytology negative women after one 
year is indicated. 
 
In RCTs where HPV positive women were followed up with cytology triage and 
retesting after 1 year if cytology negative, a less consistent picture emerged: 
Whitlock [68] reported that in the Finnish trial FPHT, where HPV testing with cytology triage 
was applied, colposcopy referrals were not elevated (0.9% vs 1.0% in the control group). 
However Whitlock criticized that only initial colposcopy rates were reported and may not 
show the full picture. Whitlock found that in POBASCAM [17] and ARTISTIC [3] the reported 
cumulative colposcopy rates were slightly higher in the cotesting group than in the cytology 
group (3.4% vs 2.8% in POBASCAM and 6.0% vs 4.9% in ARTISTC). 
 
Patanwala [66] tried to calculate colposcopy rates in round 1 per CIN3+ case detected for all 
studies and found that rates were significantly elevated in ARTISTIC (5.4 colposcopies in the 
intervention arm, 4 in the control arm p<0.01), while in the other studies rates were not 
significantly higher in the intervention group. 
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Numbers of biopsies taken in RCTs were analyzed only in the study of Ronco [39], which 
followed up all women participating in the RCTs NTCC, ARTISTIC, Swedescreen and 
POBASCAM. Ronco et al. were able to retrieve the number of women who had biopsy over 
the entire period of observation. They found that in ARTISTIC, Swedescreen and 
POBASCAM where HPV testing was followed by cytology triage, biopsy rate ratios in the 
intervention and control groups were comparable (pooled rate ratio 1.02 (0.97-1.07) with no 
heterogeneity). However in NTCC, where women of 35 years and older (NTCC1) or even 
women of all ages (NTCC2), were transferred to colposcopy after a single HPV positive test, 
the relative rate of women with biopsies was increased twofold in the intervention arm versus 
the control arm. 
 
A partial genotyping strategy where HPV 16/18 positive women are followed up with 
immediate colposcopy was indicated based on cohort study results from KPNC, 
VUSAscreen and ATHENA. They show that the risk of developing CIN3+ over the next 3 
years is higher for HPV16/18 positive/ cytology negative women than for those positive for 
other hrHPV types and positive for cytology.  
Based on cohort studies 3 systematic reviews [54, 56, 64] recommend the strategy of partial 
genotyping with direct colposcopy for HPV16/18 positive results and retesting after one year 
for women positive for other HPV strains and cytology negative. 
 
7.2.4.2 Colposcopy Rates from modelling 
Several systematic reviews came to the conclusion that the calculation of benefits and 
harms (in terms of colposcopy rates), can only be done by modelling.  
Colposcopy rates in the first screening round were typically higher in the intervention arm, in 
line with increased detection of precancerous stages [45]. What is of interest for a screening 
strategy for a health system and for the affected women, is the overall number of 
colposcopies done during the life time of each woman. As HPV based screening allows 
longer screening intervals, increased rate of colposcopies per screening round can be 
counterbalanced by reduction of number of screening rounds. 
Modelling studies were referred to by 4 systematic reviews [51, 56, 67, 85]. 
 
Saslow [67] Moyer [51] (and ACOG by making reference to Saslow), make reference to a 
modelling study of Kulasingam [86] in the context of clinical guidance development for the 
US health system. This modelling study comes to the conclusion that the number of 
colposcopies per 1000 women will be lower with HPV based screening algorithms with a 5 
year screening interval than with a cytology only based screening interval every 3 years. The 
same result was achieved using test performance data from three different studies [6, 87, 
88].  
 
Huh [64] makes reference to a modelling study done based on the data from the industry 
sponsored ATHENA cohort study. In this modelling study it was expected that the number of 
colposcopies per CIN3+ case detected would be lower with HPV testing with partial 
genotyping for HPV16/18 than with cytology [89]. 
The US-FDA came to the conclusion that partial genotyping for HPV 16/18 with direct 
referral to colposcopy and cytology triage for other hrHPV types detected more disease 
cases when compared with cytology based screening, with fewer colposcopies and 
approximately the same number of screening tests   
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7.2.4.3 Recommended HPV based strategies based on RCTs, cohort studies and 
non-health economic modelling 
In order to minimize the number of unnecessary colposcopies a number of 
recommendations were made in the systematic reviews or meta analyses. These are 
presented in the following paragraphs: 
 
Colposcopy after every HPV positive result is not recommended by any of the systematic 
reviews or meta analyses.  
 
Five yearly HPV testing with cytology triage is recommended by 3 systematic reviews based 
on modelling studies [51, 56, 67]. In this strategy colposcopy is only indicated if HPV positive 
women are also cytology positive. If women are HPV positive /cytology negative retesting 
after one year is recommended. 
 
Partial genotyping for HPV16/18 and referral to colposcopy if positive was recommended by 
3 systematic reviews [54, 56, 64]. 
 
Patanwala [66] did not make a recommendation on triage and colposcopy strategies. In 
contrast to the other systematic reviews or meta analyses, they interpreted that only in 
NTCC with direct referral to colposcopy after an HPV result, was the sensitivity of HPV 
testing higher than with cytology testing over 2 screening rounds. This was based on the fact 
that with other strategies the cumulative CIN3+ incidence rates of 2 screening rounds was 
not increased [66] (as discussed in chapter 7.2.2). 
 
The German study by IQWIG [46, 65] also did not make any recommendation on HPV based 
testing as they found the evidence for potential harms insufficient and the ideal strategy to 
follow up on positive HPV results unclear based on the RCT results. The authors questioned 
whether the results of the RCTs would be transferable to the German context as treatment 
recommendations in Germany are different from the practice applied in the RCTs. 
7.2.4.4 Number of positive primary screening test results 
The systematic review of Rebolj [48] focused on the lower specificity of the HPV test 
compared to cytology and analyzed how many women will be diagnosed with a false positive 
screening result from their primary cervical screening test, if this test is HPV versus cytology. 
A “false positive” screening result in this study is defined as the result of any primary 
screening test that leads to either retesting, triage testing of a secondary screening test or 
colposcopy and/ or biopsies, but is not associated with CIN3+. With the definition used in 
this study the frequency of false positive tests was increased with HPV testing in women 
above 30 years in the studies POBASCAM, Swedescreen and NTCC by a factor or 2 to 4, 
whereas it was not increased in ARTISTIC and lower in FPHT. Rebolj proposed that the 
latter was a result of the lower specificity of cytology testing in ARTISTIC and FPTH due to 
lower cut off values. Rebolj recommended counterbalancing the total number of false 
positive results in a woman’s lifetime by applying longer screening intervals. 
7.2.4.5 Psychosocial Aspects 
Three systematic reviews make reference to studies targeted specifically at the reaction to a 
positive HPV result [49, 56, 68]. Different to a cytological test result, a HPV infection has the 
connotation of a sexually transmitted disease and may involve stigma leading to insecurity in 
sexual behaviors and questions about relationships. Cuzick mentioned that women from 
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particular ethnic and religious backgrounds express fears that community leaders could be 
less supportive of cervical screening if they were aware of the link with sexual transmission 
[49]. Whitlock made reference to a study on 4104 women in the UK and Australia that 
showed increased levels of immediate anxiety and distress in women who tested positive for 
HPV compared with those who tested negative. This difference was resolved by 6 months 
follow up [68].  
No data were shown whether the amount of distress is different after a positive HPV result 
than after a positive cytology result. 
 
The other systematic reviews and meta analysis either did not address psychosocial aspects 
or found that available data from RCTs were insufficient. 
 
Inconvenience of more frequent testing or the absolute number of screening tests / women 
were not addressed in the systematic reviews or meta analyses.  
 
7.2.4.6 Physical damage from biopsies or treatment of precancerous lesions 
No data were reported on this topic in any of the meta analyses or systematic reviews. In 
general reporting from RCTs on potential downstream issues of follow up diagnostic tests 
and treatment were found to be insufficient. 
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7.3 Details from HTAs and health economic studies 
All extracted details from HTAs and health economic studies are shown in the Appendix in 
Table 10. Results from HTAs and health economic studies relevant for clinical effectiveness 
and the burden of screening are compiled in Table 5. The relevant information from these 
tables will be discussed in the following chapters. 
 
Thirteen health economic publications had sufficient detail of result reporting and had a 
comparator of at least 3 yearly cytology testing and so were included in the quantitative 
analysis for research questions 1a, b and c [2, 28-30, 32-37, 60, 75, 76]. One publication is 
an English publication of the central results from a German HTA. The 2 publications are 
henceforth referred to as 1 study [30, 60]. 
 
Eleven of 12 studies modelled the natural history of cervical cancer from HPV infection over 
the development of precancerous lesions to cervical cancer and successful treatment or 
death. Models were typically calibrated to reflect HPV prevalence and cancer incidence in 
the country the study was done for. The health economic study in the HTA from Belgium [28] 
used a different approach by directly simulating patterns of detection of precancerous 
lesions and cancer according to results of a meta analysis done from the European RCTs 
[28, 44] in a hypothetical cohort screened with 3 yearly cytology testing and another cohort 
screened with 5 yearly HPV based testing [80]. 
 
Modelled screening strategies include cytology only, cytology with HPV triage, HPV with 
direct referral to colposcopy, HPV with cytology triage, HPV with partial genotyping for 
HPV16/18 and cotesting. Different screening frequencies for the primary screening rounds 
and different frequencies for retesting after HPV+/cyt- results were also modelled. 
 
7.3.1 Protection against cervical cancer, life years gained and QALYs 
In all 12 studies HPV based screening strategies were more effective than cytology based 
screening. HPV with cytology triage was the most studied strategy. In 4 studies HPV based 
screening with partial genotyping for HPV16/18 was analyzed and found even more 
effective. Results on cotesting and on HPV with direct referral to colposcopy are less 
consistent between studies.  
 
Summary effects were typically measured in LYG or QALYs. Effects were discounted with 
discount rates between 1.5% and 5%. Only one study did not discount effects [36]. As 
effects in discounted life years or QALYs are small and not intuitive to understand, and 
undiscounted life years or QALYs were typically not shown, in addition effects in more 
illustrative measures such as % reduction in cancer risk or reduction in cancer incidence 
rates are shown in the summary from health economic studies in Table 5, if they were 
available. 
 
In all 12 health economic analyses, HPV based screening strategies were more effective 
than cytology based screening as measured in LYG, QALYs, reduction of cancer incidence 
rates, reduction of life time cancer risk and number of cancer cases (depending on which 
effect measures were reported). 
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The most often studied strategy was HPV with cytology triage. Other investigated strategies 
were cotesting, HPV testing with direct referral to colposcopy and HPV testing with partial 
genotyping for HPV16/18. 
 
Quantitative results of cotesting compared to HPV based testing alone or with HPV with 
cytology triage were shown in 5 studies [29, 30, 33, 36, 37, 60]. In 2 additional studies 
cotesting was modelled, but dominated in the economic analysis and no detailed numbers 
on effectiveness markers provided [2, 35]. 
Three of the 5 studies showed the same clinical effectiveness for cotesting as for HPV with 
cytology triage [29, 30, 33, 60]. In these cases the follow up algorithm after HPV and 
cytology results was similar to that after HPV with cytology triage.  
In the other 2 studies cotesting was more effective [36, 37]. In one of these two, positive 
results of either HPV or cytology were followed up directly with colposcopy. In the other one 
HPV positive/ cytology negative women were followed up with retesting [36]. 
 
One study compared only cotesting with cytology based screening. In this study 3 cotesting 
screening events in a woman’s lifetime at the age of 32, 41 and 50 were more effective than 
3 yearly cytology at the age 32-50 years followed by 5 yearly cytology until the age of 60 
[75]. 
 
“HPV testing only” was modelled in 3 studies. No clear picture emerges from these three 
studies. In one study HPV positive women were directly referred to colposcopy, which was 
more effective than HPV with cytology triage [33]. In one study follow up after positive results 
was not clearly described. In this study “HPV only” yielded slightly lower QALY numbers than 
HPV with cytology triage and the same reduction of cancer risk with 3 yearly screening and 
slightly higher reduction of cancer risk with 5 yearly screening [76]. In the 3rd study the 
strategy named “HPV only” was in fact rather a “HPV with cytology triage” strategy as 70% 
of the women with positive HPV results received cytology or cotesting as triage and only 
23% were directly referred to colposcopy (according to the description of the strategy). In 
this study not surprisingly “HPV only” had similar effectiveness as HPV with cytology triage 
[30]. 
 
HPV with genotyping for HPV16/18 was modelled in 4 studies and was always the most 
effective strategy regardless of whether it was measured in LYG, QALYs or cancer incidence 
rates [2, 29, 36, 37]. This strategy showed higher colposcopy rates in 3 of the 4 studies and 
a modest increase in 1 study [37]. The latter study calculated that the number of 
colposcopies per detected CIN3+ was lowest with HPV16/18 genotyping compared to all 
other strategies. 
 
For transparency on excluded studies it should be noted that of the 5 studies that were 
excluded from this quantitative analysis because they either lacked detailed enough result 
reporting or only 5 yearly cytology as comparator, all but one also showed that HPV based 
testing was more effective than cytology based testing. In one study results were only shown 
in a graphical representation and HPV based screening yielded fewer QALYs than cytology 
based screening. No detailed analysis of this result was possible and the result was not 
discussed in the publication [78].  
Another excluded study (de Kok [80]) aimed at simulating screening scenarios for different 
countries with varying background risks for cervical cancer and HPV prevalence. In this 
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model, HPV based testing was also more clinically effective than cytology based screening if 
applied at the same or lower frequencies. However only results for certain cost effective 
strategies are shown in the publication. 3 yearly cytology based screening was not among 
the strategies that were cost effective under the assumed Swiss scenario conditions, 
therefore no quantitative clinical and cost results were reported for this strategy. A general 
description of the study and results are included in Table 10. 
7.3.2 Surrogate Markers CIN2+ and CIN3+  
The detection rate of surrogate markers CIN2+ or CIN3+ were typically not reported in the 
health economic models. 
7.3.3 Longer Screening Intervals with HPV vs Cytology 
Screening intervals can be increased from 3 yearly to 5 yearly screening when switching 
from cytology to HPV based screening based on the results of all 6 studies that compared 
these frequencies with slightly higher numbers for LYG, QALYs and lower numbers for 
cancer incidence rates, cancer case numbers or life time cancer risk. 
 
Five yearly HPV testing was more effective than 3 yearly cytology based testing in all 6 
studies that addressed this question [28, 30, 32, 34, 35, 60, 76], and more effective than 2 
yearly cytology based testing in 1 additional study [29]. 
Three yearly HPV testing was more effective than 3 yearly cytology based testing in 2 
studies [29, 33] and more effective than 2 yearly cytology based testing in 1 study [36]. 
Six yearly HPV testing was modelled in 2 studies and was found more effective than current 
cytology based screening with 3 yearly frequencies up to 49 years followed by 5 yearly 
screening in one study [2] and less effective than 3 yearly cytology based screening in the 
other study [32].  
One study found that 3 cotesting screening events in a woman’s lifetime were more effective 
than 3 yearly cytology based testing from age 32-50 and 5 yearly cytology between 50 and 
60 years [75]. 
 
The differences between 5 yearly HPV based screening versus 3 yearly cytology based 
screening measured as reduction of cancer risk ranged from 0.2% -11%. Bigger differences 
were reported, when the same screening frequency was compared between strategies.  
7.3.4 Potential burden of HPV based Cervical Cancer screening  
7.3.4.1 Number of colposcopies  
Only 4 studies reported quantitative results for numbers of colposcopies. Strategies with 
higher clinical effectiveness typically also had higher colposcopy rates. HPV with cytology 
triage led to similar or modestly increased colposcopy rates (consistent from all 4 studies), 
while HPV16/18 genotyping showed higher colposcopy rates in 3 of the 4 studies and 
modest increase in 1 study. The latter study calculated that the number of colposcopies per 
detected CIN3+ was lowest with HPV16/18 genotyping compared to all other strategies. 
HPV with direct referral to colposcopy showed very high colposcopy rates (1 study). 
 
The potential burden of screening was addressed in 4 studies by reporting colposcopy 
numbers [2, 29, 33, 37]. 
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MSAC showed that HPV with cytology triage had slightly elevated colposcopy rates 
compared to cytology with HPV triage (4-7%) accompanied with higher clinical effectiveness. 
Cotesting had higher colposcopy rates than HPV with cytology triage with the same clinical 
effectiveness in terms of cancer incidence rates. HPV 16/18 genotyping resulted in even 
higher colposcopy rates (21-24%), however with higher clinical effectiveness in terms of 
cancer incidence rates and life years [29]. 
 
Kitchener showed that 6 yearly HPV with cytology triage had similar colposcopy rates as 
LBC with HPV triage (3 yearly from 25-49 years, then 5 yearly) (-4% up to +10% depending 
on details in the follow up). 6 yearly genotyping for HPV16/18 resulted in higher colposcopy 
rates (26-50%) with the highest clinical effectiveness [2]. 
 
Vijayaraghavan showed colposcopy rates for cytology only strategies between 170-
700/100’000 women, 3 yearly HPV with cytology triage or cotesting had slightly higher rates 
of 830 and 3 yearly HPV only with direct referral to colposcopy much higher rates of 
2000/100’000 women [33]. 5 yearly HPV with cytology triage was not modelled.  
 
Huh showed that 3 yearly HPV with cytology triage had slightly higher colposcopy rates than 
3 yearly cytology with HPV triage 2’339 versus 2’104/100’000 women/year. HPV16/18 
genotyping in this study had colposcopy rates between cytology with HPV triage and HPV 
with cytology triage (2’159). Cotesting had the highest colposcopy rates (2’967). 
In this study colposcopies / CIN3+ were calculated and were lowest for HPV 16/18 
genotyping (3.06) followed by HPV with cytology triage (3.95), cytology with HPV triage 
(4.76) and cotesting (4.79) [37]. No 5 yearly strategies were modelled; therefore no 
comparison of colposcopy rates of 5 yearly HPV based screening with 3 yearly cytology with 
HPV triage is available. 
7.3.4.2 Number of false positive results  
One study modelled the number of false positive results [34]. Unfortunately there is no clear 
definition of “false positive” in the publication. It is assumed for this thesis that a false 
positive result is a screening result that will lead to further observation, however upon follow 
up will not be associated with precancerous lesions. 
In this study 3 yearly and 5 yearly HPV with Pap triage had much lower numbers of false 
positive test results than 3 yearly Pap testing (5’585 and 2’871 versus 20’529). 2 yearly 
cotesting had the highest false positive result numbers (82’340). 
7.3.4.3 Use of QALYs 
QALYs are used in cost utility studies to differentiate between the value of a year of life in 
perfect health and a year of life with different degrees of illness. Life years are thereby 
adjusted by different factors (“utilities”) depending on the degree of physical, emotional or 
mental impairment associated with the disease and / or intervention under investigation. 
Therefore the use of QALYs has the potential to reflect the burden of screening if utilities are 
calculated for all aspects of screening that may reduce the quality of life of the participating 
women. 
 
In total QALYs were used by 6 studies. The applied sets of utilities varied between the 
studies and QALYs typically did not reflect all possible disutilities associated with screening 
strategies [29, 33, 35-37, 76]. 
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Two studies of the 6 associated disutilities (utility factors of less than 1) only with cancer [35, 
76]. 
Three assigned disutilities to precancerous lesions. In these studies HPV based screening 
strategies were still more effective than cytology based screening strategies [33, 36, 37]. 
 
Only one study associated disutilities with the experience of being screened regardless of 
the results. This was based on a recent study in Australia which was specifically designed to 
obtain weights relevant to cervical screening and HPV vaccination in an age-representative 
sample of women invited for screening. This set of QALYs was also the only one which 
associated disutilities with colposcopies. Using these utilities HPV based screening with 
genotyping and HPV based screening without genotyping had the same effectiveness [29], 
while measured in life years, HPV based screening with genotyping had been more 
effective. This is likely due to the higher colposcopy rate associated with this strategy. 
 
The other studies refrained from using QALYs due to the perceived limited evidence around 
utility generation or because specific utility sets were missing for the country the study was 
concerned with. 
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Table 5: Comparison of the clinical effectiveness and burden of the most important screening strategies modelled in HTAs and health economic studies 
Study, Country 
 
Cytology based testing HPV only or HPV with cytology triage HPV testing with HPV16/18 genotyping Cotesting 
MSAC 
2014 
Australia [29] 
 
All cytology based screening 
strategies were less effective 
than all HPV based 
strategies 
5 yearly HPV with cytology triage is more 
effective in reducing cancer incidence than 
cytology only or cytology with HPV triage at 
higher frequency at 25-49 years with modestly 
higher colposcopy rates 
5 yearly HPV with HPV 16/18 genotyping yielded 
the best result in terms of LYG and cancer 
incidence rate, however with higher colposcopy 
rates 
Cotesting 5y has the 
same effect as HPV 
with cytology triage 
but with higher 
colposcopy rates 
 Current practice in Australia is 2-yearly Pap test with Pap retest. The closest 
comparator to Swiss screening is cytology with HPV triage with 3 yearly 
testing from 25 to 49 and 5-yearly testing from 50-65 and an exit test at age 
69 (“IARC” frequencies). 
 
 
 
 
Strategies cancer incidence  discounted 
 ASR/100’000 life years 
1. Current practice 2y 6.9 not shown 
2. Cytology only IARC 7.6 21.62678 
3. Pap +HPV triage IARC 6.2 21.6276 
4. LBC + HPV triage IARC 6.1 21.62764 
5. HPV + cyt triage 5y 5.8 21.62779 
6. HPV16/18 genotyping 5y 5.7 21.62792 
7. Cotesting 5y 5.8 21.62783 
 
If QALYs were compared, with “QALY set 1” HPV with genotyping has 
similar effectiveness as HPV without genotyping. This QALY weight set 
used a new set of weights from a study conducted in metropolitan Sydney, 
which was specifically designed to obtain weights relevant to cervical 
screening and HPV vaccination in an age-representative sample of 
women invited for screening. This set of weights assigned some disutility 
to the experience of being screened, even if the test result was negative. 
 
Burden of screening as measured in colposcopies:  
Strategies number of colposcopies   
1. Current practice 2y reference 
2. Cytology only IARC -12% 
3. Pap +HPV triage IARC +13% 
4. LBC + HPV triage IARC +16% 
5. HPV + cyt triage 5y +20% 
6. HPV16/18 genotyping 5y +37% 
7. Cotesting 5y +33% 
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Study, Country 
 
Cytology based testing HPV only or HPV with cytology triage HPV testing with HPV16/18 genotyping Cotesting 
Kitchener et al. 
2014 
UK [2] 
 
LBC with HPV triage was 
less effective than any HPV 
based strategy 
6 yearly HPV with LBC triage was more 
effective than cytology based testing at 
moderately higher colposcopy rates  
6-yearly HPV based testing with HPV 16/18 
genotyping was more effective than strategies 
without genotyping, however at higher colposcopy 
rates 
No results are 
shown for cotesting 
as it was dominated 
in the cost 
effectiveness 
analysis 
 The burden of screening was addressed by showing colposcopy rates. Strategies with HPV with LBC triage had lower or slightly elevated colposcopy rates 
compared to current practice., whereas strategies with HPV16/18 genotyping elevated colposcopy rates by 26 to 50%. 
 
Strategy coded as follows: Strategy Code, months follow up after negative triage test, age of switch from cytology to HPV based strategy if strategy was not 
applied from 25 years on.  (CP) current practice =, 3-yearly from 25-49 years, then 5-yearly. All HPV based strategies shown had a frequency of 6 yearly 
 
strategy code  
Life 
years 
Increase of 
colposcopies vs CP 
 CP LBC with HPV triage 26.2307   
 S1 24m 30y HPV with LBC triage 26.2308 1% 
 S2 24m HPV with LBC triage (immediate) and HPV 16/18 genotyping (after 24 months) for women 
who were HPV pos/ cyt neg 
26.231 -4% 
 S2 24m 30y HPV with LBC triage (immediate) and HPV 16/18 genotyping (after 24 months) for women 
who were HPV pos/ cyt neg 
26.231 10% 
 S3 24m HPV with HPV 16/18 genotyping 26.2316 26% 
 S1 12m HPV with LBC triage 26.2317 10% 
 S2 12m HPV with LBC triage (immediate) and HPV 16/18 genotyping (after 24 months) for women 
who were HPV pos/ cyt neg 
26.232 26% 
 S3 12m HPV with HPV 16/18 genotyping 26.2323 50% 
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Study, Country 
 
Cytology based testing HPV only or HPV with cytology triage HPV testing with HPV16/18 genotyping Cotesting 
Huh, 2015, USA 
[37] 
Cytology with HPV triage 
was less effective than HPV 
based testing  
HPV with cytology triage was effective than 
cytology based testing 
HPV16/18 genotyping was more effective than 
cytology triage and resulted in the lowest 
colposcopy rate / CIN3+ detected 
Cotesting was less 
effective than 
HPV16/18 
genotyping with 
higher colposcopy 
rates 
 3 yearly HPV testing with HPV16/18 genotyping yielded the most Life-years (LY), the most QALYs and the lowest mortality (not shown). 
 
Strategy (3 yearly) LY QALY Colposcopies/ 100’000 women / year colposcopies /CIN3+ 
 cytology + HPV triage =  37.978 22.856 2.104 4.76 
 HPV + cytology triage =  37.981 22.866 2.339 3.95 
 cotesting  =  37.982 22.868 2.967 4.79 
 HPV + 16/18 genotyping =  37.984 22.874 2.159 3.06 
 
Burden of screening: HPV testing with genotyping increased colposcopies only slightly compared to cytology with HPV triage and less than HPV testing 
with cytology triage and cotesting. HPV testing with genotyping had the lowest number of colposcopies per CIN3+. 
QALYs: Disutilities were assigned to CIN1,2,3 and cervical cancer, however not to screening itself, or being in triage after an initial positive screening test 
Vijayara-ghavan et 
al. 
2010 
USA [36] 
 
2 yearly cytology based 
screening  was less effective 
than any 3 yearly HPV based 
screening strategy 
3 yearly HPV with cytology triage was more 
effective than 2-yearly cytology  
HPV with 16/18 genotyping and cotesting with 
16/18 genotyping was more effective than HPV 
with LBC triage 
3 yearly cotesting 
with HPV 16/18 
genotyping was the 
most effective 
strategy 
  
Strategies cancer  QALYs 
 incidence 
 LBC (2y) 9.17 28.6623 
 LBC with HPV triage (2y) 8.56 28.6651 
 HPV with LBC triage (3y) 7.86 28.6670  
 co- testing (3y) 7.49 28.6714 
 HPV with genotyping (3y) 7.57 28.6725 
 co- testing. + genotyping (3y)  6.62 28.6745 
 
 
The burden of screening was only addressed by using QALYs.  
Disutilities were assigned to CIN and cancer not to being screened per se or 
to being in triage after positive test result.  
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In the following studies no genotyping strategy was included 
Study, 
Country 
Cytology based testing HPV only or HPV with cytology triage Cotesting 
Sroczynski 
et al.  
2010, 2011 
Germany 
[30, 60] 
 
3 yearly cytology was less effective than any HPV 
based strategy 
 
Life Years  
 
% reduction  
cancer risk 
28.869 70% 
 
3 yearly HPV based testing had higher effectiveness than 3 yearly cytology  
5-yearly HPV based testing had similar effectiveness than 3 yearly cytology  
 Life Years % reduction  
cancer risk 
3 yearly 28.875 85% 
5 yearly Not shown 72% 
 
Same effect 
as HPV with 
Pap triage 
The burden of screening was not modelled (no numbers of colposcopies were calculated, no QALYs were used). 
Arbyn et 
al. 
2015 
Belgium 
[28] 
 
3 yearly cytology with HPV triage was less effective 
than 5 yearly HPV with cytology triage 
 
Life Years  
 
# of cancer 
cases 
3’658’751 462 
 
 
 
5-yearly HPV testing was more effective than 3 yearly cytology 
 
 
5 yearly HPV 
with cytology 
triage 
Life Years # of cancer 
cases 
3’660’369 222 
 
Not assessed 
The burden of screening was not modelled (no numbers of colposcopies were calculated, no QALYs were used). 
Accetta et 
al. 2010 
Italy 
[76] 
 
3 yearly Pap testing with HPV triage was less effective 
than HPV based testing 
 
 
 
 
 QALYs  
 
% reduction  
cancer risk 
3y Pap 29.42822 52.9 
3y Pap with 
HPV triage  
29.42803 49.5 
 
Compared to Pap test only or to 3-yearly Pap test with HPV triage,  
3 yearly or 5 yearly HPV with Pap triage was more effective in reducing life time risk of 
cancer.  
3-yearly HPV test only reduced the risk of cancer to the same level but yielded fewer 
QALYs than HPV with Pap triage. 
 QALYs  
 
% reduction  
cancer risk 
3y HPV/PAP triage 29.43048 56.0 
3y HPV only  29.43042 56.0 
5y HPV/PAP triage 29.42991 55.0 
5y HPV only  29.42958 53.7 
 
Not assessed 
The burden of screening was partially addressed by using QALYs. However, no disutilities were assigned to screening itself, colposcopies, being in triage or being 
treated for CIN. 
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Study, 
Country 
Cytology based testing HPV only or HPV with cytology triage Cotesting 
Burger et 
al. 2012 
Norway 
[32] 
 
3 yearly cytology testing with cotesting triage was less 
effective than 5 yearly HPV based testing 
 
 
 
 
 
 Life Years  
 
% reduction  
of cancer  
3 y Cytology with 
cotesting triage 
32.9502 55.45 
   
 
3, 4, or 5 yearly HPV with cotesting triage was more effective than 3 yearly cytology  
6-yearly HPV with cotesting triage was less effective than 3 yearly cytology  
 
Strategies coded by yearly frequency, Primary screening test, months to rescreen 
triage negative women, colposcopy after three HPV+/cyt- results if not otherwise 
mentioned 
Strategy (all with cotesting triage) Life Years 
 
% reduction  
of cancer  
HPV 6y, 12m  32.9500 55.59 
HPV 5y, 12m  32.9510 58.82 
HPV 4y, 12m 32.9524 63.44 
HPV 4y, 6m  32.9529 65.26 
HPV 3y, 6m  32.9542 70.22 
HPV 3y, 6m, colposcopy after 1 repeated 
HPV+/cyt- 
32.9543 70.49 
 
Not assessed 
The burden of screening was not modelled (no numbers of colposcopies were calculated, no QALYs were used). Some burden (women ’s time and productivity 
loss was translated into cost and has influenced the cost effectiveness of strategies (see cost effectiveness results) 
Goldhaber-
Fiebert et 
al. 2008 
USA [35] 
 
3 yearly cytology based testing was less effective than  
5 yearly HPV based testing  
 
 
 
 
 QALYs  
 
% reduction  
of cancer risk 
3 y Cytology with 
HPV triage 
26.72766 61.5% 
 
  
5 yearly HPV with cytology triage is slightly more effective than 3 yearly cytology with 
HPV triage  
3 yearly HPV with cytology triage is much more effective  
Strategies are coded as follows: 
Start age with cytology, switch age, strategy after switch, frequency in years,   
Strategy  % reduction QALYs 
 cancer risk 
25, 35, HPV with cyt triage, 5y 61.6% 26.72609 
25, 30, HPV with cyt triage, 5y 62.3% 26.72733 
25, 35, HPV with cyt triage, 3y 70.7% 26.73237 
25, 30, HPV with cyt triage, 3y 71.5% 26.73344 
As this 
strategy was 
either 
dominated in 
the cost 
effectiveness 
analysis or at 
an ICER 
<3Mio$/QALY 
no data were 
shown  
The burden of screening was not directly addressed apart from time and travel cost of women for screening, diagnostic follow up and treatment. No numbers of 
colposcopies were compared between studies. QALYs had no disutilities assigned to screening, being in triage or being treated for CIN2/3. 
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Vijayara-
ghavan et 
al. 
2010 
Canada 
[33] 
 
3 yearly cytology with HPV triage was less effective 
than HPV based strategies  
 
Screening 
Strategy 
Annual 
Cancer 
Incidence 
QALY 
No screening 1’282 17.7817  
Cytology only 3y 339 17.8196  
Cytology+HPV 
triage 3y 
291 17.8215  
 
3 yearly HPV with direct referral to colposcopy was most effective  however at 2 times 
higher colposcopy rates (2’000 per 100’000 women) 
3 yearly HPV with cytology triage was more effective than cytology with HPV triage 
with moderately increased colposcopy rates (830 /100’000 women) 
Screening 
Strategy 
Annual 
Cancer 
Incidence 
QALY 
HPV+cytology 
triage 3y 
163 17.8263  
HPV only 3y 145 17.8272  
 
Cotesting 
was as 
effective as 
HPV with 
cytology 
triage 
The burden of screening was briefly discussed as number of expected colposcopies. QALYs had disutilities assigned to CIN and Cancer stages, but not to 
screening itself, being in triage or follow up.  
The HPV only strategy had the highest colposcopy rates of 2000/100’000 women, while HPV with cytology triage or cotesting had 55-59% fewer colposcopy rates 
(830) compared to cytology based strategies with 160-700 colposcopies 
Kulasingam 
et al. 2009 
Canada 
[34] 
 
The study did not have a comparator of cytology with 
HPV triage with 3-yearly frequency. The closest 
comparator to the Swiss strategy is 3-yearly Pap 
testing. 
 
 Cancer false  
Strategy cases positives 
Pap test only 3y 809 20’529 
 
3 yearly and 5 yearly HPV testing with Pap triage starting at 25 years were more 
effective than 3 yearly cytology testing  starting at 18 years 
 
 
 Cancer false  
Strategy cases positives 
HPV + Pap triage 3y 467 5’585 
HPV + Pap triage 5y 736 2’871 
 
2 yearly 
cotesting was 
most effective 
(229 cancer 
cases, but 
with 82’340 
false positive 
results) 
Concerning the burden of screening the number of false positive test results (Pap or HPV) was reported. HPV only (with direct referral to colposcopy) and 2 yearly 
cotesting of cytology and HPV (with direct referral to colposcopy if either test was positive) led to disproportionately high numbers of false positive tests  
Bistoletti et 
al. 2008 
Sweden 
 
[75] 
 
 
Three screening events at ages 32, 41 and 50 with 
cytology and HPV cotesting were more effective in 
terms of life years than 9 screenings with cytology (3-
yearly from 32-50, then 5-yearly until age 60). 
Adding HPV testing once at 32 years had no beneficial 
effect.  
 Life years  
1. cytology  29.67 
2. added HPV testing once  29.67 
3. only 3x cotesting  29.69 
Not assessed 3 times 
cotesting 
dominated 9 
times 
cytology 
based testing 
No data on the potential burden of screening (e.g. number of false positive results nor number of colposcopies were reported) nor were QALYs calculated. 
However it is likely that with only 3 screenings the burden of screening is lower or at least not higher than with 9 screenings 
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8 Results Research Question 1b “What is the best Age to start 
Screening with HPV tests in terms of clinical effectiveness and 
cost effectiveness?” 
8.1 Summary Results Research Question 1b 
In the combined follow up of four European RCTs, HPV based screening was found to have 
a strong protective effect in women between 30 and 34, however none in women younger 
than 30 years [39]. In younger women HPV based screening leads to more overdiagnosis 
than in older women [12, 47, 48]. Therefore most clinical systematic reviews and meta 
analyses recommend 30 years as the best starting age for HPV based testing. One 
systematic review considered 25 years based on the recent results of the ATHENA study 
[64]. 
Results on the optimal starting age from health economic studies are ambiguous. Most 
studies point at an optimal starting age of 25 or 30 years from a cost effectiveness 
standpoint and a balance of clinical benefit and burden of screening in terms of colposcopy 
rates. 
8.2 Evidence on research question 1b from Clinical systematic reviews 
and meta analyses 
Table 9 includes an excerpt of answers to research question 1b from clinical systematic 
reviews and meta analyses. The answers, the clinical background for this research question 
and available RCTs are summarized in the following paragraphs. 
 
Screening young women with HPV testing has a different benefit-harm profile than that for 
older women. First, young women have a higher prevalence of regressive HPV infections, 
while in older women HPV infections are more often persistent and present therefore a 
higher risk for subsequent development of cervical cancer [90-92]. Second, for women of 
child bearing age any risk for complications during future pregnancies introduced by 
treatment of cervical lesions with conizations and LEEP must be minimized. 
 
Therefore some RCTs were restricted to women older than 29 years (POBASCAM 29-60 
years, Swedescreen 30-38 years), or they analyzed two age groups of younger and older 
women with partially different screening algorithms (e.g. in NTCC1 women younger than 35 
years who tested positive for HPV but negative with cytology were invited for retesting after 
12-18 months, while women of 35 years and older were sent immediately to colposcopy). 
 
The phase 1 and 2 NTCC studies allowed comparison of HPV based versus cytology based 
screening algorithms between 2 age groups within one study. The authors of the study 
observed a high increase of cumulative detection of CIN2 and CIN3 in younger women and 
conclude that HPV testing in younger women leads to overdiagnosis and overtreatment [12]. 
Based on the data from NTCC the systematic reviews of Murphy [45] and Arbyn [44] state 
that HPV based testing in the age group between 25 and 34 will lead to higher detection of 
regressive CIN2. 
 
The study of Ronco [39], which followed up all women participating in the RCTs NTCC, 
ARTISTIC, Swedescreen and POBASCAM, analyzed how many invasive cancer cases were 
detected per age group. They showed that the effect of reduced numbers of invasive cancer 
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was strong in women of 30-34 years at screen entry with 5/117’345 invasive cancer cases in 
the intervention group versus 15/102’598 in the control group. The protective effect of HPV 
based screening in these women was at least as high as in older women. Ronco et al. 
therefore conclude that screening with HPV testing should commence in women of 30 years. 
No protective effect was observed in women below 30 years at entry. In almost 90’000 
women of this age group there were in total 5 cancer cases observed, of which 3 were in the 
intervention arm.  
 
The systematic review of Rebolj [48] focused on the lower specificity of the HPV test 
compared to cytology and analyzed how many women will be diagnosed with a “false 
positive” screening result from their primary cervical screening test if this test is HPV versus 
cytology. A false positive screening result in this study is defined as the result of any primary 
screening test that leads to either retesting, triage testing of a secondary screening test or 
colposcopy and/ or biopsies, but is not associated with CIN3+. With the definition used in 
this study the frequency of false positive tests is increased with HPV testing at all ages, 
however the effect is more prominent in younger women than in women of 30 years and 
older (mostly based on the results of NTCC). The study comes to the conclusion that it is 
favorable to refrain from screening with HPV before the age of 30. 
 
Pileggi [47] performed an analysis of the relative specificity and relative PPV of HPV based 
screening versus cytology based screening and found that over all age groups the relative 
specificity and PPV of HPV based screening was lower than with cytology based screening. 
For women of 30 years and older however, relative specificity and relative PPV were similar. 
 
In contrast to the other systematic reviews, Huh considers starting HPV based screening at 
age 25 based on the results of the ATHENA cohort study that included women of 25 years 
and older [5, 64]. In ATHENA, approximately 30% of CIN3+ cases were found in women 
between 25 and 29 years of age. More than half of the women 25– 29 years of age with 
CIN3+ were found to have normal cytology. Starting HPV based screening with genotyping 
for HPV16/18 and reflex cytology for women with other hrHPV genotypes at 25 years of age, 
doubled the number of colposcopies but resulted in a 54% greater detection of CIN3+ when 
compared to the same strategy starting at 30 years of age [64]. 
 
Six further systematic reviews or meta analyses made a statement that HPV based testing 
should be restricted to women of 30 years and older based on existing current US screening 
guidelines and/ or the thought that in younger women HPV infections are more often 
transient than in older women [51, 52, 56, 67, 68]. 
 
This research question was not addressed by 4 systematic reviews or meta analyses [43, 
46, 49, 65, 66]. 
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8.3 Evidence on research question 1b from HTAs and Health Economic 
Studies 
Table 10 in the Appendix includes an excerpt of answers to this research question from 
HTAs and health economic studies. The answers are summarized in the following 
paragraphs. 
 
Only 6 health economic studies addressed the research question about the optimal age to 
start HPV based screening.  
 
When a starting age of 30 or older was compared, there was a tendency to favor the 
younger age as a starting age. Goldhaber-Fiebert found that 30 years is more cost effective 
than 35 years [35] and Berkhof found that 31 years dominated 34 years [79]. In the study of 
Kitchener, 30 years dominated 35 years [2], while van Rosmalen found 32 years as the 
threshold for cost effectiveness [31]. 
 
When starting ages below 30 years were analyzed, 3 studies came to the conclusion that 
younger ages are not cost effective: de Kok found screening with HPV below 30 years was 
not cost effective [80], van Rosmalen found screening with HPV below 32 years was not cost 
effective [31] and Goldhaber-Fiebert found 30 years was more cost-effective than 25 years 
[35]. On the other hand Kitchener came to the conclusion that 25 years was more cost 
effective than 30 years, however with elevated colposcopy rates in younger women [2]. 
Kulasingam only compared 25 years and 18 years and favored 25 years as the starting age 
[34].  
 
Two other studies had 25 years at the starting age and did not compare other options [29, 
76].  
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9 Results: Research Question 1c, cost effectiveness of HPV based 
screening 
For this research question 13 health economic publications had sufficient detail of result 
reporting, had a comparator of at least 3 yearly cytology testing and were therefore included 
into the quantitative analysis for research question 1c [2, 28-30, 32-37, 60, 75, 76].  
One paper is an English publication of the central results from a German HTA. The 2 
publications are henceforth referred to as 1 study [30, 60]. 
 
All studies included direct medical costs for the screening test, follow up diagnosis, treatment 
of precancerous lesions and cervical cancer. Some studies included additional costs such as 
cost for travel and time of women, costs for the organization of a screening program 
(invitations, registrations), or other costs as mentioned in the relevant chapters. 
 
All detailed results on the cost and incremental cost effectiveness ratios of all studies and 
relevant strategies are shown in the Appendix in Table 10.  
A condensed overview of the cost effectiveness of the most important strategies is shown at 
the end of this chapter in Table 6. 
9.1 Summary of Health Economic Evidence Questions 1c 
9.1.1 Synthesis cytology based testing 
Cytology based testing was dominated by HPV based strategies in 9 out of 13 studies. In the 
remaining 4 studies cytology was less effective and cheaper. 
 
Cytology based testing was dominated by HPV based strategies in 9 out of 13 studies. In the 
remaining 4 studies cytology was less effective and cheaper. In these cases HPV based 
strategies were either dominant or cost effective at higher ICERs. 
Whether cytology based testing was dominated or on the cost effectiveness frontier 
depended in 1 study on the assumed sensitivity for cytology based testing and in another on 
the price of HPV testing: In the German study [60] 3 yearly cytology based testing was less 
effective but cheaper than HPV based testing (where sensitivity of cytology was taken from 
international studies), but dominated in a scenario with lower sensitivity values for cytology 
as observed in German studies. In Belgium [28] cytology based testing was dominated in the 
base case, and less effective but cheaper when higher HPV test prices were assumed (58 € 
instead of 35 €). 
9.1.2 Synthesis HPV with cytology triage 
HPV with cytology triage is the most researched and most often recommended cost effective 
strategy. 
 
HPV with cytology triage was more clinically effective than cytology based testing if applied 
at the same frequency in 11 out of 11 studies. In 9 out of 9 studies it was also more effective 
or similarly effective if applied at lower frequencies than cytology based testing (e.g. 5 yearly 
instead of 3 yearly). 
In 7 of the 11 studies HPV with cytology triage was not only more effective but also cheaper 
and thus dominated cytology based testing. In 4 studies HPV with cytology triage was more 
expensive with an ICER of 9’000 Euro/LYG (3-yearly [30, 60], Germany), 33’000 Australian 
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$/LYG (5 yearly [29], Australia), 12’300 Canadian $/QALY (3 yearly [33], Canada) and 
51’000 US $/QALY (3 yearly [37], USA). 
9.1.3 Synthesis HPV with partial genotyping for HPV 16 /18 
HPV with partial genotyping for HPV 16/18 was clinically highly effective and always on the 
cost efficiency frontier. In 2 studies it was more effective and had higher ICERs than HPV 
with cytology triage, in 2 studies it dominated (directly or by extended dominance) HPV with 
cytology triage. 
 
HPV with partial genotyping was analyzed in 4 studies. In this strategy women with an initial 
positive result for HPV 16 or 18 are directly transferred to colposcopy and women positive 
for other hrHPV types are referred to cytology triage. 
 
In 2 studies HPV with genotyping was on the cost efficiency frontier with higher ICERs 
compared to HPV with cytology triage of 34’000$/QALY [36] (USA) and 100’000 Australian 
$/QALY [29] (Australia). 
In 1 study HPV with genotyping dominated HPV with cytology triage at an ICER of 7’667 
$/QALY [37] (USA, ICER compared to cytology with HPV triage). 
In the UK study HPV with genotyping had an ICER of 15’000£/LYG or 30’000£/LYG 
depending on the frequency of follow up of HPV+/cyt- women [2] (UK, ICERs against the 
mixed strategy described below).  
 
The UK study [2] in addition evaluated a mixed strategy. In this strategy primary screening 
was done 6 yearly using HPV testing with cytology triage. HPV positive/ cytology negative 
women were retested after 24 months or 12 months with HPV16/18 genotyping. Positive 
women were then directly transferred to colposcopy and women positive for other HPV types 
received cytology triage again. This strategy was also on the cost effectiveness frontier at an 
ICER of 10’000£/LYG (24m follow up) or 20’000£/LYG (12 months follow up). 
In comparison to the strategies of HPV genotyping and the mixed strategy, HPV with 
cytology triage suffered extended dominance [2]. 
 
9.1.4 Synthesis Cotesting 
Cotesting is clinically more effective than cytology based testing, however not cost effective 
when compared to other HPV based strategies.  
 
Cotesting was assessed in 10 studies. 
Cotesting dominated cytology based testing in 2 studies [75, 77], where no other HPV based 
strategy was analyzed. No ICERs could be derived from these two studies. 
When cotesting was compared to other HPV based studies (8 studies), cotesting was 
dominated in 5 out of 8 studies. In the remaining 3 studies cotesting was on the cost 
effectiveness frontier with an ICER (against HPV with cytology of 17’204 US $/QALY [36], or 
at very high ICERs above an acceptable threshold of far beyond 100’000 $/QALY [35], [34]. 
9.1.5 Synthesis HPV with direct referral to colposcopy 
HPV testing with direct referral to colposcopy is clinically effective, however strongly elevates 
colposcopy rates. Cost effectiveness results vary between studies. 
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This strategy was modelled in 3 studies and was dominated in 2 of the 3 studies by HPV 
with cytology triage [76] [34]. In the 3rd study HPV testing with direct referral to colposcopy 
was the most cost effective strategy at 11’400 Canadian $/LYG [33]. However it had double 
the colposcopy rates compared to the moderately more expensive study of HPV with 
cytology triage with an ICER of 12’300 Canadian $/QALY. (Both ICERs were calculated 
against cytology with HPV triage). 
 
9.1.6 Differences between ICER values of seemingly similar strategies 
 
While there is a consistent picture that HPV based screening will likely be cost effective, 
there are also considerable differences between the exact numbers for the ICERs found in 
the different studies for a seemingly similar strategy.  
 
There was no correlation between ICERs and the cost of the HPV test or the relative 
cost between HPV or cytology test. 
 
Different perspectives and costs taken into account may have an influence. In the 
Norwegian study in addition to direct medical costs, productivity costs of women during 
screening, diagnosis and follow up were included, which may have led to higher ICERs. 
 
While it is obvious that the variation of the screening interval of the primary screening 
strategy has a big impact on clinical effects and costs, also variations in the follow up of 
HPV+/cyt- women had a strong effect. As an example in the UK study, variations in the 
follow up time after an initial HPV positive/ cytology negative result from 24 months to 12 
months increased the ICER of the strategy by a factor of 2. 
 
The use of QALYs instead of LYG potentially may better reflect benefits and burden of 
screening than LYG and lead to different costs. However the use of QALYs was applied very 
differently between studies. In some studies disutilities were only assigned to cancer stages 
[35, 76]. In this case QALYs are reduced only by mortality and incidence of cervical cancer. 
In others disutilities were also assigned to precancerous lesions. In this case a strategy that 
overdetects precancerous lesions will yield lower QALYs, thus also reflecting some burden 
of screening [33, 36, 37]. Some studies calculated QALYs with different sets of utility weights 
but due to the perceived unreliability of the results, relied on cost/LYG for their 
recommendations [2, 29]. Kulasingam also assigned disutilities in their sensitivity analysis to 
a false positive screening test result (but not to precancerous lesions). The rank order of 
strategies was not influenced in this case by using QALYs instead of LYG.  
 
Within the same study QALYs must always be lower than LYG (otherwise the life years 
would not be quality adjusted). Thereby the use of QALYs will lead to lower clinical 
effectiveness numbers at the same cost and therefore have higher ICERs. Therefore it was 
analyzed whether studies that reported results only in cost/QALY versus cost/LYG had 
systematically higher ICER values. However between the different studies, there was no 
correlation between the ICER values and the use of QALYs or LYG. 
 
The use of different discounting rates is known to influence the cost /LYG or /QALY [63] 
with higher discount rates leading to higher cost / LYG or /QALY.  
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There was no clear picture that studies with higher discounting rates had systematically 
higher ICERs than the other studies (Table 7). However there was one study [28] with a very 
low ICER of only 4’319 €/LYG for the strategy of 5 yearly HPV testing with cytology triage (in 
the scenario with a higher HPV test price of 58€). In this case discounting was higher for 
costs (3%) than for benefits (1.5%), which may have contributed to lower ICERs. The other 
studies had the same discount rate for costs and benefits.  
However, the most likely explanation for the low ICER in this study is that the ICER was 
compared to 3 yearly cytology with HPV triage, which was a dominated strategy in most 
other studies. In those studies the HPV based strategies were compared to other HPV 
based strategies, which were slightly less effective than 3 yearly cytology based screening. 
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Table 6: Comparison of the cost effectiveness of the most important screening strategies 
If not otherwise stated, ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study 
Study, Country 
 
Cytology based testing HPV only or HPV with cytology triage HPV testing with HPV16/18 genotyping Cotesting 
MSAC 
2014 
Australia [29] 
 
Cytology only with 3 
yearly testing from 25-49 
years and 5-yearly from 
50-64 was less effective 
and cheaper than HPV 
based testing.  
Other cytology based 
strategies were 
dominated 
5 yearly HPV with cytology triage was 
more effective at an ICER of 33’000 
Australian $/LYG 
5 yearly HPV with HPV 16/18 genotyping was 
even more effective at an ICER of 100’000 
Australian $/LYG 
Dominated 
Huh et al. 
2015 
USA 
[37] 
 
Cytology with HPV triage 
was less effective than 
HPV based testing but 
cheaper 
HPV with cytology triage was more 
effective than cytology based testing, but 
dominated by the genotyping strategy 
3 yearly HPV with HPV 16/18 genotyping was 
the most clinically effective strategy at an 
ICER of 7’667 $/QALY  
(compared to cytology with HPV triage) 
Dominated by 
HPV with cytology 
triage and by HPV 
with genotyping 
Vijayaraghavan 
et al. 
2010 
USA [36] 
 
Dominated 3 yearly HPV with cytology triage was 
more effective than 2-yearly cytology and 
cost effective at an ICER of 13’617 US 
$/QALY 
HPV with 16/18 genotyping and cotesting 
with 16/18 genotyping was yet more effective 
at ICERs around 34’000$/QALY 
3 yearly cotesting 
was less effective 
than genotyping, 
but cost effective 
at an ICER of 
17’204 US $/ 
QALY 
Kitchener et al. 
2014 
UK [2] 
 
Dominated 6 yearly HPV with LBC triage dominated 
cytology based testing, but suffered 
extended dominance from HPV testing 
with HPV 16/18 genotyping and the 
mixed strategy described below  
6-yearly HPV based testing with HPV 16/18 
genotyping was most cost effective at 15’000 
£/LYG (24 months follow up) or 30’000£/LYG 
(12m follow up) 
dominated 
In a mixed strategy HPV with cytology triage was followed up with HPV16/18 genotyping 
for women persistently HPV+/cyt- after 12m. This strategy was cost effective at 
20’000£/LYG (against immediate HPV 16/18 genotyping with 24m follow up)  
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Study, Country Cytology based testing HPV only or HPV with cytology triage (no genotyping strategy was included) Cotesting 
Sroczynski 
et al., 2010, 2011, 
Germany 
[30, 60] 
In the base case 3 yearly 
Pap testing was cost 
effective at 7’100 Euro / LYG 
against 5 yearly Pap testing. 
 
In the scenario with lower 
sensitivity values for cytology 
based testing (from German 
studies sensitivities it was 
dominated 
In the base case with higher sensitivity of cytology based testing, 
3 yearly HPV based testing had higher effectiveness than 3 yearly cytology based testing at an 
ICER of 9’000 Euro /LYG. 
5-yearly testing with HPV based strategies were slightly more effective than 3 yearly Pap testing, 
however suffered extended dominance from a combination of 3 yearly Pap testing and 3 yearly 
HPV base testing. It is important to note that in the HPV based strategies, women below 30 years 
received 2 yearly Pap testing, which makes interpretation of the comparison to 3 yearly Pap 
testing more difficult. 
In the scenario with lower sensitivity values for cytology based testing (from German studies)  
5 yearly HPV based testing was cost effective at 3’700 €/LYG (versus no screening) and  
3 yearly HPV based testing was cost effective at 6’100 €/LYG (versus 5 yearly HPV) 
Dominated 
Arbyn et al. 2015, 
Belgium [28] 
Dominated in the base case In the base case 5-yearly HPV testing with cytology triage dominated 3 yearly cytology. 
If higher HPV prices (58 €) are assumed, cost effective at an ICER of 4319 €/LYG vs cytology 
Not assessed 
Accetta et al. 
2010, Italy, [76] 
Dominated 5 yearly HPV with Pap triage is more effective than 3 yearly Pap test at an ICER of 4’444 
Euro/QALY, 3 yearly HPV with Pap triage is yet more effective at 68’421 Euro/ QALY 
HPV with direct colposcopy referral was dominated 
Not assessed 
Burger et al. 2012 
Norway [32] 
Dominated 6-yearly HPV with cotesting triage was less effective than 3 yearly cytology but cheaper ICER 
compared to no screening 29’000 Euro/LYG 
5 yearly HPV with cotesting triage was more effective than 3 yearly cytology and cheaper at 
57’000 Euro/LYG 
Not assessed 
Goldhaber-
Fiebert et al. 
2008, USA [35] 
3 yearly cytology based 
testing was dominated 
5 yearly HPV with cytology triage is more effective than 3 yearly cytology with HPV triage at 
12’000 (start at 25y, switch to HPV testing at 35 years) or 29’000 $/QALY (switch at 30 years) 
3 yearly HPV with cytology triage is yet more effective at ICER of 37’000 (25y,35y) or 53’000 
(25y,30y) or 78’000 $/QALY (21y,30y) 
Dominated or too 
costly (ICER > 3Mio 
$/QALY) 
Vijayaraghavan et 
al., 2010 
Canada [33] 
3 yearly cytology with HPV 
triage was cost effective at 
9’600 Canadian $/LYG 
(against no screening) 
3 yearly HPV with direct referral to colposcopy was most effective and dominated all other 
strategies however at 2 times higher colposcopy rates (ICER 11’400 Canadian $/LYG) 
3 yearly HPV with cytology triage was more effective than cytology with HPV triage with 
moderately increased colposcopy rates at 12’300 Canadian $/QALY (vs cytology with HPV triage) 
Dominated 
Kulasingam et al. 
2009 
Canada [34] 
 
Dominated 3 yearly and 5 yearly HPV testing with Pap triage were more effective than 3 yearly cytology 
testing at ICERs of 6720 (against no screening) and 24257 Canadian $/LYG (against 5 yearly 
HPV with Pap triage) 
HPV with direct referral to colposcopy led to disproportionately high numbers of false positive 
tests and was not on the cost effectiveness frontier 
2 yearly cotesting was 
on the cost 
effectiveness frontier 
with an ICER of 
432’751 Canadian $ 
Bistoletti et al. 
2008, Sweden 
[75] 
Dominated  Not assessed 3 times cotesting 
dominated 9 times 
cytology based testing 
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9.2 Correlation of Results with Study Quality 
No correlation of results with study quality was identified.  
 
Study quality was assessed by application of the EURONHEED checklist. The results of all 
entries of the checklist and the overall quality data score and transferability data score are 
shown in the Appendix in Table 13. 
Two publications were excluded from quantitative analysis based on insufficient detail of 
effectiveness results reporting (question E5). Quality data scores of the remaining 
publications ranged from 0.93 to 0.65.  
 
When a comparison was done, whether certain screening strategies were only analyzed by 
studies with low or high quality data scores, no association was found. E.g. HPV with 
cytology triage was analyzed by almost all studies across all quality data scores. The second 
most important strategy with HPV 16/18 genotyping was analyzed by 4 studies ranging from 
the highest quality data score of 093, [37], over 0.89 [29] and 0.86 [2] to a comparatively low 
data score of 0.73 [33]. 
 
When ICERs of 5 yearly HPV screening with cytology triage were compared with the quality 
data score of the studies, there was a tendency to higher ICERs in studies with a lower 
quality data score. While this result should not be over interpreted, it is at least a hint that 
poorer study quality did not bias cost effectiveness results in favor of HPV based strategies. 
 
As only 2 studies with HPV 16/18 genotyping were found potentially transferable to the 
Swiss Health system and only for these the ICERs were adapted to CHF no correlation 
between the quality data score and the ICERs were calculated. 
9.3 Summary of the Transferability Analysis  
Three studies have similar parameters to Swiss screening with results that may be 
transferable to the Swiss health system. Recommended strategies were 3 – 5 yearly HPV 
with cytology triage. 
Two studies had lower screening frequencies for cytology based screening in women over 
49 years. Costs for organized screening were added into the model. The results may 
become transferable if Switzerland decides to install organized screening in the future. The 
studies recommend HPV with HPV16/18 genotyping or HPV with cytology triage with 5 or 6 
yearly frequencies starting at 25 or 30 years.  
Two studies started modelling only at the age of 30. If additional costs for screening are 
added for younger women, one of these studies may be transferable to the Swiss health 
system. The study recommended 5 yearly HPV with cytology triage.  
The results of 4 studies seem not to be transferable due to different treatment options or 
relevant differences in the primary screening strategy compared to the Swiss 
recommendations. 
In 2 studies data were insufficient to conclude transferability 
 
In order to assess how the cost effectiveness results might translate into the Swiss situation 
a transferability analysis was done. 
 
For this research question the same 13 health economic publications were considered as for 
research question 1c [2, 28-30, 32-37, 60, 75, 76]. As described above 1 paper is an English 
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publication of the central results from another (a German HTA). The 2 publications are 
therefore referred to as 1 study [30, 60]. 
 
As described in the methods chapter 5.4, model parameters of each study were compared to 
the reference values for the Swiss health system. If differences were found for any of the 
relevant transferability parameters an estimation was done, of how this might influence the 
result of the model if the Swiss parameters had been used. The detailed results of all 
questions for the transferability analysis are described in Appendix 7: “Transferability 
Analysis for the health economic studies” in Table 14.  
 
The transferability analysis showed that the studies with the most similar comparator 
to Swiss screening are those by Goldhaber-Fiebert (USA, [35]), Burger (Norway, [32]) and 
Sroczynski (Germany, [30, 60]). The results of these studies may be transferable to the 
Swiss setting. 
 
Goldhaber-Fiebert (USA) [35] showed results for 3 yearly cytology with HPV triage with 
starting ages of 21 or 25 years and modelled a switch to HPV based testing at ages of 30 or 
35 years. Treatment strategies seem to be close and HPV prevalence data slightly lower 
than in Switzerland [62]. It was found that the order of strategies in terms of clinical and cost 
effectiveness were independent of attendance rates. 3 yearly and 5 yearly HPV with cytology 
triage were recommended cost effective strategies. 
 
Burger (Norway) [32] showed results for 3 yearly cytology with cotesting triage starting at 25 
years and switching to HPV based strategies at 31 years. Treatment strategies seem 
sufficiently close to Swiss recommendations. No HPV prevalence data were available. 4 or 5 
yearly HPV based testing with cotesting triage were the recommended strategies in this 
model. 
 
Sroczynsky (Germany) [30, 60] showed results for 3 yearly cytology with HPV triage and 
modelled strategies switching to HPV based strategies at 30 years. Screening, follow up and 
attendance rates seem sufficiently close to the Swiss situation. No HPV prevalence data 
were available. 3 yearly HPV based screening was a cost effective recommended strategy. 
 
The following studies had slightly different frequencies for screening than in 
Switzerland.  
 
The studies of Kitchener (UK) [2] and MSCA (Australia) [29] modelled cytology with HPV 
triage screening starting at 25 years with 3 yearly screening until 49 years followed by 5 
yearly screening for older women. Treatment options seem to be similar. The background 
HPV prevalence in Australia seemed to be lower than in Switzerland. In the UK HPV 
prevalence was higher than in Switzerland until the age of 40. Big differences in HPV 
prevalence were found in the UK between different cities. In the UK cancer incidence rates 
of women between 25 and 35 years of age are much higher than in Switzerland. Both 
countries have organized screening programs. Different attendance rates were modelled 
both for primary screening as well as for triage tests and colposcopies. It was found that 
ensuring compliance with follow up colposcopies is important to ensure effectiveness of HPV 
based strategies. All strategies including those that were HPV based started at 25 years.  
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Even though in one study prevalence is higher and in the other lower than in Switzerland, 
the studies come to the same conclusions regarding recommended strategies. Therefore 
prevalence may not negatively affect the transferability of these studies.  
Both models come to the same conclusion that HPV with HPV16/18 genotyping is the most 
clinically and cost effective strategy followed by HPV with cytology triage (either 5 or 6 
yearly). 
 
The following studies only modelled screening starting ages of 30 years. These 
strategies may therefore start with a higher background risk than in Switzerland and they 
may be cheaper and less effective than current Swiss screening. The results are however 
still interesting for a comparison of cytology based and HPV based strategies after the age of 
30 years. If in Switzerland cytology based screening for younger women is maintained and a 
switch to HPV based strategies considered at the age of 30 years, the cost for screening in 
younger women would have to be added to both intervention and comparator strategies in 
the models.  
 
Among these studies the Belgian study is probably closest to the Swiss situation. Arbyn 
(Belgium) [28] modelled cytology with HPV triage with 3 yearly frequencies. All CIN stages 
seem eligible for treatment. HPV prevalence is higher in Belgium than in Switzerland (which 
would rather favor cytology based screening [80]). Attendance rates were modelled between 
40 and 80% which likely includes Swiss attendance rates. 5 yearly HPV with cytology triage 
was more clinically and cost effective than cytology based screening.  
 
Due to different treatment options for CIN2 and the assumption of 100% compliance the 
results of the study of Huh [37] may not be transferable to the Swiss context 
 
Huh (USA) modelled 3 yearly cytology based screening with HPV triage and compared it to 
various HPV based strategies. Treatment options seemed not to include CIN2 treatment 
which is different from Swiss recommendations. HPV prevalence was assumed slightly lower 
than in Switzerland. 100% compliance with primary screening and follow up was modelled, 
thus showing the maximum possible cost and benefit of strategies. However, real life 
effectiveness and cost will be lower. HPV with HPV 16/18 genotyping dominated all other 
strategies in this study.  
 
For the following publications data are insufficient to conclude transferability. 
Vijayaraghavan (Canada) [33] modelled 3 yearly cytology testing with HPV triage for 
younger women and switching to HPV based strategies starting at 30 years. Treatment 
options were only available in referenced supplementary materials that were impossible to 
retrieve from the author despite several attempts. HPV prevalence was similar in women of 
30-39 years, and lower for older women in Canada than in Switzerland [62]. Attendance 
rates were varied. This did not change the relative cost effectiveness of the screening 
strategies. With similar treatment patterns the study results would be transferable. 3 yearly 
HPV only and HPV with cytology triage were clinically more effective at slightly higher ICERs 
than 3 yearly cytology with HPV triage. 
 
Accetta (Italy) [76] modelled 3 yearly cytology testing with HPV triage from 25-65 years 
however follow up after primary screening tests was not described. Treatment options seem 
not to include CIN1 treatment. HPV prevalence is comparable to Switzerland. Average 
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compliance rates of 70% were assumed. Sensitivities of cytology and HPV tests seem to be 
rather favorable for cytology based screening. Under the assumption that the follow up after 
cytology testing with HPV triage is similar as in Switzerland the results of the study may be 
transferable. 5 yearly HPV with cytology triage was found clinically and cost effective.  
 
The following studies were excluded from further transferability analysis due to 
comparator strategies that were considered not close enough to the current Swiss strategy. 
 
In the Swedish study of Bistoletti [75] the follow up after a primary screening test results 
(cytology) was not described. Therefore it is not clear whether the strategy is close enough 
to Swiss recommendations. In addition the study mentioned that Swedish cytology screening 
may be less sensitive than in other countries. This would favor HPV based testing. In this 
study 3 times cotesting in a woman’s life was more clinically and cost effective than 3 yearly 
cytology between 32 and 50 years followed by 5 yearly cytology. It is unclear whether these 
strategies would compare equally in the Swiss situation. 
 
The study of Vijayaraghavan (USA) [36] had shorter screening frequencies (2 yearly) in their 
cytology based screening strategy than the recommended Swiss 3 yearly intervals. It is 
assumed that this strategy is more costly than the current Swiss strategy and economic 
results will not be transferable. Cytology based strategies were dominated by HPV based 
strategies. 
 
The study of Kulasingam [34] had a 3 yearly Pap testing strategy, but without HPV triage. 
Annual Pap testing with HPV triage was also modelled. This strategy is most probably much 
more expensive than current Swiss screening and results will not be transferable.  
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9.4 Deduction of costs and cost effectiveness values in CHF by 
adaptation using purchasing power parities 
Five yearly HPV with cytology triage dominated cytology based screening in 4 out of 5 
studies. It resulted in ICERs between 6’862 CHF/LYG (against 3 yearly cytology based 
screening) and 56’723 CHF/QALY (against 6 yearly HPV with cytology triage). In all studies 
this strategy was more effective than 3 yearly cytology based screening.  
 
Three yearly HPV with cytology triage was on the cost effectiveness frontier in 3 potentially 
transferable studies with ICERs between 17’450 CHF/LYG (against cytology based 
screening), 96’192 CHF/QALY (against 5 yearly HPV with cytology triage) and more than 
100’000 CHF/LYG (against 4 yearly HPV with cytology triage). 
 
HPV testing with genotyping for HPV 16/18 was cost effective in 2 potentially transferable 
studies at ICERs (against HPV with cytology triage of the same frequency) between 32’171 
CHF/QALY and 89’961 CHF/LYG. 
 
None of the studies provided results in a way that allowed direct adaptation of the results 
into Swiss values (e.g. by providing cost and units for all aspects). Therefore it was only 
possible to translate values for cost and cost effectiveness ratios into CHF/LYG or /QALY by 
adaptation to purchasing power parities. While this rather simple transformation cannot 
reflect the true costs in Switzerland, the values in CHF show better where the potential costs 
in Switzerland might be than the values in the currency of another country. They also make 
values of different studies more comparable by using the same currency and cost year. An 
overview of all deducted values is shown in Table 15.  
In this chapter only the results for strategies with potential transferability are shown (Table 
7). In summary, the following results were achieved: 
 
5 yearly HPV with cytology triage dominated cytology based screening in 4 out of 5 
studies. It yielded ICERs between 6’862 CHF/LYG (against 3 yearly cytology with HPV 
triage) and 56’723 CHF/QALY (against 6 yearly HPV with cytology triage) in the studies from 
Belgium [28], Australia [29], UK [2], the US [35], and Norway [32]. In all these studies 5 
yearly HPV with cytology triage was more effective than 3 yearly cytology.  
In the base case of the German study [30, 60] with high sensitivity of the Pap test, 5 yearly 
HPV with cytology triage suffered extended dominance from the combination of 3 yearly Pap 
testing and 3 yearly HPV based testing. In the scenario with German (lower) sensitivity 
values of the Pap test, 5 yearly HPV with cytology triage dominated cytology based testing 
and had an ICER of 6’786 CHF/LYG against no screening. It is important to note that in this 
study HPV based screening strategies involved 2 yearly Pap based screening for women 
below 30 years, which increased the cost of HPV based screening strategies compared to 3 
yearly cytology. 
 
3 yearly HPV with cytology triage had an ICER of 17’450 CHF/LYG (against 3 yearly Pap 
testing) in the German study [30, 60] and in a US study of 96’192 CHF/QALY (against 5 
yearly HPV with cytology triage) [35]. 
A threshold of 100’000 CHF/LYG was exceeded by 3 yearly HPV with cytology triage in the 
study from Norway [32], where this strategy was compared to 4 yearly HPV with cytology 
triage. The Norwegian study included more costs into the model than others by adding the 
cost for women’s time for screening, diagnosis and follow up into the calculation. In addition 
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the follow up time of HPV positive/ cytology negative findings was short with only 6 months 
compared to 12 months or more in other models. (For comparison with the German study: 
had the ICER been calculated against 3 yearly cytology based screening it would have been 
below 40’000 CHF/LYG.)  
 
HPV testing with genotyping for HPV16/18 yielded ICERs (against HPV with cytology 
triage of the same frequency) of 21’447 CHF/LYG in the UK with 6 yearly screening and 24 
months follow up time or 64’342 with 12 months follow up time [2], and with a 5 yearly 
screening frequency in the Australian study of 89’961 CHF/LYG [29]. 
 
Costs of cytology and HPV tests from the studies were also translated into CHF by 
adaptation to purchasing power parities and are shown in Table 7. The numbers can give an 
impression how close the test cost assumptions in the models are to Swiss costs. Cytology 
costs varied from 11 CHF to 71 CHF. HPV tests were varied between 20 and 92 CHF. The 
cost of cytology testing in Switzerland is within that range. For HPV testing no price for 
primary screening is fixed yet for Switzerland. Also after conversion of local currency costs 
into CHF by adaptation to purchasing power no correlation was found between ICERs and 
HPV test costs (the correlation factor of the HPV test cost to the ICERs was -0.11). 
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Table 7: Test Costs and ICERs translated into 2015 CHF by adaptation using purchasing power parities 
A footnote was added that explains which strategy the ICERs was calculated against. If no footnote is added, the ICER was calculated against the next more cost effective strategy shown for the study 
in this table. An overview of all relevant strategies and their relative effectiveness and ICERs in original currency can be found in Table 10. 
Study  Cytology test  HPV test  Discount rates (%) 
Cost/ benefits 
ICERs  3-yearly HPV testing ICERs 5 yearly HPV testing 
(Kitchener 6 yearly) 
Arbyn, [28], 
Belgium 
35 CHF (52 if 
2
nd
 reading 
necessary) 
56 CHF 
up to 92 
CHF 
3 1.5  Cytology was dominated in the base case 
With an HPV test price of 92 CHF the ICER of 
HPV with cytology triage = 6’862
2
 CHF /LYG 
Goldhaber-
Fiebert, [35],USA 
55 CHF  100 CHF 3 3 Cytology based testing was dominated. 
HPV testing with cytology triage = 96’192
3
 CHF/QALY 
Cytology based testing was dominated. 
HPV with cytology triage = 52’634
4
 CHF/QALY 
Sroczynski, [30] 
Germany 
71 CHF  101 CHF 
(thereof 42 
for the test) 
3 3 3-yearly HPV based screening (where most of the 
HPV positive samples were followed up with cytology 
triage) = 17’450
5
 CHF/LYG (base case) and 11’827 
CHF/LYG (scenario with lower sensitivity of Pap test) 
Dominating cytology in the scenario with lower 
sensitivity of the Pap test at 6’786 CHF/LYG  
versus no screening 
Burger, [32], 
Norway 
50 CHF 62 CHF 4 4 Cytology based testing was dominated.  
HPV testing (6 month follow up time of HPV+/cyt- 
women) > 100’000
6
 CHF/LYG. 
Cytology based testing was dominated. 
HPV with cytology triage( 12 months follow up) = 
56’723
7
 CHF/LYG 
MSAC, [29], 
Australia 
54 CHF 64 CHF 5 5  HPV with cytology triage = 29’687
8
 CHF/LYG.  
HPV with16/18 genotyping = 89’961 CHF/LYG. 
Kitchener, [2], 
UK 
11 CHF if 
negative 
32 CHF if 
positive 
20 CHF 3.5 3.5  Cytology based testing was dominated  
HPV with LBC triage (after 24m HPV 16/18 for 
women persistently HPV+/cyt-) = 21’447
9
 CHF/LYG 
HPV16/18 (24m follow up) 32’171 CHF/LYG 
HPV with LBC triage (after 12m HPV 16/18 for 
women persistently HPV+/cyt-) = 42’895 CHF/LYG 
HPV16/18 (12m follow up) = 64’342 CHF/LYG 
                                                          
 
2 Against 3 yearly cytology with HPV triage 
3
 Against 5 yearly HPV with cytology triage 
4
 This strategy dominated 3 yearly cytology. The ICER was calculated against the next less effective strategy on the cost effectiveness frontier (5 yearly HPV with cytology triage, with a switch from 
cytology to HPV based testing at 35 years instead of 30 years, which was less effective than cytology based testing) 
5 Against 3 yearly Pap testing 
6
 Against 4 yearly HPV with cytology triage (6 months follow up time ) 
7
 This strategy dominated 3 yearly cytology. The ICER was calculated against the next less effective strategy on the cost effectiveness frontier (6 yearly HPV with cytology triage, 12 months follow up 
time, which was less effective than cytology based testing) 
8
 Against 3 yearly cytology at ages 25-49 and 5 yearly cytology at ages 50-64 
9
 This strategy dominated cytology based CP. The ICER was calculated against the next less effective strategy on the cost effectiveness frontier:  HPV with LBC triage (after 24m HPV 16/18 for 
women persistently HPV+/cyt-  with 10 yearly frequencies for women >50 years, which was less effective than CP) 
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10 Results Research Question 2: Feasibility of HPV based primary 
cervical cancer screening 
No hard barriers were identified for the implementation of HPV based cervical cancer 
screening. The most important concern raised was that adherence to screening algorithms 
and quality control should be ensured by appropriate measures, e.g. by implementation of 
an organized screening setup. Active stakeholder management of GPs/ gynecologists 
should be considered and communication tools provided to ensure that women receive the 
necessary information on cervical cancer screening with HPV and to minimize psychosocial 
distress. 
10.1 Extraction of answers from publications 
Answers to research question 2 were extracted from 36 publications (clinical systematic 
reviews and meta analyses as well as HTAs and health economic studies), according to the 
algorithm described in the methods chapter 5.5. Answers were then classified into “concern 
categories” and focus areas identified based on the frequency that the different concerns 
were mentioned. All detailed information retrieved and the associated concern categories 
are displayed in Table 11 and Table 12. The results are summarized in the following 
paragraphs ordered by the frequency a concern was raised across publications: 
10.1.1 Adherence to Policy 
Ensuring adherence to policy is the predominant concern of 16 publications [2, 28, 30, 35, 
37, 44, 46, 51, 52, 60, 65, 67, 68, 78, 80, 81]. It is clear that the projections of models will 
only translate into the same level of clinical and cost effectiveness, if the strategies are 
indeed implemented as modelled. If age restrictions for HPV testing, screening frequencies 
and follow up recommendations are ignored, a less specific primary screening test may lead 
to more overdiagnosis and overtreatment. 
 
Special attention should be put on the adherence to follow up schedules for HPV positive/ 
cytology negative women as cited by 5 publications. If these women are lost to follow up, the 
benefit of the superior sensitivity of the HPV test could be eroded [2, 28, 31, 32, 45]. 
One detail in HPV testing with cytology triage is the question how to sample for the triage 
test. van Rosmalen et al. [31] compared sequential sampling, where women with a positive 
HPV test are invited for a second visit to take the triage test sample, to concurrent sampling, 
where the triage test sample is always taken together with the sample for the HPV screening 
test but only analyzed if the HPV test is positive. Concurrent sampling has been found more 
cost effective. The additional cost of collecting the cytology sample was outweighed by the 
combined benefits of not losing HPV positive women at this stage of the screening algorithm 
and avoiding the cost for a second visit. 
 
Both health care professionals as well as women themselves influence adherence. Whitlock 
questioned whether policy will be accepted by (US) physicians [68] and Schiffman pointed to 
evidence that in the US current evidence-based guidelines for cervical cancer screening and 
management are being widely ignored [52] [93]. 
Women’s preferences are important as some women may feel insecure about longer 
screening intervals as mentioned by 2 publications [30, 37]. Prolongation of screening 
intervals may be perceived by women as a money saving activity of policy makers [30]. 
Therefore, when policy is changed to longer screening intervals, this needs to be 
accompanied by proper information about the benefits of longer screening intervals. 
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10.1.2 Organized Screening Setup 
The concerns addressed in the previous chapter led to the recommendation to implement 
HPV based screening in an organized screening program (10 publications [29, 30, 44-46, 
49, 60, 65, 81]), where adherence to recommended practice and many of other concerns 
listed here can be better controlled. 
10.1.3 Piloting, Monitoring and Evaluation 
Ongoing monitoring and evaluation whether the expected outcome is achieved is 
recommended in 9 publications [30, 32, 46, 49, 56, 60, 65, 74, 81] (thereof 5 publications are 
from Germany). This measure allows the timely identification of issues in the implementation 
of a screening program and targeted actions to address these. 
In order to verify that all practical implementation aspects have been fully and effectively 
addressed, a pilot project should be done before roll out of HPV based screening as 
recommended by 7 publications [2, 30, 46, 60, 65, 79, 81] in line with European Guidelines 
for Quality Assurance in Cervical Cancer Screening [94]. 
10.1.4 Quality Control, validated HPV tests 
Quality control of all aspects of cervical cancer screening is recommended by 7 publications 
[28-30, 46, 60, 65, 81]. 
The most critical quality control step is that only clinically validated HPV tests must be used, 
which have proven sensitivity and specificity as seen in RCTs and assumed in models. This 
recommendation was emphasized in 6 publications [28-30, 54, 60, 64, 81].  
 
As an advantage of HPV based screening it was stated that quality control of HPV tests may 
be easier than that for cytological testing due to the higher degree of automation and 
standardization of HPV tests [28]. 
To further strengthen quality control the implementation of a central reference laboratory for 
HPV testing was recommended by 1 publication [28]. 10 
10.1.5 Call/ Recall Systems 
To improve adherence of women to screening and follow up schedules, 4 publications 
recommended implementation of a call/ recall system that consists of invitations and 
reminders if invitations are missed [29, 30, 45, 60]. 
10.1.6 Communication  
Appropriate communication about HPV based screening and the significance of a positive 
test result, especially in conjunction with a negative cytology result, was mentioned by 2 
publications [28, 45]. One of these recommend the development of a standardized patient 
leaflet to ensure that all women receive the same scientifically based information [28].  
10.1.7 Psychosocial aspects 
As HPV infections occur through sexual interactions, a positive HPV test result has the 
connotation of a sexually transmitted disease. This may involve stigma and lead to insecurity 
in sexual behaviors and questions about relationships [49, 56]. The presence and amount of 
stigma related to a sexually transmitted infection differs between cultural backgrounds and 
requires special consideration to ensure that all women in a society can participate in and 
benefit from the screening program to the same extent [49]. 
                                                          
 
10
 A reference laboratory already exists in Switzerland 
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More research into how a positive HPV test results affects quality of life was recommended 
by 2 publications [2, 30].  
10.1.8 Effects on health care professionals 
HPV based testing algorithms were found more complex than cytology based algorithms by 
2 publications [32, 52] and as such require special education of health care professionals 
[49, 52]  
Two publications mentioned that longer screening intervals may be perceived as an 
economic threat to GPs or gynecologists [30, 52]. Fewer visits to the doctor was seen as 
positive in the Australian publication [29] as it freed resources for other activities. 
Also if screening activities should be centralized (either sampling, testing or communication) 
the role of GP/ gynecologist as a central point of contact and information for women’s health 
would change [28].  
10.1.9 Side effects on other aspects of women’s health 
In the German publications there was a concern about the potential side effects of longer 
screening intervals on regular attendance at gynecological checkups [30, 46, 65]. 
10.1.10 Practical implementation aspects 
Several practical implementation aspects were noted: 
 
A central database containing the screening data of all eligible women and enabling both 
call/ recall systems as well as monitoring and evaluation of the screening program was an 
important aspect mentioned by 2 publications [29, 30]. 
Reimbursement policies need to be adapted [67] so that all women have access to the new 
technology regardless of socioeconomic background. It is also recommended that 
reimbursement policies be defined in a way that enforces adherence to screening algorithms 
[28].  
Resource availability needs to be ensured according to the needs of the new technology 
[33].  
Two publications recommended centralization of laboratory services to achieve economy of 
scale and better prices for the HPV testing [80, 81]. 
10.1.11 Address the underscreened, self-sampling as opportunity 
Finally 4 publications noted that the introduction of a new technology will not solve the 
problem that a high amount of cervical cancers occur in women who never attend screening 
or attended less often than recommended [35, 51, 64, 67]. E.g. in the US half of the women 
with cervical cancer have never participated in cervical cancer screening and another 10% 
had their last cytological screening test more than 3 years ago [67]. 1 additional publication 
recommended to use the money saved by implementing HPV based screening to target 
women who previously did not attend [76]. 
One publication saw a benefit of HPV based screening for women attending infrequently as 
they will have longer protection against cervical cancer with a negative HPV result than with 
a negative cytology result.  
Self-sampling of cervical smears for HPV analysis was suggested in 4 publications [28, 29, 
49, 67] as a method to reach women who do not see a gynecologist for reasons of shame, 
stigma, no time for a visit or other social reasons. Indeed, self-sampling is implemented in 
the new HPV based Dutch cervical screening program for women who otherwise would not 
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attend screening [28]. It is also recommended for implementation for underscreened women 
in Belgium [28] and in Australia [29]. 
 
10.1.12 No concerns 
Eight publications expressed no implementation concerns [34, 36, 43, 47, 48, 66, 75, 77] 
(partly due to their focus on specific research questions that did not contain implementation 
aspects).  
 
10.2 Relevance for the Swiss Health Care setting 
 
The identified concerns for implementation are relevant for the Swiss context, as screening 
in Switzerland is opportunistic and implementation of clinical guidelines in ambulatory care is 
currently not systematically enforced nor is adherence to policy systematically monitored.  
In Switzerland health care professionals are the most important source of information on 
cervical cancer screening for the eligible women and have a big impact on the trust of 
women in the screening program and their adherence. Therefore it will be important to obtain 
the support of the affected health care professionals for a potential policy change.  
 
In case of a switch to HPV based screening in Switzerland, measures should be 
implemented to address the concerns as described in chapters 11.2 and 11.4. 
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11 Discussion 
The discussion chapters 11.1 and 11.2 evaluate the evidence for the hypotheses of this 
master thesis. The answers to each research question are briefly summarized and any 
inconsistencies are discussed and evaluated. Chapter 11.3 addresses the limitations of this 
thesis and in chapter 11.4 conclusions are drawn for potential policy changes for the Swiss 
health system.  
11.1 Hypothesis 1 
The evidence found in this thesis confirms hypothesis 1: The use of HPV as the first line 
screening test improves clinical effectiveness of cervical cancer screening at lower screening 
frequencies and is cost effective. 
A 5 yearly strategy of HPV based screening with cytology triage seems ideal for women of 
30 years or older. In younger women cytology based testing should be maintained. Women 
with HPV positive/cytology negative results should be retested after 12 months. This strategy 
is likely to reduce the incidence of cervical cancer without increasing the burden of screening 
– or even reducing the burden of screening by having longer screening intervals. 
Alternatively a strategy with 5 yearly HPV 16/18 genotyping can be recommended with direct 
referral to colposcopy for HPV16/18 positive women and cytology triage for other hrHPV 
types.  
From a health economic perspective the above mentioned HPV based cervical cancer 
screening strategies may be either cheaper than cytology based testing or cost effective at 
ICERs below acceptable threshold.  
Cotesting is not a recommended strategy from a health economic perspective. 
 
11.1.1 Research Question 1a: What is the best test or combination of tests which 
results in the highest clinical effectiveness to prevent cervical cancer at the 
lowest burden of follow up? 
Agreement is strong across systematic reviews and meta analyses, that HPV based 
screening is more sensitive than cytology and thus more effective to identify women with 
precancerous lesions. These women can then be properly surveilled and treated before 
cervical cancer develops. The combined follow up of the 4 European RCTs was powered 
enough to show a significant decrease of cervical cancer incidence by HPV based testing.  
The effect was strongest in the NTCC trial with direct referral of hrHPV positive women to 
colposcopy, followed by Swedescreen and POBASCAM and weakest in ARTISTIC. In the 
latter study it was discussed that as a comparator LBC was used with an unusually low 
positive threshold which resulted in unusually high sensitivity and lower specificity in the 
cytology arm of the study. This explanation seems plausible.  
 
The downside of the HPV assay is its lower specificity compared to cytology. As only 
persistent HPV infections may lead to cancer, and many infections are cleared by the 
immune system within one or two years, many positive HPV results will not be associated 
with advanced precancerous lesions or cancer (CIN3+). Therefore several studies analyzed 
whether HPV testing will lead to more false positive results and overdetection of early 
precancerous lesions. 
 
This aspect has been addressed by meta analyses that measured relative detection rates of 
CIN2+ and CIN3+ over 2 screening rounds. Based on the fact that cumulative detection 
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rates of CIN2+ and CIN3+ were the same with HPV with cytology triage but higher with 
direct referral to colposcopy, all but one study came to the conclusion that direct referral to 
colposcopy after every HPV positive result led to overdetection of precancerous lesions, 
while HPV with cytology triage did not. One study concluded that only with direct referral to 
colposcopy did HPV based screening have increased sensitivity compared to cytology based 
screening [66].  
This thesis cannot follow this conclusion, as also in the RCTs POBASCAM and 
Swedescreen, which did not refer HPV positive women directly to colposcopy but used an 
HPV with cytology triage approach, cervical cancer incidence rates were reduced [39]. 
Therefore overdetection of precancerous lesions by direct referral to colposcopy is 
considered the more likely explanation of the results. 
 
The study of Rebolj found that the rate of “false positive” results is elevated with HPV based 
testing compared to cytology based testing. In this case a positive result was any result 
leading to triage, retesting after shorter frequencies or colposcopies and not associated with 
a CIN3+ finding. The author assumed that the rate of false positive results over the life time 
of a woman may be more similar, if longer screening intervals are adopted with HPV based 
testing.  
This thesis comes to the conclusion that the definition of a false positive result in this study is 
very narrow. It will be important to effectively communicate the significance of a positive HPV 
result to the affected women, so they understand that an HPV infection is a risk factor that 
indicates closer surveillance rather than “having cancer” or a precancerous lesion. 
 
At the same time the risk of overdetection of precancerous lesions is real if women are 
screened for HPV at too young an age, as in this cohort HPV infections are more often 
transient than persistent (see also research question 1b). Also in older women too short 
screening intervals bear the risk of identifying more transient HPV infections. Therefore with 
HPV based screening it is important to adhere to recommended screening intervals to 
balance benefits and harms.  
 
Systematic reviews criticized all RCTs for incomplete reporting on colposcopy rates. 
Therefore data on colposcopy rates are mostly based on modelling.  
Modelling data show that colposcopy rates of HPV with cytology triage are either lower or 
moderately higher than with cytology based screening. Based on the data this thesis comes 
to the conclusion that colposcopy rates are likely to be in a comparable range to current 
policy. 
Colposcopy rates were higher with the HPV16/18 genotyping strategy along with higher 
clinical effectiveness. Studies came to different conclusions about how much colposcopy 
rates will be elevated. To date this strategy has been less frequently researched. The 
evidence on partial genotyping can therefore be considered emerging. However when 
analyzed it was always found more effective than cytology triage. Most convincingly, cohort 
studies show that the CIR to develop CIN3+ over 3 years is higher for HPV16/18 but 
cytology negative women than for women positive for other hrHPV types and positive for 
cytology [71]. This shows that HPV16/18 genotyping increases the specificity of the 
screening algorithm more than cytology triage. 
 
In meta analyses cotesting did not have a relevant benefit over HPV with cytology triage 
[28]. One systematic review raised the concern that issues with HPV sampling might lead to 
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false negative results not being identified in test internal controls, which could be detected by 
cotesting with a cytology sample. No concerns about false negative results with HPV testing 
due to sampling issues have been reported in any other systematic review. It is therefore 
concluded that this is not a widespread concern. Nevertheless this is a topic that must be 
addressed during the clinical evaluation of HPV assays that are approved for use in primary 
screening.  
 
11.1.2 Research Question 1b: What is the best age to start using HPV as primary 
screening test in terms of clinical effectiveness and cost effectiveness? 
Thirty years seems to be a reasonable choice for the age to start HPV based screening. 
 
As only persistent HPV infections lead to cancer and most HPV infections in young women 
are cleared quickly by the immune system [95], it is important to find a balance between 
identification of women at risk to develop cancer and avoidance of unnecessary anxiety, 
follow up tests or treatment of potentially regressive early precancerous lesions. 
 
Recommended start ages vary between 25 and 32 years with the majority of studies coming 
to the conclusion that 30 years is the best cut off age. The combined follow up of the 
European RCTs by Ronco showed no protective effect against cervical cancer in women 
below 30 years at study entry. At the same time, in women of 30-34 years at study entry the 
effect of HPV based screening on reduced numbers of invasive cancer was substantial with 
5/117’345 invasive cancer cases/ person years in the intervention group vs 15/102’598 in the 
control group.  
On the other hand in the ATHENA study 30% of the CIN3+ cases were found in women 
between 25 and 29 years and more than half of these women had normal cytology. This 
indicates that advanced precancerous lesions exist in this age group that will go undetected 
with cytology screening only. Based on these findings one could come to the conclusion that 
a start age for HPV based screening of 25 years may be better. One possible explanation for 
this apparent discrepancy for women between 25 and 30 years may be that CIN3+ 
progression to invasive cancer is slow enough that many of these lesions can be caught at 
the age of 30 -35.  
What is the best strategy for a country may also be related to the age specific cancer 
incidence rates. E.g. the UK seems to have much higher cervical cancer incidence rates in 
women of 25-35 years than Switzerland (around 17/100’000 in the UK versus less than 8 in 
Switzerland in this age group). Therefore in the UK an HPV based screening start age of 25 
may be better than 30. Indeed in the UK HTA all HPV based screening strategies start at 25 
years [2].  
In Switzerland the cervical cancer incidence rate in women below 30 years is low but 
reaches a first peak in women between 35 and 39 years. Therefore, in Switzerland, it seems 
prudent to start testing with HPV at the age of 30. This should avoid unnecessary 
colposcopies and overdetection of regressive early precancerous lesions in women between 
20 and 30 years and still allow better prevention of cancer cases in the age group between 
30 and 40.  
 
Health economic studies also support this cut off age. Most studies that compared 30 years 
with younger or older ages came to the conclusion that 30 years is the most cost effective 
solution. 
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11.1.3 Research Question 1c: How does the optimal algorithm for first line screening 
with HPV compare to the current testing with cytological tests in terms of 
Incremental cost effectiveness ratios (ICERs) of costs per modelled life years 
gained (LYG) or quality adjusted life years (QALYs)? 
Cost effectiveness results consistently show that HPV based screening is either cheaper 
than cytology based testing or cost effective at ICER rates below acceptability thresholds. 
11.1.3.1 Cost effectiveness within country specific studies 
 
The most often analyzed strategy of HPV with cytology triage dominated cytology based 
testing in 9 out of 13 studies. In these cases often no ICERs were shown. In the remaining 
studies the strategy was more expensive at ICERs below acceptability thresholds.  
 
HPV based screening with partial genotyping and direct referral to colposcopy for 
HPV16/18 positive women and cytology triage for other hrHPV types, was the most clinically 
effective solution in all 4 studies that modelled this strategy. It dominated HPV with cytology 
triage in 2 studies and was more expensive at ICERs below acceptability thresholds in the 
other 2 studies. 
 
Cotesting was only a cost effective solution in one study. In all other studies it was either 
dominated or resulted in ICERs above an acceptable threshold.  
 
In conclusion, from a cost effectiveness standpoint HPV with cytology triage and HPV16/18 
genotyping strategies seem attractive by being either cheaper than cytology based 
screening or by being more effective and affordable at ICERs below acceptability thresholds. 
Cotesting is not an attractive solution from a cost effectiveness standpoint. 
 
11.1.3.2  Transferability of health economic studies to the Swiss health system 
In order to assess how the cost effectiveness results might translate into the Swiss situation 
a transferability analysis was done. 
 
This analysis depends on several assumptions about Swiss reference parameters as 
described in the methods chapter. The assumptions have a number of limitations.  
 
It has been assumed that Swiss screening follows the recommendations published by 
the Swiss Society for Gynecology and Obstetrics (“Schweizerische Gesellschaft für 
Gynäkologie und Geburtshilfe, SGGG”) [53]. It is however probable that these 
recommendations are not followed completely. Indeed, a recent survey by the Swiss BAG 
showed that many women are invited far more frequently than recommended for cervical 
cancer screening by their gynecologist [96].  
If a higher frequency for cytology based screening is assumed (e.g. 2 yearly), the cost of 
current screening in Switzerland would be higher. As 2 yearly cytology based screening was 
also dominated by HPV based screening strategies [29, 30, 35, 36, 60] the case for a 
change to HPV based screening would be even more favorable. 
 
HPV prevalence data for Switzerland were taken from only one publication [97] as cited in 
[62] based on 7’254 women from the cantons of Jura, Neuchâtel and Fribourg tested in 
2000-2001. Studies in the UK have found differences of a factor of 2 between HPV 
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prevalence rates in different cities [62]. It is not known whether similar differences exist 
between Swiss regions or if the prevalence data assumed as Swiss reference are 
representative for the whole country.  
Compared to other European countries the available Swiss HPV prevalence rates are lower 
in younger women and higher in older women over 40 years old.  
Based on the study of de Kok [80], higher HPV prevalence rates should make cytology 
based screening more favorable (and vice versa). However, the Australian and UK studies 
which used the same Markov model for their studies (albeit calibrated to their specific HPV 
prevalence and cancer incidence rates), come to similar conclusions in terms of clinical and 
cost effectiveness of different HPV based strategies compared to cytology based strategies 
even though Australia has lower and the UK higher HPV prevalence rates than Switzerland. 
Also in Belgium HPV prevalence is higher than in Switzerland but HPV based screening was 
still more effective and cost effective than cytology based screening [28]. Therefore there is 
no strong reason that results from other countries may not be transferable due to the 
described differences in HPV prevalence. 
 
No publications were found on the sensitivity of cytology based screening in Switzerland. 
This is an important limitation, as the sensitivity is an important influential parameter for the 
relative clinical and cost effectiveness of cytology or HPV based screening. As an example 
in the German health economic study, cytology based screening was less effective and 
cheaper than HPV based screening when sensitivities from international publications were 
used. On the other hand it was dominated, when the lower sensitivities observed in German 
studies were modelled [30, 60]. In the absence of data, it was impossible to assess whether 
the different studies modelled lower or higher sensitivities than representative for 
Switzerland.  
It is important to note that regardless of the sensitivities assumed in the studies all came to 
the conclusion that cytology based screening was less effective. The differences between 
studies were rather in the incremental cost effectiveness ratios for the strategies being 
assessed. 
 
When studies were analyzed against the Swiss reference data, 3 studies were potentially 
transferable as is [30, 32, 35, 60], 1 study was potentially transferable with an offset (no 
screening was modelled below 30 years) [28] and 2 studies may become transferable, if 
Switzerland should decide to switch to an organized screening program [2, 29].  
The remaining studies either had insufficient data to decide on transferability or showed 
relevant differences that indicate no transferability. 
The potentially transferable studies recommended either HPV with cytology triage with a 3 to 
5 yearly frequency or a HPV 16/18 genotyping strategy with 5-6 yearly frequency. 
 
11.1.3.3 Deduction of cost by adaptation of purchasing power parities 
None of the studies provided model results in a way that allowed direct adaptation of the 
results into Swiss values. Therefore it was only possible to translate values for cost and cost 
effectiveness ratios into CHF/LYG or /QALY by adaptation to purchasing power parities.  
 
After translation to CHF by adaptation to purchasing power parities for the studies that 
showed potential transferability, a consistent picture showed with the results from country 
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specific studies: 5 yearly HPV with cytology triage and HPV with partial genotyping remained 
cost effective strategies with values below acceptability thresholds. 
 
The costs for cytology and HPV tests were also adapted to CHF by application of purchasing 
power parities. Current Swiss costs for cytology were within the range that was used in 
models, which is an important aspect for the plausibility of the transferability. 
The costs for HPV tests in the models varied between 20 and 92 CHF. In Switzerland a 
Tarmed value for HPV testing has yet to be defined for use in primary cervical cancer 
screening. If the future costs of HPV testing in Switzerland were to be above that range, 
further analysis would be necessary to verify that the results of the studies can still be 
considered transferable. 
 
In conclusion, from the wide range of studies with different input parameters and specifically 
from the studies that showed potential transferability, it is highly likely that in Switzerland 
HPV based screening will be cost effective with ICERs below 100’000 CHF/LYG or QALY.  
 
Given the large number of health economic studies consistently indicating superior clinical 
and cost effectiveness of the strategy of 5 yearly HPV with cytology triage, the evidence in 
favor of this strategy is considered strong. When a decision has to be taken concerning 
follow up frequencies of women with HPV+/cyt- results, a 12 months interval may be ideal. 
Shorter intervals of 6 months led to much higher costs while longer intervals of 24 months 
may involve a higher loss to follow up of affected women [2, 32]. 
 
For the strategy involving HPV16/18 genotyping the number of studies is smaller, but results 
from health economic studies are highly consistent concerning clinical effectiveness. Also all 
studies found this strategy on the cost effectiveness frontier, albeit at different ICERs. The 
evidence on this strategy is therefore judged as emerging. 
As a side note – HPV16/18 genotyping was described as a highly attractive strategy in 
vaccinated women. The prevalence of HPV16/18 is much lower in these women than in the 
general population and the rates of colposcopy / CIN3+ detected become increasingly 
attractive. In fact in the UK it was assumed that in vaccinated women this strategy will have 
lower colposcopy rates than current cytology based screening [2]. Therefore this strategy 
should be considered for implementation in Switzerland in the future. 
 
11.2 Hypothesis 2: HPV based cervical cancer screening is feasible 
It is concluded that HPV based cervical cancer screening is feasible. However measures 
have to be taken to ensure adherence to policy, as suggested in chapter 11.4. 
 
No hard barriers were identified for the implementation of HPV based cervical cancer 
screening. However, the results of the feasibility analysis show that certain basic conditions 
should be fulfilled when cervical cancer screening with HPV is implemented. A number of 
relevant aspects for a successful introduction of HPV based screening are described in 
chapter 10.  
 
Adherence to policy was identified as the most important aspect. If the HPV test is 
performed at too young an age or more frequently than necessary, more transient infections 
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will be identified and more women will be referred unnecessarily to follow up tests and 
treatment procedures. 
 
Opportunistic screening in Switzerland has been very effective in reducing cervical cancer 
incidence in Switzerland. However there are indications that women are currently invited 
more often to screening than recommended [96].  
The Belgian HTA showed that stricter control of reimbursement has led to better compliance 
with reduced screening frequencies in the current cytology based screening program [28].  
In Switzerland this would require that stricter controls are done e.g. by the health insurance 
companies for the reimbursement of screening tests.  
 
Successful implementation in an opportunistic setting requires that the new 
recommendations are implemented by the most influential stakeholder groups. In 
Switzerland gynecologists have a strong influence on screening participation by provision of 
information to women on the topic and sending out invitations. A stakeholder analysis by 
Altermatt [98] showed that a potential switch from the current cervical cancer screening to 
HPV based screening with longer screening intervals is perceived as an economic threat to 
gynecologists in Switzerland. A moral hazard occurs, if the adherence to policy is in conflict 
with economic interests of the drivers of adherence to policy.  
 
All measures to monitor and drive adherence are more easily set up within an organized 
screening system, which currently in Switzerland does not exist. Extra costs for the 
implementation of an organized screening program would occur. On the other hand the 
benefit of implementing an organized screening system is not only that quality and cost can 
be better controlled, but also that women may be reached that currently do not attend 
screening at all. The overall benefit of this may even be higher than that of replacing 
cytology by HPV as the primary screening test [81].  
 
11.3 Limitations of this study, further research areas 
The following limitations apply to this study: 
11.3.1 Literature selection and analysis process 
In the literature selection process language restrictions were applied. Only English and 
German language publications were included. In addition only Pubmed and the CRD 
databases were searched. This may have biased for publications from the US, UK, Australia 
and Germany, so that the viewpoints from these health systems may be overrepresented in 
the analyzed literature. Indeed in the literature process one Italian HTA and 2 systematic 
reviews from France and Spain were identified in local language that were not included in 
the study.  
On the other hand both the US and Germany have opportunistic cervical cancer screening 
programs and many points raised in these publications are relevant for the Swiss health 
system. In addition meta analyses independent of a specific health system and health 
economic studies and HTAs from several other European countries were included so it is 
assumed that the literature is representative of the current knowledge and opinions on the 
topic. 
 
No documented quality assessment of systematic reviews and meta analyses was done by 
application of a checklist. Instead only a sanity check was done that the included 
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publications fulfilled basic quality criteria such as clear definition of the research question, 
description of the literature search process, inclusion of recent literature, critical appraisal of 
the analyzed studies (e.g. risk of bias), and discussion of limitations.  
From the sanity check done it seemed that the results of the different publications seem not 
to correlate with their quality but rather with the date of publication. More recent publications 
seem to be more favorable for HPV based screening based on the additional data available 
to them from European RCTs and US cohort studies.  
 
Several systematic reviews exist on the clinical evidence of HPV based cervical cancer 
screening. However, to the knowledge of the author no similarly comprehensive and detailed 
systematic review on the health economic evidence on the topic is currently available. 
Therefore the focus of this study was layed on a structured quality assessment of the health 
economic evidence by application of the EURONHEED checklist. 
 
11.3.2 Available data on the current Swiss screening execution and effectiveness 
As discussed in chapter 11.1.3.2 the transferability analysis is based on only published 
recommendations for Swiss screening and no analysis of the actual adherence to these 
recommendations in Switzerland was done. No data on the actual sensitivity of cytology 
screening in Switzerland were available. HPV prevalence data rely on one publication with 
data from 3 cantons only. These limitations are relevant and may have biased the results of 
the current study. 
However, based on the wide range of input parameters that were used across the different 
included studies and the fact that all came to the conclusion that HPV based testing is more 
clinically effective than cytology based screening, and either cheaper or cost effective with 
ICERs below acceptability thresholds, it appears likely that these results will apply to the 
situation in Switzerland as well. 
Nevertheless further research is indicated to determine the adherence to recommendations, 
the sensitivity of cytology based screening in Switzerland and HPV prevalence in women of 
30 years and older.  
 
11.3.3 Deduction of cost in CHF 
None of the studies provided results in a way that allowed direct adaptation of the results 
into Swiss values (e.g. by providing cost and units for all aspects). Therefore it was only 
possible to translate values for cost and cost effectiveness ratios into CHF/LYG or /QALY by 
adaptation to purchasing power parities. 
Even though it is impossible to deduce the true costs for Switzerland by this rather simple 
transformation, the values in CHF are better able to show where the potential costs in 
Switzerland might be than the values in the currency of another country and they make 
values of different studies more easily comparable by using the same currency and cost 
year. 
In order to calculate the true costs for Switzerland a Swiss health economic evaluation 
should be done. Potentially one of the existing health economic models of another country 
could be used, and adapted to the Swiss health care system by calibration to Swiss 
epidemiological data of HPV prevalence and cervical cancer incidence and Swiss costs for 
screening, diagnosis and treatment. 
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11.3.4 Self-sampling for HPV based screening 
This study was limited to HPV based screening with samples taken by health professionals 
and did not address self-sampling for HPV based screening.  
With this approach sampling, storage and transport of samples are under a comparable level 
of control as with sampling for cytology based screening. Therefore this approach allowed 
comparison of the efficacy of cytology versus HPV based screening without introducing 
additional complexity. 
However, with HPV based screening self-sampling by women is possible and was indicated 
as a way to reach women who currently do not participate in cervical cancer screening for 
different reasons [28, 29, 49, 67]. Several publications on the topic are available [99-103], 
but were not analyzed for this thesis. According to Cuzick, self-sampling for an HPV test 
leads to lower sensitivity than when samples for an HPV test are taken by a health 
professional, but to higher sensitivity than with a cytological test [49].  
The effect of self-sampling on the sensitivity and specificity of HPV based screening should 
be further analyzed.  
This thesis comes to the conclusion that unless self-sampling has comparable sensitivity, the 
preferred screening involves sampling by health professionals. Self-sampling should be 
considered for women who otherwise would not attend screening. For this population a test 
that may be less sensitive would still be more advantageous than no screening at all. 
11.3.5 Focus on unvaccinated women 
This study focused on the population of unvaccinated women even though primary 
prevention of cervical cancer involves vaccination of young women before they become 
sexually active.  
In Switzerland, according to a national representative survey of the BAG in 2014, only 41% 
of the 18-24 year old women had received the necessary 3 vaccination doses against HPV 
and 47% were not vaccinated at all [96].  
Therefore unvaccinated women still represent the majority of women eligible for cervical 
screening in Switzerland. 
In several studies analyzed, strategies for vaccinated women were also discussed. It was 
indicated that one of the recommended strategies with HPV16/18 genotyping is even more 
favorable in vaccinated women than in unvaccinated women. Adoption of this strategy may 
therefore serve both vaccinated and unvaccinated women allowing one algorithm for all 
women independent of vaccination status. Having one algorithm for all women would reduce 
complexity and facilitate adherence to recommendations. 
 
Nevertheless a separate study should be done to confirm what the best strategy is for 
vaccinated women in Switzerland. A list of all model based cervical screening evaluations 
including vaccinated and unvaccinated populations was published recently by Mendes and 
could serve as a starting point for this further research [104]. 
11.3.6 New biomarkers 
Finally, the ideal tumor screening marker is 100% sensitive and 100% specific (and does not 
exist yet). More research is therefore ongoing and results should be closely monitored how 
the specificity of HPV based screening can be further enhanced.   
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11.4 Conclusions for potential policy changes for the Swiss screening 
settings  
 
It is concluded that clinical and health economic evidence strongly supports the 
recommendation of 5 yearly HPV based screening for women of 30 years and older. 
The best algorithms seem to be 5 yearly HPV testing with cytology triage or HPV16/18 
genotyping with direct referral to colposcopy for HPV16/18 positive women.  
Consideration should be given to offering self-sampling to women who currently do not 
attend cervical cancer screening. 
 
At the same time it will be important that measures are taken to ensure adherence to policy.  
 
Setting up an organized screening program is the ideal solution, which would also allow 
systematic evaluation of the clinical and cost effectiveness of cervical cancer screening in 
combination with the cantonal cancer registries. 
 
Experience in the Swiss Health System shows, that setting up country wide organized 
screening programs may face political opposition. Centrally organized programs will shift 
some costs from women and health insurance companies (who will have to pay for fewer 
screening tests), to cantons, which will have to fund infrastructure for data collection and 
invitations and reminders. In the light of the effectiveness of the current opportunistic 
screening in Switzerland, which has among the lowest cervical cancer incidence rates in 
Europe, it may be difficult to convince political opponents of centrally organized screening 
programs of the importance and urgency for a change. 
 
Other ideas to ensure adherence to policy should therefore be explored during the absence 
of an organized screening program. Reimbursement controls are one important element. In 
addition, in the absence of a central database and full electronic health records, an 
“electronic screening booklet” could be established analogous to the existing “electronic 
vaccination booklet” to document screening events and results. This would allow an 
overview of screening tests and frequencies even when women change gynecologists and / 
or health insurance companies. It may also provide an opportunity for reminders by mail or 
SMS with minimal additional infrastructure. 
 
A comprehensive stakeholder analysis for cervical cancer screening in Switzerland is 
available in the master thesis of Prof. HJ. Altermatt “Strategieoptionen zur Einführung des 
HPV-Tests in das Vorsorge-Screening für Gebärmutterhalskrebs in der Schweiz“ [98]. 
The thesis of Altermatt shows that the most critical stakeholders may be gynecologists, who 
may perceive a change in policy to longer screening intervals and particularly to a potential 
centralization of screening as an economic threat or an interference in their relationship to 
their patients.  
Measures to ensure support for a policy change by this important stakeholder group may 
consist of education on current clinical and health economic evidence, involvement in the 
creation of policy and refraining from centralization of sampling and communication of 
screening results. Thus, gynecologists would still remain the central contact person for 
women’s health questions. In addition, should an organized screening program be 
implemented, this might reach women, who currently do not attend screening at all. Besides 
better effectiveness of screening in the population of the eligible women, this would provide 
MPH master thesis   Martina Hahn 
  85 
additional income for gynecologists and compensate for longer screening intervals in women 
who attend already now. 
 
Stakeholders that would most benefit from a change are the women. They are currently 
invited more often than necessary to cervical cancer screening and undergo screening with 
a test that does not lead to the best possible clinical effectiveness. As the majority of 
screening occurs in healthy women, screening tests are often paid out of pocket as part of 
the health insurance franchise. In addition, taking a cervical smear is often considered as 
unpleasant. Information that a negative HPV test will allow fewer screening events and 
greater security against cervical cancer may therefore create a strong demand by this 
stakeholder group. 
 
It is concluded that the evidence in favor of HPV based cervical cancer screening is strong 
enough to challenge the current clinical effectiveness, cost effectiveness and suitability of 
the cytology based screening approach in Switzerland. In line with the regulations of the 
federal law for health insurance a reassessment of the current reimbursed strategy should 
therefore be done e.g. as part of the new HTA process by the BAG. 
 
It is hoped that the data and references provided by this study will be helpful as input for this 
HTA process. 
 
Martina Hahn, Zug, July 2016 
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13 Appendix 1: “Literature search algorithms”  
13.1 Search algorithm for Clinical Systematic Reviews and Meta-
analyses in PubMed 
Search  
(((((((((((((“Papanicolaou Test”[Mesh]) OR “Cytological Techniques”[Mesh]) OR liquid 
cytology) OR cytology) OR pap test) OR pap screening))  
AND (((((((((((((“Atypical Squamous Cells of the Cervix”[Mesh]) OR “Squamous 
Intraepithelial Lesions of the Cervix”[Mesh]) OR “Uterine Cervical Dysplasia”[Mesh]) 
OR “Cervical Intraepithelial Neoplasia”[Mesh]) OR “Uterine Cervical 
Neoplasms”[Mesh]))) OR cervix cancer))  
AND (((“Early Detection of Cancer”[Mesh]) OR screening) OR screen*))  
AND ((((((“DNA Probes, HPV”[Mesh]) OR “Papillomaviridae”[Mesh]) OR “Human 
Papillomavirus DNA Tests”[Mesh]))) OR (((HPV) OR Human Papillomavirus) OR 
Human Papilloma Virus)))  
AND (“2008/01/01”[Date – Publication] : “3000”[Date – Publication])))))))))  
Filters: Meta-Analysis; Systematic Reviews 
 
Output March 12, 2016: 123 records 
13.2 Search algorithm for Clinical Systematic Reviews, Meta-analyses, 
HTAs and Health economic Studies in CRD Databases 
 
http://www.crd.york.ac.uk/CRDWeb/ 
 
 
Output March 12, 2016: 93 records 
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13.3 Search algorithm for HTAs, Health economic Studies and Evidence-
Based Medicine Publications in PubMed 
 
(((((((“Papanicolaou Test”[Mesh]) OR “Cytological Techniques”[Mesh]) OR liquid 
cytology) OR cytology) OR pap test) OR pap screening))  
AND (((((((((((((“Atypical Squamous Cells of the Cervix”[Mesh]) OR “Squamous 
Intraepithelial Lesions of the Cervix”[Mesh]) OR “Uterine Cervical Dysplasia”[Mesh]) 
OR “Cervical Intraepithelial Neoplasia”[Mesh]) OR “Uterine Cervical 
Neoplasms”[Mesh]))) OR cervix cancer))  
AND (((“Early Detection of Cancer”[Mesh]) OR screening) OR screen*))  
AND ((((((“DNA Probes, HPV”[Mesh]) OR “Papillomaviridae”[Mesh]) OR “Human 
Papillomavirus DNA Tests”[Mesh]))) OR (((HPV) OR Human Papillomavirus) OR 
Human Papilloma Virus)))  
AND (((((((((“Models, Economic”[Mesh]) OR “Models, Econometric”[Mesh]) OR 
“Economics”[Mesh]) OR “Evidence-Based Medicine”[Mesh]) OR “Cost-Benefit 
Analysis”[Mesh]) OR “Markov Chains”[Mesh]))) OR ((((((health technology 
assessment) OR ebm) OR evidence based medicine) OR economic evaluation) OR 
comparative effectiveness research) OR Cost effectiveness)))  
AND (“2008/01/01”[Date – Publication] : “3000”[Date – Publication])) 
 
Output March 12, 2016: 238 records 
 
MPH master thesis   Martina Hahn 
  89 
14 Appendix 2: “Description of Randomized Controlled Trials and Cohort Studies”  
Table 8: Description of Randomized Controlled Trials and Cohort Studies 
Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
RCTs     
POBASCAM 
Netherlands 
 
[16] 
[17] (intermediate 
report) 
29-56  
 
I=19’999 
C=20’106 
Round 1 
I= HPV+cyt  
C= cyt 
Round 2 after 5 
years: 
HPV+cyt for both 
arms 
Cytology 
findings of 
HSIL or 
worse or 
repeated 
ASC-US  
 
or 
persistently 
HPV pos 
after 18 
months 
 
In the first round of screening there was a non-significantly higher relative detection rate of cancers 
and CIN3+ and a significantly higher detection rate of CIN2+ 
 
In the 2
nd
 screen after 2 years there was a significant reduction of cervical cancer and CIN3+ and a 
non-significant reduction of CIN2+ 
 
Over both screening rounds cancer detection rates were non-significantly reduced, CIN3+ about the 
same in both arms and CIN2+ detection was non-significantly augmented. 
 
Relative detection of CIN3+ in round 1 for I vs C=  1.15 (0.92-1.43) 
Relative detection of CIN3+ in round 2 for I vs C=  0.73 (0.55-0.96) 
Relative detection of CIN3+ over both rounds for I vs C=  0.96 (0.81-1.14) 
 
Relative detection of CIN2+ in round 1 for I vs C=  1.25 (1.05-1.50) 
Relative detection of CIN2+ in round 2 for I vs C=  0.88 (0.71-1.08) 
Relative detection of CIN2+ over both rounds for I vs C=  1.08 (0.94-1.24) 
 
 
There were no significant differences between age groups of  
29-33 vs 34-56 
 
The authors conclude that HPV testing should be implemented in the Dutch screening system starting 
at the age of 30 years 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
ARTISTIC 
England 
[4] 
[27] 
 
20-64 
 
I=18’386 
C=6’124 
I=HPV+LBC  
 
C= LBC (+HPV 
measured, but 
masked from 
patients and 
investigator and not 
taken for treatment) 
 
2 rounds of 
screening 3 years 
HPV + LBC for all  
 
Cytology 
findings of 
HSIL or 
worse 
 
or if two 
consecutive 
LSIL or three 
consecutive 
ASC-US 
 
or 
persistently 
HPV pos 
after 12 -18 
months 
 
Relative detection of CIN3+ in round 1 for I vs C=  0.97 (0.75-1.25) 
Relative detection of CIN3+ in round 2 for I vs C=  0.53 (0.30-0.96) 
Relative detection of CIN3+ over both rounds for I vs C=  0.85 (0.67-1.08) 
 
Relative detection of CIN2+ in round 1 for I vs C=  1.14 (0.94-1.38) 
Relative detection of CIN2+ in round 2 for I vs C=  0.63 (0.42-0.96) 
Relative detection of CIN2+ over both rounds for I vs C=  0.99 (0.83-1.19) 
 
Different from other studies ARTISTIC did not detect more CIN3+ in round 1 with HPV based testing.  
However consistent with other studies in round 2 CIN3+ rates were significantly reduced with HPV 
based testing and over both rounds there was no significant difference between intervention and 
control group. 
 
This study suffered from a comparatively high loss of follow up as less than 70% of the women 
participating in round 1 complied with rescreening within the timeframe of the study 
 
Round 2 was therefore excluded from the analysis of the systematic review of the German IQWiG 
 
The systematic review of Arbyn 2012 excluded the ARTISTIC study round 1 from meta-analysis. They 
assume that this study used a comparatively low threshold of considering LBC samples as positive 
leading to abnormal cytology rates of up to 17%.  
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
 
Swedescreen   
 
Sweden 
 
[18], calculation of 
sensitivities and 
PPV of different 
screening 
strategies based on  
[19] 
 
 
32-38 
 
I=6257 
C=6270  
 
I= cyt + HPV  
C= cyt 
 
C= ASC-US 
or worse (in 
Stockholm) 
or Pap 
retesting with 
ASC-US or 
CIN1 (other 
cities) 
 
I=cyt pos as 
above, if cyt 
normal and 
HPV pos: 
retest after 
12 m, 
colposcopy if 
either cyt 
positive or 
HPV type 
persistently 
positive 
 
Authors conclude in [19] that HPV testing is more sensitive than cytology testing to detect CIN2+ 
which can be treated as precursors of cervical cancer and lead to reduced incidence of CIN3+ in 
subsequent screening rounds. 
There seems to be some overdiagnosis of CIN2 as the combined detection of CIN2 over both round 1 
and 2 was higher in the intervention group than the control group. 
 
 CIN3+  CIN2+ CIN2 
Round 1: 1.31 (0.92-1.87) 1.51 (1.13-2.02) 2.01 (1.19-3.40) 
Round 2:   0.53 (0.29-0.98) 0.58 (0.36-0.96) 0.85 (0.38-1.90) 
 
A strength of this study is that CIN2, CIN3 and cancer cases were taken from cancer registries and 
not only collected through study data. Results were calculated on an intention to treat basis and 
protocol violations were not excluded from the analysis, so that they potentially represent a real life 
screening setting. 
 
In [18] the authors compare different potential screening strategies based on the data (including HPV 
subtyping) from women in the intervention arm.  
They conclude that sensitivity of detection of CIN2+ or CIN3+ is only increased compared to 
cytological testing if all hrHPV subtypes are followed up with retesting. 
 
Cotesting with both cytology and HPV did not significantly increase sensitivity, but had lower PPV 
than HPV testing followed by cytology triage and retesting for cytology negative women. 
The authors also calculated that cotesting resulted in 105% more screening tests performed, while 
HPV testing with cytology triage only increased the number of screening tests by 12%. 
 
Relative sensitivity for CIN3+, CIN2+ and  relative PPV compared to cytology only: 
 
 CIN3+ PPV 
Cotesting of HPV with cytology 1.40 (1.23-1.60) 0.43 (0.33-0.56) 
HPV with cytology triage and retesting after 12 months 1.34 (1.16-1.54) 0.90 (0.70-1.16) 
 
 CIN2+ PPV 
Cotesting of HPV with cytology 1.35 (1.15-1.60) 0.42 (0.28-0.61) 
HPV with cytology triage and retesting after 12 months 1.30 (1.09-1.54) 0.87 (0.60-1.26) 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
NTCC 1 and 2 General conclusion of the authors after 2 screening rounds: 
HPV testing protects against the development of invasive cancers 
HPV testing in women between 25-34 leads to overdetection of regressive lesions 
In women between 35-60 years the data support the use of stand-alone HPV testing as the primary screening test. Cytology triage is recommended 
before colposcopy to increase PPV and reduce the number of unnecessary colposcopies. 
The addition of LBC to HPV testing in primary screening does not improve sensitivity but reduces PPV.  
 
Results over 2 screening rounds  [12] 
Number of invasive cancers for older women 
Pooled results of NTCC1 and NTCC2 showed a reduced number of invasive cancers  
Round 1 I=6, C=8 
Round 2 I=0, C=7 
Over both rounds I=6, C=15 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
NTCC 1 
Italy 
 
Younger women 
[12] 
[14] 
25-34 
years 
 
I=6002 
C=5808 
NTCC1: 
Round 1 
HPV+LBC vs. Pap 
Round 2 : Pap 
 
Interval 3 years 
C= ASC-US 
or worse (7 
centers) or 
Repeat 
cytology with 
ASC-US and 
colposcopy 
with LSIL or 
worse (2 
centers) 
 
I=retest after 
12 m, 
colposcopy if 
either test 
was positive 
 
The authors conclude that “HPV testing in younger women results in overdiagnosis of regressive 
CIN2” 
 
In focus were: Sensitivity and positive predictive value for CIN2+ (some data on CIN3+). In addition 
from the data obtained the theoretical sensitivity and PPV of other screening algorithms were 
calculated 
 
Authors conclude from results after recruitment [14] that  
 
Sensitivity was increased for the detection of CIN2+ (relative sensitivity 1.61 (1.05-2.48 )) but not for 
CIN3+ (0.70 (0.37-1.34)), while relative PPV was lower in the experimental arm for both CIN2+ (0.55 
(0.37-0.82)) and CIN3+ (0.24 (0.13-0.45)) 
 
On cotesting vs HPV testing alone: 
“Adding LBC to HPV testing had a negligible effect on sensitivity but strongly reduced PPV compared 
with HPV screening alone. Therefore HPV testing alone as primary test, with triage of HPV-positive 
women by cytology seems to be the most reasonable approach” 
 
On refining the HPV test: improvements of PPV can be obtained with minimum loss in sensitivity by 
use of a cutoff of 2pg/ml  
 
On feasibility: 
“We had some difficulty in compliance to repeat testing. Only 70% of women returned for a repeat test 
despite intensive reminders, which reduced the recorded gain in sensitivity by HPV testing compared 
with the potential gain.” 
 
Results reported after Round 2 [12] 
Results on round 2 were not reported as CIN3+ but CIN3 or AIS without invasive cancers. 
Relative detection of CIN3 or AIS CIN2 
Round 1: 0.93 (0.52-1.64) 4.09 (2.24-7.48) 
Round 2:   1.34 (0.46-3.84) 0.43 (0.11-1.66) 
Over both rounds: 0.99 (0.61-1.65) 2.81 (1.69-4.66) 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
NTCC 1 
Italy 
 
Older women 
[12] 
[15] 
35-60 
years  
 
I=16706 
C=16658 
NTCC 1: 
Round 1 
HPV+LBC vs. Pap 
Round 2 : Pap 
 
Interval 3 years 
C= ASC-US 
or worse (7 
centers) or 
repeat 
cytology with 
ASC-US and 
colposcopy 
with LSIL or 
worse (2 
centers) 
 
I=HPV pos 
ASC-US or 
worse 
In focus were: Sensitivity and positive predictive value for CIN2+ (some data on CIN3+ and invasive 
cancer) 
In addition from the data obtained the theoretical sensitivity and PPV of other screening algorithms 
were calculated 
 
Authors conclude from results after recruitment (2006-2) that  
Sensitivity was increased for the detection of CIN2+ (relative sensitivity 1.47 (1.03-2.09 )) but not for 
CIN3+ (1.25 (0.78-2.01)), while relative PPV was lower in the experimental arm for both CIN2+ (0.40 
(0.23-0.66)) and CIN3+ (0.34 (0.21-0.54)) 
 
On cotesting vs HPV testing alone: 
With HPV testing alone the gain in sensitivity compared with the comparator group was similar (for 
CIN2+ 1.43 (1.00-2.04) for CIN3+ 1.22 (0.76-1.96) but relative PPV improved (for CIN2+ 0.58 (0.33-
0.98) and CIN3+ 0.50 (0.32-0.79) 
 
On refining the HPV test:  
Setting the cutoff to 2pg/ml instead of 1pg/ml results in similar relative sensitivity (CIN2+ 1.41 (0.98-
2.01 and CIN3+ 1.19 (0.74-1.92)) and yet improved PPV (CIN2+ 0.75 (0.45-1.27) and CIN3+ 0.63 
(0.40-1.00))  
 
Round 2  
Number of invasive cancers 
Pooled results of NTCC1 and NTCC2 showed a reduced number of invasive cancers  
Round 1 I=6, C=8 
Round 2 I=0, C=7 
Over both rounds I=6, C=15 
 
Results on round 2 were not reported as CIN3+ but as CIN3 or AIS 
Relative detection of  CIN3or AIS CIN2 
Round 1: 1.85 (1.16-2.95) 2.07 (1.32-3.24) 
Round 2:   0.72 (0.23-2.28) 0.76 (0.26-2.19) 
Over both rounds: 1.61 (1.05-2.47) 1.77 (1.18-2.67) 
 
The authors comment that the increase of CIN2 and CIN3 over both rounds can either reflect 
overdetection of regressive lesions or the lead time gain of HPV testing. In the latter case the control 
group might have much higher CIN2 or CIN3 cases in a later screening round. 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
NTCC 2 
Italy 
 
[12] 
[13] 
25-60 
years  
(separate 
analysis 
for 25-34  
and  
35-60 
years) 
 
I=24’535 
C=24’661 
NTCC 2: 
Round 1:  
HPV vs. Pap 
Round 2 : Pap 
 
Interval 3 years 
C= ASC-US 
or worse (7 
centers) or 
Repeat 
cytology with 
ASC-US and 
colposcopy 
with LSIL or 
worse (2 
centers) 
 
I=HPV pos 
Authors conclude from results after recruitment [13] that  
In women of 35-60 years 
Relative sensitivity was increased for the detection of both CIN2+ (relative sensitivity 1.92 (1.28-2.87 ) 
and for CIN3+ (2.06 (1.16-3.68)), while relative PPV was non significantly lower in the experimental 
arm for both CIN2+ (0.80 (0.55-1.18)) and CIN3+ (0.86 (0.49-1.52)) 
 
In women of 25-34 years 
Relative sensitivity was increased for the detection of both CIN2+ (relative sensitivity 3.50 (2.11-5.82 ) 
and CIN3+ (2.61 (1.21-5.61)), while relative PPV was non significantly lower in the experimental arm 
for both CIN2+ (0.89 (0.55-1.44)) and CIN3+ (0.66 (0.31-1.40)) 
 
Results on round 2 were not reported as CIN3+ but CIN3 or AIS. 
Older women 
Relative detection of  CIN3 or AIS CIN2 
Round 1: 2.40 (1.43-4.05) 1.93 (1.20-3.09) 
Round 2:   0.30 (0.08-1.11)  0.29 (0.06-1.40) 
Over both rounds: 1.70 (1.08-2.67)  1.58 (1.02-2.44) 
 
The authors comment that the increase of CIN2 and CIN3 over both rounds can either reflect 
overdetection of regressive lesions or the lead time gain of HPV testing. In the latter case the control 
group might have much higher CIN2 or CIN3 cases in a later screening round. 
 
Younger women 
Relative detection of  CIN3 or AIS CIN2 
Round 1: 3.91 (2.02-7.57) 4.96 (2.80-8.79) 
Round 2:   0.20 (0.04-0.93) 0.64 (0.21-1.95) 
Over both rounds: 2.14 (1.28-3.59)  3.38 (2.11-5.43) 
 
On the right age to start HPV testing: 
When the results of Phase 1 (calculated sensitivities for HPV testing only) were compared with 
measured results of Phase 2, there was no significant heterogeneity for women aged 35-60 but 
significant heterogeneity for women aged 25-34. 
“Among women aged 25-34 the large relative sensitivity of HPV testing compared with conventional 
cytology and the difference between relative sensitivity of HPV testing during NTCC phases 1 and 2 
suggests that there is frequent regression of CIN2+ that is detected by direct referral of younger HPV 
positive women to colposcopy. Thus triage test or repeat testing is needed if HPV is to be used for 
primary testing in this context” 
 
After round 2 the authors state that “HPV testing in younger women results in overdiagnosis of 
regressive CIN2” 
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Study Age 
Size 
Intervention 
and 
Comparator 
Colposc
opy 
threshold 
Most important results 
 
Combined 
follow up of  
Swedescreen   
ARTISTIC 
POBASCAM 
NTCC 
 
[39] 
 
 
20-64  
 
176’464 
persons 
 
Median 
follow up 
6.5 years 
 
As 
described 
for individual 
studies 
 
As 
above 
Authors conclude that HPV based screening provides 60-70% greater protection against invasive cervical cancer 
compared with cytology. They support HPV based screening from age 30 on and recommend screening intervals of 5 
years. 
 
Even though the interventions differed greatly between the four studies there was a common effect of protection against 
cervical cancer. Using HPV testing in cervical cancer screening resulted in a significantly lower number of cervical 
cancers (Rate Ratio = 0.60 (0.40-0.89)), with no significant heterogeneity between studies (p=0.52) 
 
HPV testing protects especially better against adenocarcinoma (RR 0.31 (0.14-0.69)), where sensitivity of cytological 
testing is lower than for squamous-cell carcinoma (RR 0.78 (0.49-1.25)) 
 
A negative HPV test had a very high negative predictive value for later occurrence of carcinoma  
 
Cumulative Incidence Rate (CIR) of invasive cervical carcinoma per 100’000 women 
 After 3.5 years after 5.5 years 
I=HPV negative women 4.6 (1.1-12.1) 8.7 (3.3-18.6) 
C=cytology negative women 15.4 (7.9-27.0) 36.0 (23.2-53.5) 
This means that 5 yearly testing with HPV is more protective than 3 yearly cytological testing 
 
On cost and unwanted side effects of HPV screening 
 
Even though all HPV based screening algorithms were better than cytology only, the potential burden by unnecessary 
colposcopies is different between protocols. Number of biopsies taken were compared between studies: 
The data show that immediate referral to colposcopy (NTCC) leads to doubling of biopsies taken, while strategies relying 
on retesting of HPV positive, cytology negative women have comparable biopsy rates as in the control group. 
 
Rate Ratio for biopsies between Intervention and Control Arm 
 Rate ratio heterogeneity between  
  studies 
NTCC 2.24 (2.09-2.39) 
POBASCAM 1.01 (0.94-1.08) 
Swedescreen   0.97 (0.87-1.07) 
ARTISTC 1.08 (0.97-1.19) 
Pooled rate ratio (fixed effects) 1.35 (1.30-1.40) p<0.0001 
Pooled rate ratio (fixed effects, NTCC excluded) 1.02 (0.97-1.07) p= 0.236 
 
On the age to start screening: 
Comparison of different age groups revealed that the gain in efficacy with HPV testing is similar at age 30-34 years 
compared to older women. The authors discuss that a possible explanation is an increased proportion of 
adenocarcinomas in younger age groups. They therefore recommend starting HPV based testing at the age of 30 
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Study Age 
Size 
Intervention 
and 
Comparator 
Colposc
opy 
threshold 
Most important results 
FPHT 
 
Finland 
 
[10] 
[9] 
[7] 
[8] 
25-65 
Years 
 
I=35’837 
C=35’500 
C=Pap  
I= HPV test 
with 
cytology 
triage 
C and I= 
ASC-US 
or worse 
(or 
cytologic
al 
rescreeni
ng after 
12 
months,  
Colposc
opy and 
biopsy 
with LSIL 
 
 
Treat-
ment 
threshold 
CIN1+ 
(LEEP) 
 
After 
2006 in 
women 
<30 
years 
only 
CIN2+  
treated  
[7, 8] Results at round 1:  
Authors conclude that primary HPV DNA screening with cytology triage is more sensitive than conventional screening (even 
though CIN3+ detection was not enhanced significantly). In addition they conclude that in women aged 35 or older, primary 
HPV DNA screening with cytology triage is more specific than cytology only and decreases colposcopy referrals and follow-
up tests. 
 
[7] 
Relative detection of CIN3+  (I vs C) 
All ages (25-65): 1.44 (1.01-2.05) (all invited women = intention to screen) 
All ages (25-65): 1.77 (1.16-2.74) (those women who really attended screening) 
[8] 
The specificity of HPV with cytology triage was equal to that of cytology alone (99.2 vs 99.1% for CIN2+ p=0.13). Test 
specificity increased with the age of the women being screened. 
Relative PPVs for HPV testing with cytology triage vs cytology alone were significantly higher for the outcomes CIN1+ and 
CIN2+ (1.34 (1.04-1.72)) and non-significantly higher for CIN3+ (1.22 (0.78-1.92). Relative PPVs for HPV testing alone vs 
cytology would have been only 20% of those of conventional screening by cytology.  
Colposcopy referrals were 1.2% in both screening arms 
 
Special aspects of this study 
The incidence of cancer and precancerous states after initial screening was only obtained through the cancer registries. The 
advantage of this approach is that also cancer rates in women not attending the study were reported. The disadvantage is 
that according to the authors opportunistic screening in addition to the official screening is frequently performed in Finland 
(about the same number of cervical smears are taken opportunistically as in the organized program) and these screening 
activities are not registered in the cancer registry. [7]). It is therefore unclear, what triggered the detection of cancer and 
precancerous lesions. In addition there is a delay in registration of CIN detection and cancer. As discussed in [9] “owing to 
the use of different registries and delays in registration it was not possible to assess whether cervical lesions were diagnosed 
during intensive screening of the program or diagnosed outside of the program but initiated by the entry screening test 
result.” 
 
The most recent publication [10] does not describe results of screening round 2, but number of cancers and CIN3+ detected 
since round 1 either through additional screening, opportunistic screening or with testing due to symptoms. The results show 
that incidence of cancer was similar on a low level in both initial screening negative HPV and cytology tested women and 
overall cumulated incidence of CIN3+ including round 1 was significantly higher with the HPV intervention group. 
In the systematic reviews and meta-analyses only round 1 results were therefore reported.  
The Finnish trial had the lowest described treatment threshold with LEEP treatment after CIN1+ findings. 
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Study Age 
Size 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
India 
[70] 
30-59 
years 
I1 34’126 
I2 32’058 
C31’488 
I1=HPV test 
I2=Pap test 
C= no screening 
(“standard care”) 
Only one 
screening 
round, 
colposcopy 
was done if 
either HPV 
or Pap test 
was positive. 
 
Treatment of 
LSIL+ was 
done with 
cryotherapy, 
conization, 
LEEP or 
cancer 
therapy 
depending 
on 
histological 
findings 
Women were screened once and when positive underwent colposcopy and directed biopsies. 
Precancerous lesions or cancer were treated. Women were followed up for 4-8 years. 
 
One time HPV screening significantly reduced mortality from cervical cancer while one time Pap 
testing did not 
 
Incidence of cervical cancers 
  (rate per 100’000 women) 
I1 HPV tested 47.4 
I2 Pap test 60.7 
C unscreened 47.6 
Typically with HPV testing fewer cancer cases were at advanced stages than in the control 
 
Cervical cancer mortality rate per 100’000 person-year and hazard ratio (95% CI) 
I1HPV test 34 0.52 (0.33-0.83) 
I2 Pap test 54 0.89 (0.62-1.27) 
C unscreened 64 1.00 
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Study  
RCTs with only one 
round/ cross 
sectional studies 
Population 
Women 
Age 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
CCCaST 
 
Cross sectional 
study 
 
Canada 
[6] 
30-69 
years 
Women 
who 
presented 
for 
screening 
in an 
opportuni
stic 
setting 
were 
randomiz
ed to 2 
groups 
 
10’154 
women 
 
1 round only: 
 
HPV plus Pap  vs  
Pap plus HPV 
Samples taken in 
different order in 
the same visit 
Pos HPV test 
Pos cyt test 
(ASC-US 
/AGC or 
worse) 
 
Plus a 
random 
sample of 
women with 
neg tests  
Sensitivity and specificity of HPV testing  
 
Depending on the definition of a positive colposcopy result in a  
“conservative” (CIN2+ was only confirmed if also present in LEEP excision sample) or “liberal” way 
(CIN2+ was confirmed, if so classified by pathologist) the sensitivity and specificity of HPV vs Pap 
were the following 
 
Authors of systematic reviews only used data obtained with the “conservative definition” 
 
Sensitivity with conservative definition 
HPV: 94.6% (84.2-100.0) 
Pap: 55.4% (33.6-77.2) 
 
Specificity with conservative definition  
HPV: 94.1% (84.2-100.0) 
Pap: 96.8% (96.3-97.3)  
 
Sensitivity with liberal definition 
HPV: 45.9% (18.9-72.9) 
Pap: 43.4% (13.2-73.6) 
 
Specificity with liberal definition  
HPV: 94.2% (93.5-94.9) 
Pap: 96.9% (96.4-97.4)  
 
The order of taking a sample for HPV testing or Pap testing does not influence the result 
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HPV Focal 
Canada, organized 
setting 
 
[105] 
25-65 
years 
 
C:  
6154 LBC   
I1:  
6215 
HPV LBC 
triage 
I2:  
6279 
HPV LBC 
triage 
Round 1 
LBC at entry and 
after 2 years 
 
 
 Not used for any quantitative analysis in systematic reviews.  
 
Only first round described, expect to complete trial by Dec 2016 
Cohort Studies Population 
Age 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
Kaiser Permanente 
Cohort Study 
KPNC 
USA 
[11] 
30 years 
 
331’818 
women 
All women 
underwent 
cotesting as part of 
the US cervical 
cancer screening 
program 
 
Retesting was done 
after 3 years 
 
Total follow up: 4-6 
years 
 
Cumulative 
incidence rates are 
described 
Cytology 
LSIL or 
worse 
(regardless 
of HPV) 
 
HPV pos and 
cytology 
ASC-US 
 
HPV 
negative and 
cytology 
ASC-US 
were 
retested after 
1 year 
 
If HPV 
positive 
retesting 
after 1 year, 
if persistently 
positive, 
colposcopy 
was offered 
regardless of 
cytology 
Authors conclude that for women aged  30 years and older a single negative test for HPV is sufficient 
to reassure against cervical cancer over 5 years and that testing for HPV without adjunctive cytology 
might be sufficiently sensitive for primary screening for cervical cancer 
 
5 year cumulative incidence rates per 100’000 women 
 
 Cancer 
 
HPV negative women:   3.8 
HPV and cytology neg:  3.2 
Cytology negative:  7.5 
 
Cytology positive findings in HPV negative women do not indicate a substantially increased risk over 
5 year to develop  CIN3+ (even though the difference is significant): 
 
 Risk to develop CIN3+ over 5 years 
HPV negative cytology positive: 0.86% 
HPV negative cytology negative: 0.16% 
 P=0.004 
 
However cytology positive findings in HPV positive women indicate a greatly and significantly  
increased risk over 5 years to develop  CIN3+: 
 
 Risk to develop CIN3+ over 5 years 
HPV positive cytology negative: 5.9% 
HPV positive cytology positive: 12.1% 
 P0.0001 
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Cohort Studies Population 
Age 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
ATHENA 
 
Industry sponsored 
study to 
characterize the 
cobas HPV test 
 
(yields separate 
result for HPV 16, 
HPV18 or 12 other 
hrHPV types) 
 
[5] 
25 years 
 
42’209 
All women were 
tested for cytology 
and HPV at entry. 
Follow up was 3 
years with annual 
retesting for both 
cytology and HPV 
 
Women with CIN2+ 
exited the study 
 
Colposcopy was 
offered to all 
women at the end 
of the study 
Cytology 
 ASC-US or  
 
HPV positive 
 
A random 
sample of 
women 
negative for 
both tests 
obtained 
colposcopy 
to determine 
true 
sensitivities 
The effect of different screening strategies were calculated from the cumulative incidence rates of 
CIN2+ and CIN3+ in women who were not CIN2+ at baseline 
 
Over three years 347 cases of CIN3+ were identified  
 
47.3% occurred in baseline cytology neg women 
9.8% occurred in baseline HPV neg women 
P<0.001 
 
6/8 invasive cancers were identified at baseline 
8/8 invasive cancers were HPV positive at baseline 
7/8 invasive cancers were cytology positive at baseline 
 
17/20 cases of adenocarcinoma were HPV positive 
13/20 cases of adenocarcinoma were cytology positive 
 
CIN3+ 
At baseline in 17.8% of HPV pos women 
 
CIN3+  CIR of over three years: 
 
25.2% (21.7-28.7) in HPV16 pos women 
5.4% (4.5-6.3) in women HPV pos for other types than HPV16/18 
0.3% (0.1-0.7) in HPV neg women 
0.8% (0.5-1.1) in cytology neg women 
0.3%(0.1-0.6) in HPV and cytology neg women 
 
Colposcopies per 1 case of CIN3+ 
 
in women  25 years   
with cytology  10.8 (9.4-12.6) 
with cytology for women of 25-29 years and HPV testing for women 30 years  12.9 (11.5-14.8) 
with HPV  12.8 (11.7-14.5) 
 
in women 30 years 
with cytology  10.1 (8.6-12.2) 
with HPV  13.1 (11.5-15.2) 
 
  
MPH master thesis   Martina Hahn 
  102 
Cohort Studies Population 
Age 
Intervention and 
Comparator 
Colposcopy 
threshold 
Most important results 
VUSA-Screen 
Netherlands 
[71] 
 
29-61 
years 
 
Women 
within 
normal 
Dutch 
screening 
program 
At entry all women 
were cotested for 
cytology and HPV 
and HPV subtyping 
was done 
(n=25’871) 
 
A subcohort was 
formed from all cyt 
neg HPV pos 
women who were 
age matched to 3 
cyt neg HPV neg 
women each 
(n=1021) 
 
Repeat cytology 
testing was done 
on HPV pos women 
at 12 m 
and cyt and HPV 
testing done after 
24 m for all women 
(n=3063) 
Cytology 
>BMD or  
Cytology 
BMD and 
HPV pos 
 
 
Cyt -/HPV+ 
plus  
Testing with HPV alone with cytology triage and with genotyping triage allows reduction of risk for 
CIN3+ sufficiently to not refer directly to colposcopy 
Starting HPV testing with 30 years looks suitable 
 
Relative sensitivity for CIN3+  HPV vs cyt  = 1.42 (1.19-1.67) 
Relative specificity for CIN3+ HPV vs cyt  = 0.969 (0.966-0.971) 
 
Cotesting vs HPV alone with cytology triage for HPV positive: 
Small, non-significant difference in CIR for CIN3+ within 3 years: 
Cotesting cyt neg and HPV neg CIR= 0.05% (0.01-0.42) 
HPV neg  CIR= 0.06% (0.02-0.46) 
 
HPV subtyping 
Cyt+ and HPV 16/18+  CIR= 26.1% (21.4-31.4) 
Cyt+ and other hrHPV types  CIR= 6.6% (4.8-9.0) 
 
Cyt- and HPV +  CIR= 5.22% (3.72-7.91) 
Cyt- and HPV 16/18+  CIR= 13.0% (7.93-23.6) 
Cyt- and other hrHPV types + CIR= 2.44% (1.61-5.25) 
 
When stratifying HPV pos women with abnormal cytology into 2 age groups (29-33 and 34) no risk 
difference between the older and younger age group was observed for CIN3+ and CIN2+ 
 
Potential weaknesses of the study: 
 
All probabilities were adjusted for non-attendance of retesting after 12 and 24 months. As women 
were blinded to their HPV status, only about 60% of cytology negative women attended the retesting 
at 12 or 24 months.  
 
Also no colposcopies were done in women negative for both cytology and HPV to verify the amount of 
false negative results 
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15  Appendix 3: “Research Question 1a and b Qualitative results from systematic reviews and meta-
analyses” 
Table 9: Summary of information on research questions from the clinical systematic reviews and meta-analyses 
Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
Huh, 2015, 
USA 
[64] 
This systematic review was 
performed to provide new 
interim clinical guidance for the 
US based on new publications 
after 2011 
 
The review is based on the 
most recent publications from 
the studies ARTISTIC, NTCC, 
POBASCAM, FPHT, the 
combined follow up of women 
from ARTISTIC, NTCC, 
POBASCAM and Swedescreen 
[39]  and a recent test 
characterization study for a 
new HPV DNA test [5]. 
“hrHPV screening is highly sensitive, but specificity depends 
on subsequent evaluation strategies and screening 
frequencies” 
A modelling study of triage options based on the ATHENA 
trial showed that  
“Triaging positive hrHPV tests with genotyping for 16/18 and 
reflex cytology for women positive for the 12 other hrHPV 
genotypes achieved an appropriate balance between safety 
and test utilization.” (test utilization includes number of 
screening tests and number of colposcopies required to 
detect one case of CIN3+) 
“A negative HPV test provides greater reassurance of low 
CIN3+ risk than a negative cytology result” 
“Screening should not occur at intervals 
shorter than 3 years among women with 
negative screening results.” 
 
On combined HPV and cytology testing vs 
HPV testing alone: 
“These results suggest that primary hrHPV 
testing with a negative result with a 3-year 
screening interval is at least as effective as 
five-year cotesting”. “ 
 
“Primary hrHPV 
screening 
should not be 
initiated prior to 
25 years of age. 
“ 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[46, 65] 
IQWiG 2011, 
2014  
Germany 
This systematic review was 
performed by the German 
“Institut für Qualität und 
Wirtschaftlichkeit im 
Gesundheitswesen” to provide 
information for the German 
Health System 
 
It is based on the studies 
ARTISTIC, POBASCAM, 
NTCC 1 and 2, FPHT, 
Swedescreen , CCCaST and 
“India” 
Results of the studies indicate that HPV testing alone or in 
combination with cytology leads to lower incidences of 
CIN3+ and invasive cervical cancer. 
 
However these reviews come to the conclusion that no 
recommendation can be made yet for a specific screening 
strategy as the available data are incomplete regarding the 
patient-relevant endpoint of cervical cancer related mortality. 
In addition is was not possible to compare harms of HPV 
based screening alone or in combination with cytology 
compared to cytology alone. 
 
Transferability of study findings to the German setting was 
questioned, as screening strategies in the randomized 
controlled trials are different from current clinical practice. 
E.g. CIN2 was often treated in the studies, while in Germany 
this histological finding will rather lead to intense 
surveillance. 
Not analyzed Not addressed 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[47] 
Pileggi, 2014 
The goal of this study was to 
characterize relative detection, 
relative specificity and relative 
positive predictive value (PPV) 
of HPV DNA testing compared 
to cytology. 
This meta-analysis is based on 
the randomized controlled trials 
ARTISTIC, POBASCAM, 
NTCC 1 and 2, FPHT, 
Swedescreen , CCCaST and 
“India”  
According to this study: 
Relative detection of CIN2+ and CIN3+ is significantly higher 
with HPV testing than with cytology testing. 
 
Specificity was based on availability of colposcopy data and 
is therefore based on NTCC 1 and 2, FTPH, ARTISTIC and 
Swedescreen only 
 
Specificity over all age groups is higher with cytology testing 
than with HPV testing. 
 
However for women  30 years the specificity of HPV testing 
and cytology testing was similar. 
PPV was not significantly lower with HPV testing than with 
cytology 
 
“The high sensitivity of HPV DNA testing 
could only marginally improve by 
systematically adding the cytology test with 
an irrelevant increase of precancerous 
lesions detected “ 
 
“Primary 
screening of 
cervical cancer 
by HPV DNA 
testing appears 
to offer the right 
balance 
between 
maximum 
detection of 
CIN2+ and 
adequate 
specificity, if 
performed in the 
age group  30 
years.“ 
 
[44] 
Arbyn 2012 
The goal of the study was to 
inform clinicians about recent 
meta-analyses and systematic 
reviews on 3 possible clinical 
applications (HPV) testing: 
including as a primary cervical 
cancer screening test.  
This systematic review is 
based on cross sectional, 
cohort and test characterization 
studies, as well as the RCTs 
ARTISTIC, NTCC, 
Swedescreen  , POBASCAM, 
FPHT 
 
“Primary screening for hrHPV generally detects more CIN2, 
CIN3 or cancer compared to cytology at cut-off ASC-US or 
LSIL, but is less specific.” 
 
“The loss in specificity associated with primary HPV-based 
screening can be compensated by appropriate algorithms 
involving reflex cytology and/or HPV genotyping for HPV16 
or 18.”  
 
“Combined HPV and cytology screening 
provides a further small gain in sensitivity 
at the expense of a considerable loss in 
specificity if positive by either test is 
referred to colposcopy, in comparison with 
HPV testing only.” “Randomized trials and 
follow-up of cohort studies consistently 
demonstrate a significantly lower 
cumulative incidence of CIN3+ and even of 
cancer, in women aged 30 years or older, 
who were at enrollment hrHPV DNA 
negative compared to those who were 
cytologically negative. The difference in 
cumulative risk of CIN3+ or cancer for 
double negative (cytology & HPV) versus 
only HPV-negative women is small.“ 
“There exists a 
substantial 
evidence base 
to support that 
HPV testing is 
advantageous 
… in primary 
screening of 
women aged 30 
years or older. “ 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[66] 
Patanwala 
2013 
The objective of this study was 
to assess the sensitivity and 
specificity of HPV testing for 
cervical cancer screening in 
randomized trials.  
This systematic review is 
based on the RCTs ARTISTIC, 
NTCC, Swedescreen, 
POBASCAM, FPHT and the 
study “India” 
Authors come to the conclusion that : 
“This systematic review indicates that after 2 rounds of 
screening, HPV-testing based screening strategies are more 
sensitive than cytology for the detection of CIN3 or greater 
only when referral to colposcopy follows a single positive 
HPV test. This strategy results in more colposcopies needed 
to detect a single case of CIN3 or greater or cancer, 
especially in women over 35 years of age. Because CIN3 
and cervical cancer are rare in well screened populations, 
the impact on increased disease detection needs to be 
balanced with the impact on cost, numbers of colposcopies, 
and morbidity associated with potential overtreatment.” 
Sensitivity over 2 screening rounds in this case is interpreted 
as increased cumulated detection of CIN2+ or CIN3+ over 
both screening rounds. 
This interpretation is in contrast to other systematic reviews, 
where the increased cumulative detection of CIN over 2 
rounds is rather taken as a potential indicator of over- 
diagnosis of regressive lesions.  
 
Patanwala also tried to calculate colposcopy rates for all 
studies and found that colposcopy rates in round 1 per 
CIN3+ case detected was significantly (p=0.04) elevated in 
NTCC1 (even though SD-bars of confidence intervals in the 
graph overlap) and in ARTISTIC (5.4 colposcopies in the 
intervention arm, 4 in the control arm p<0.01) while in the 
other studies colposcopy rates were non significantly higher 
in the control arm 
Not addressed Not addressed 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[67] 
Saslow 2012 
USA 
This publication represents US 
screening guidelines based on 
systematic reviews of RCTs 
and cohort studies 
For women aged 30-65 years, evidence was found strong to 
recommend either cotesting with HPV and cytology every 5 
years (preferred) or cytology alone every 3 years. 
 
Addition of HPV testing to cytology enhances detection of 
adenocarcinoma of the cervix and its precursors as 
cytological screening seems to be especially ineffective to 
protect against adenocarcinoma. 
 
Screening with HPV at intervals less than 3 years leads to 
unnecessary procedures and to potentially harmful 
treatment of regressive lesions. 
 
Cotesting with HPV is more sensitive for CIN3+ than 
cytology alone and a negative HPV test has a substantially 
lower subsequent risk of CIN3+ than a negative cytology 
test. 
 
HPV testing in RCTs was often associated with increased 
colposcopy rates, which can be minimized by extending the 
interval of screening. 
Based on the studies available at this point 
in time working group 6 on future strategies 
came to the conclusion (even though as a 
weak recommendation) that the evidence 
for the effectiveness of screening based on 
HPV DNA testing alone is still too 
preliminary to recommend hrHPV testing 
alone in the general population: 
 
“in most clinical settings in the US, we 
recommend against the use of hrHPV 
testing as a primary screening strategy 
(even with defined follow up triage)” based 
on the rational that the available data on 
specificity and relative harms associated 
with this strategy are of low quality.” 
“Data are limited to women over the age of 
30 years and are derived primarily from 
studies conducted outside of the United 
States. HPV-based screening approaches 
may be most appropriate for countries with 
organized screening programs where 
women are invited periodically for 
screening and referred to specialized 
centers for evaluation, management, and 
treatment. 
 
 “Screening intervals may be extended to 5 
years if HPV testing is used for primary 
screening among women ages 30 and 
older, when the HPV test results are 
negative” 
There is 
insufficient data 
to conclude if 
the currently 
recommended 
cutoff age of 30 
for cotesting 
might be 
decreased 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[54] 
Massad 2013 
USA 
This publication represents US 
guidelines for the management 
of abnormal cervical cancer 
screening tests and cancer 
precursors based on 
systematic reviews of RCTs 
and the Kaiser Permanente 
cohort studies (KPNC) [11, 72] 
 
It makes reference to [67] 
 
The strength of this publication 
is the discussion of risk based 
approaches for screening 
frequency and treatment of 
screening positive women 
As screening strategies do not only depend on the primary 
screening test, but also on the regime of follow up, a risk 
based approach for women with positive primary screening 
tests was developed. 
 
Immediate colposcopy was recommended when the 5-year 
risk of CIN3+ exceeds 5%, a 6- months to 12-month return 
for risk of 2-5%, a 3 year return for risk of 0.1-2%, and a 5-
year return interval for risk comparable to co-testing in 
women with negative primary screening tests or a risk of 
0.1% 
 
Based on this approach the preferred primary screening for 
women of 30 - 64 years is cotesting every 5 years with HPV 
and cytology. 
 
Cytology positive women should be treated as per previous 
guidelines. The fraction of cytology positive HPV negative 
women was considered so low, that no differentiation of 
treatment of HPV positive and negative women was deemed 
necessary. 
 
HPV positive, cytology negative women should receive 
repeat co-testing after 1 year. If HPV test is persistently 
positive after 1 year or cytology is ASC-US or worse, 
colposcopy is recommended. 
If HPV test is negative after 1 year and cytology is negative 
too, repeat co-testing after 3 years is recommended. 
 
HPV genotyping was found an acceptable method. For 
women with HPV 16 or HPV 18 positive tests immediate 
colposcopy instead of repeat testing after one year is 
recommended 
HPV testing only was not considered 
 
However implicitly the recommendations in 
this publication say that if HPV testing only 
would be applied, HPV positive women 
should receive always cytology triage 
instead of immediate colposcopy and 
possibly HPV subtyping for HPV 16 and 
18. 
 
Cotesting is 
preferred for 
women of 30 
years and older 
 
For younger 
women cytology 
alone should be 
done 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[56] 
ACOG, 2012 
USA 
The goal of this study is to 
provide clinical management 
guidelines for screening for 
cervical cancer 
 
The methods of extracting the 
literature are not described. 
 
Included studies are RCTs with 
cotesting of HPV and cytology 
(POBASCAM, Swedescreen, 
NTCC, 
The Cohort Study KPNC and 
Modelling done by the US 
Agency for Healthcare 
Research and Quality and a 
European Cohort Study from 
2008 [83] 
The authors state that in women aged 30-65 years cotesting 
every 5 years achieves slightly lower cancer rates compared 
to cytology testing every three years, with less screening 
and fewer follow-up colposcopy procedures. This is based 
on a probabilities of CIN3+ development in a European 
cohort study [83], the KPNC cohort study [11], results of 
RCTs (POBASCAM and NTCC showed lower CIN3+ values 
with HPV based testing in the second screening round [12, 
16]) and modelling done by the authors [86].  
 
HPV positive cytology negative women should be managed 
with repeat cotesting after 12 months and receive 
colposcopy at that time, if cytology is LSIL or HPV is 
persistently positive 
 
Alternatively HPV positive cytology negative women should 
undergo HPV type testing and colposcopy should be 
performed directly if HPV 16 or 18 is found. 
 
The rational for cotesting is derived from cohort studies, 
where most transient infections were cleared after 12 
months.  
HPV testing alone cannot be 
recommended until it is clarified how to 
further evaluate patients with positive HPV 
results. 
“With resolution of this important limitation, 
primary HPV screening may become 
important in the future, particularly because 
a recent systematic review and a large 
population-based observational study [11] 
both suggest that co-testing may have only 
marginal benefit when compared with HPV 
testing alone .” 
No HPV testing 
should be 
performed as 
primary 
screening in 
women younger 
than 30 years 
due to the high 
frequency of 
transient 
infections and 
the low 
incidence of 
cervical cancer 
in this age 
group. 
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Systematic 
Review / 
Meta-
analysis 
Motivation,  
included Studies 
Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[43] 
Bouchard-
Fortier 
2014 
A Meta-analysis was done on 
RCTs comparing cotesting with 
HPV and cytology versus 
cytology alone. 
 
It is based on the RTCs 
POBASCAM, ARTISTIC, 
NTCC1 and Swedescreen 
Meta-analysis showed that at baseline screening cotesting 
was associated with significantly higher detection rate of 
CIN2+ (RR=)) and non-significantly higher detection rates 
for CIN3+. 
The pooled analysis for the second screening round (follow-
up) showed that co-testing was significantly associated with 
a lower detection rate of CIN 2+ and of CIN 3+ lesions  
The overall detection rate ratio of CIN2+ lesions was not 
statistically significantly higher with co-testing versus 
cytology alone and about the same for CIN3+. 
 CIN2+ RR (95% CI) CIN3+ RR (95% 
CI) 
Round 1 1.41 (1.12-1.76) 1.15 (0.99-1.33) 
Round 2 0.77 (0.63-0.93) 0.68 (0.55-0.85) 
Cumulative 1.19 (0.99-1.46) 0.99 (0.87-1.14) 
 
They state that harms from screening could not be analyzed 
from the RCTs as the data provided from the RCTs are 
incomplete on the number of unnecessary colposcopies, or 
the number and types of interventions performed at or after 
colposcopies 
 
They recommend modelling analysis to compare different 
screening algorithms for potential harms. 
Only cotesting was analyzed 
 
Age groups 
were pooled in 
the analysis. No 
separate 
analysis for 
younger or older 
women 
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Systematic 
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Meta-
analysis 
Motivation,  
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Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[51] 
Moyer 
2012 
USA 
The US Preventive Services 
Task Force (UPSTF) 
performed a systematic review 
to update screening guidelines 
 
RCTs POBASCAM, NTCC, 
ARTISTIC and Swedescreen 
were analyzed and the cohort 
study KPNC 
Cotesting every 5 years offers a comparable balance of 
benefits and harms as cytology testing every 3 years. 
 
They summarize the result of the RCTs as follows: 
 
In all 4 trials there were slightly lower rates of CIN3+ 
detected in the second round of screening and fewer cancer 
cases in the co-testing group than in the cytology group. 
Differences were small and not always significant 
 
From the KPNC cohort study they note that cumulative 5-
year incidence of cervical cancer was lower in the HPV-
negative and cytology-negative groups than in the cytology 
negative group. 
 
The authors state that the studies did not allow detailed 
analysis of harms from screening.  
They say that in general incorporating HPV testing into 
primary cervical cancer screening will lead to more positive 
screening results. Therefore the likelihood of prolonged 
surveillance (after the age of 65, where otherwise screening 
would be stopped) and overtreatment may increase. 
 
In the US it is expected that 11% of women aged 30-65 
years will have a normal cytology test result and a positive 
HPV test result. 
 
The authors discuss that evidence on the 
benefits and harms of HPV testing alone is 
limited. 
However “an emerging chain of evidence 
suggests that HPV testing followed by 
cytology in women with positive HPV test 
results may also be a reasonable 
screening strategy.” 
Women younger 
than 30 years 
should be tested 
with cytology 
only 
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Research Question 1a: 
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testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[48] 
Rebolj 
2012 
This systematic review aims at 
the determination of specificity 
of HPV testing vs cytology in 
different age groups and is 
based on the studies NTCC1 
and 2, ARTISTIC, 
Swedescreen, POBASCAM, 
FPHT, CCCaST and “India” 
 
 
Besides analyzing the relative detection of CIN1 and CIN2, 
which are precancerous lesions that often regress, Rebolj 
analyses how many women will be diagnosed with a “false 
positive” screening result from their primary cervical 
screening test, if this test is HPV vs cytology.  
 
The authors defined excess detection of CIN2 (compared 
with cytology screening) as an adverse effect of HPV 
testing, as CIN2 is often treated, even though many CIN2 
lesions will regress.  
“Adverse screening effects (detection of CIN2) were less 
common among women aged at least 30 years than among 
younger women. However, in older women HPV testing still 
led to more CIN1/CIN2 diagnoses and false-positive tests 
than cytology.” The authors state that this was seen in some 
RCTs, but not all (ARTISTIC and FPHT), due to the low 
cytology thresholds applied in the latter studies 
They cited data from NTCC (with immediate colposcopy 
after a positive HPV result) where 17 extra CIN2 versus 9 
extra CIN3 cases were treated for each extra prevented 
cancer case [12, 106], indicating an increased burden of 
CIN2 overdiagnosis by switching from cytology to HPV 
testing” 
 
However they also state that longer screening intervals 
permitted with HPV testing (based on [79, 83]) may partially 
compensate the false positive result rate during a woman’s 
life time. 
 
With the definition used in this study the frequency of “false 
positive” tests is increased at all ages. 
The authors recommend that triage should be added to HPV 
testing to define a “positive” test result. No colposcopy 
referral should be done solely based on an HPV positive test 
result.  
Not addressed 
 
The effect of 
elevated 
detection of 
CIN1 and CIN2 
was less 
prominent with 
women aged at 
least 30 years 
than among 
younger women. 
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On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[45] 
Murphy 
2012 
This systematic review aims to 
assess whether the increase in 
baseline detection with HPV 
testing in RCTs corresponds to 
lower rates in subsequent 
screening rounds and is based 
on the studies NTCC1 and 2, 
ARTISTIC, Swedescreen, 
POBASCAM, FPHT, CCCaST 
and “India” 
“Across studies, HPV testing was more accurate than 
conventional cytology and detected significantly more CIN3+ 
in the first screening round (Mantel-Haenszel [M-H] risk ratio 
1.67; 95% CI 1.27 to 2.19) and significantly less in the 
second screening round (M-H RR 0.49; 95% CI 0.37 to 
0.66). There were no differences in pooled rates of CIN2+ 
(M-H RR 1.19; 95% CI 0.94 to 1.50) and CIN3+ (M-H RR 
1.09; 95% CI 0.84 to 1.42), but there was a higher pooled 
rate of CIN2 (M-H RR 1.37; 95% CI 1.12 to 1.68) over two 
screening rounds. A trend towards lower rates of invasive 
cervical cancer was observed.” 
 
“Colposcopy rates were generally higher with HPV testing at 
baseline screening and among younger women, reflecting 
higher detection rates among these groups. The variety of 
different management strategies resulted in referral rates 
ranging from 1.1% for women aged 30 to 69 who underwent 
primary HPV testing (referral threshold of 1 pg/mL) with 
cytology triage of positive results (referral threshold of ASC-
US)(C1), to 13.0% for women aged 25 to 34 who were 
directly referred to colposcopy after a positive HPV test 
(referral threshold of 1 pg/mL)” 
Not in focus 
 
 
Additional 
results from the 
NTCC trial 
…indicate that 
for the 25 to 34 
age group, 
detection of 
CIN2 was more 
than four times 
higher (RDR = 
4.54; 95% CI 
3.00 to 6.88) for 
the intervention 
group (i.e., 
comparing co-
testing to 
cytology testing 
alone), and 
CIN2+ detection 
was over three 
times higher 
(RDR = 3.03; 
95% CI 2.28 to 
4.03). 
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Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[68] 
Whitlock 
2011 
USA 
This systematic review was 
done 2011 for the US 
preventive services task force 
and is based on the RCTs 
ARTISTIC, POBASCAM, 
Swedescreen, FPHT, NTCC 
and CCCaST 
“Six fair- to good-quality diagnostic accuracy studies showed 
that 1-time HPV screening was more sensitive than cytology 
for detecting CIN3+/CIN2+ but was less specific.  
On the basis of 2 fair- to good-quality randomized, controlled 
trials (RCTs) (120 533 participants), primary HPV screening 
detected more cases of CIN3 or cancer in women older than 
30 years.  
Four fair - to good-quality diagnostic accuracy studies and 4 
fair- to good-quality RCTs showed mixed results of cotesting 
(HPV plus cytology) in women aged 30 years or older 
compared with cytology alone, with no clear advantage over 
primary HPV screening.  
Incomplete reporting of results for all screening rounds, 
including detection of disease and colposcopies, limits our 
ability to determine the net benefit of HPV-enhanced testing 
strategies.” 
“On the basis of indirect comparisons 
between NTCC phases 1 and 2 cotesting 
offers no additional CIN3+ detection above 
HPV screening alone, but may yield more 
false-positive results” 
This review only 
analyses the 
benefits and 
harms of HPV 
testing for 
women 30 years 
and older. No 
analysis was 
done for 
younger women 
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Research Question 1a: 
On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[49] 
Cuzick 
2008 
A review of meta analyses and 
systematic reviews on possible 
clinical applications of HPV 
testing is provided including the 
use as a primary cervical 
cancer screening test. 
This systematic review is 
based on early cross sectional 
studies and the first rounds of 
RCTs NTCC, POBASCAM and 
Swedescreen   
 
“Primary screening with Hybrid Capture® 2 (HC2) generally 
detects more than 90% of all CIN2, CIN3 or cancer cases, 
and is 25% (95% CI): 15–36%) relatively more sensitive 
than cytology at a cut-off of abnormal squamous cells of 
undetermined significance (ASC-US) (or low-grade 
squamous intraepithelial lesions (LSIL) if ASC-US 
unavailable), but is 6% (95% CI: 4–7%) relatively less 
specific.” 
 
“Basic principles suggest that in such circumstances the 
more sensitive test should be applied first (i.e., HPV DNA 
testing) and the more specific test (i.e., cytology) should 
then be used only for HPV-positive women to determine 
management.”  
“This approach of using HPV DNA testing as the sole 
primary screening modality has several advantages: HPV 
DNA detection assays provide an automated, objective and 
very sensitive test. This allows for better quality control and 
reduces the basis for medico-legal claims; (2) cytology can 
thus be reserved for the 5–15% of women who are HPV-
positive. This facilitates high quality cytology and allows the 
employment of fewer, more focused cyto-screeners; (3) it 
also avoids the unnecessary triage of HPV-negative ASC-
US/LSIL; and (4) a longer screening interval is likely to be 
safe which would improve both the cost and convenience of 
screening” 
 
Not addressed Not addressed 
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Review / 
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Motivation,  
included Studies 
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On the clinical effectiveness of HPV testing versus cytology 
testing  
Research Question 1a: 
Cotesting of HPV with cytology versus HPV 
testing alone as primary screening test 
Research 
Questions 1b: 
Age to start HPV 
testing 
[52] 
Schiffman 
2011 
USA 
 
“To inform an evidence-based 
transition to a new public health 
approach for cervical cancer 
screening, we summarize HPV 
natural history and cervical 
carcinogenicity, review the 
efficacy of currently available 
cervical cancer prevention 
methods, discuss how optimal 
prevention strategies are 
guided by HPV biology and 
technology, and describe 
important remaining 
uncertainties and concerns 
regarding the possible misuse 
of new screening strategies” 
This systematic review is 
based on the RCT studies 
NTCC, CCCast, Swedescreen, 
India, POBASCAM, ARTISTIC 
and cohort studies (especially 
KPNC) 
Now that the sensitivity of HPV tests is beyond question, 
waiting for results of randomized clinical trials of the various 
possible HPV screening and management protocols relative 
to cytology would risk postponing health benefits for many 
women. Where practical, and following proper regulatory 
approvals, we advocate implementation of HPV tests as the 
primary cervical screening test in a well-controlled and 
evaluable fashion that will allow the best strategies to be 
sorted out as HPV-based screening (and vaccination) 
methods continue to improve [e.g. (81,131)]. As we start to 
use HPV testing for the key function of screening—risk 
stratification—what we need most is to determine how best 
to 1) make use of negative HPV tests to lengthen screening 
intervals substantially and 2) manage women with positive 
HPV tests while avoiding overtreatment. 
To save the most lives, HPV testing should be adopted 
worldwide, especially in low-resource settings where the 
burden of cervical cancer is the greatest. Now that practical 
tests are available, the most pressing need is for simple and 
inexpensive treatments for HPV infections to permit optimal 
screen-and-treat programs in the poorest places, where 
women are most threatened by invasive cervical cancer. 
“Triage of women who have a positive HPV 
test with cytology is more economical than 
cotesting all women with both tests. 
However, cytology is also an imperfect 
second test for triaging HPV-positive 
women; an abnormal cytology finding 
(especially HSIL) further increases risk 
(positive predictive value) of CIN3+ among 
HPV-positive women, but their risk remains 
substantial after a negative cytology triage 
result. Therefore, at least in the United 
States; HPV-positive cytology-negative 
women require some kind of intensified 
follow-up before resumption of routine 
screening” 
“Current practice 
in the United 
States to restrict 
carcinogenic 
HPV testing to 
women aged 30 
years or older, 
who are past the 
peak of acute 
HPV infections, 
results in a 
higher positive 
predictive value 
of HPV testing 
because a 
higher 
proportion have 
HPV infections 
that are 
persistent.” 
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16 Appendix 4: “Research question 1a-c – Excerpt of answers from HTAs and Health Economic Studies” 
Table 10: Extraction of Answers to Research Questions 1a, b and c from Health Economic Studies 
Publication 
Year 
Country 
Study Description Research Question 1a 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to 
test for HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios
11
 
Sroczynski 
et al.  
2010, 2011 
Germany 
[30, 60] 
 
Goal: Analysis of cost-effectiveness 
of primary HPV screening for cervical 
cancer in Germany.  
A cohort of unvaccinated women of 
15 years until end of life was 
modelled 
 
Strategies 
 Pap test (63% of Pap pos receive 
repeated Pap test, the rest either 
HPV testing, cotesting or direct 
colposcopy) 
 Pap + HPV cotesting 
 HPV + Pap triage (all HPV positive 
women receive Pap testing) 
 HPV only (43% HPV positive 
women receive Pap testing, 27% 
cotesting, 23% directly 
colposcopy, 3% HPV test 
repetition, 3% direct therapy) 
 
Frequency: 1-5-yearly intervals for all 
strategies were modelled  
Perspective: 3
rd
 party payer 
Results reported in 2007 Euro 
Costs and benefits discounted at 3% 
Quality score: 0.87  
Transferability data score: 0.87 
Clinical effectiveness of not dominated strategies 
shows that primary testing with HPV based 
strategies is always more effective than testing with 
cytology of the same frequency. 
5-yearly testing with HPV based strategies are 
slightly more effective than 3 yearly Pap testing 
 
Strategy Discounted 
effects (LY) 
% reduction  
lifetime cancer risk 
no screening 28.832 - 
Pap 5y 28.861 53% 
Pap 3y 28.869 70% 
HPV 3y 28.875 85% 
HPV + pap 
triage 3y 
Not shown 85% 
Cotesting 3y Not shown 85% 
HPV 5y Not shown 71% 
HPV + pap 
triage 5y 
Not shown 72% 
Cotesting 5y Not shown 72% 
HPV 2y 28.877 91% 
HPV + Pap-
Triage, 2y 
28.877 92% 
HPV 1y 28.879 97% 
 
The burden of screening was not modelled (no 
numbers of colposcopies were calculated, no QALYs 
were used).  
Not addressed 
in this study 
 
Based on an 
earlier German 
HTA study 
[107] HPV 
testing below 
30 years is 
likely to result 
in increased 
cost for the 
health system, 
due to high 
prevalence of 
HPV in 
younger 
women. For 
this reason all 
models use 2-
yearly Pap 
testing as 
primary 
screening test 
in women <30 
years.  
3-yearly HPV based testing had an ICER of 
9’000 €/Life year gained (LYG) in the base 
case compared to cytology based testing. 
5-yearly testing with HPV based strategies 
were slightly more effective than 3 yearly Pap 
testing, however suffered extended dominance 
from a combination of 3 yearly Pap testing and 
3 yearly HPV base testing.  
 
The cost effectiveness of all not dominated 
strategies is as follows in the base case  
Strategy Discounted 
costs (€) 
ICER 
(€/LYG) 
no screening 87 - 
Pap 5y 159 2’600 
Pap 3y 215 7’100 
HPV 3y 266 9’000 
HPV 2y 345 28’400 
HPV + Pap-
Triage, 2y 
362 93’700 
HPV 1y 637 155’500 
 
In a scenario, where Pap test sensitivity was 
lower based on German studies all Pap test 
based strategies were dominated and  
5 yearly HPV based testing was cost effective 
at 3’700 €/LYG (versus no screening) and  
3 yearly HPV based testing was cost effective 
at 6’100 €/LYG (versus 5 yearly HPV) 
                                                          
 
11
 ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
MPH master thesis   Martina Hahn 
  118 
Publication 
Year 
Country 
Study Description Research Question 1a 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to 
test for HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios
11
 
Bistoletti et 
al. 2008 
Sweden 
 
[75] 
 
 
Goal: estimate life expectancy and 
health care cost per woman of 32 
years during their remaining lifetime 
for 3 screening strategies compared 
to no screening in Sweden 
 
A cohort of unvaccinated women of 
32 years until end of life was 
modelled 
 
Strategies 
 cytology every 3 years for women 
of 32-50 years and 2 additional 
cytological tests at ages 55 and 60 
 added HPV testing once at age 32 
 only 3 screenings with combined 
cytology and HPV testing at ages 
32, 41 and 50 
 
Frequency: as described above  
 
Perspective: health care payer 
Results reported in 2005 US $ 
Costs and benefits discounted at 
0%,3% and 5% 
Quality score: 0.85 
Transferability data score: 0.77 
 
It is important to note that the 
interventions were not described in 
detail in terms of follow up on positive 
primary screening results. 
Three screening events at ages 32, 41 and 50 with 
cytology and HPV cotesting were more effective in 
terms of life years than 9 screenings with cytology 
(3-yearly from 32-50, then 5-yearly until age 60). 
Adding HPV testing once at 32 years had no 
beneficial effect.  
 
 Discounted Life years (3%) 
cytology  29.67 
added HPV testing once  29.67 
only 3x cotesting  29.69 
 
 
No data on the potential burden of screening (e.g. 
number of false positive no results or number of 
colposcopies were reported) nor were QALYs 
calculated, as none of the data from the literature 
was considered sufficiently reliable. 
 
However it is likely that with only 3 screenings the 
burden of screening is lower or at least not higher 
than with 9 screenings 
Not addressed 
 
All screening 
strategies start 
at 32 years 
This 3
rd
 strategy dominated the other two in 
that it yielded slightly more life years at lower 
costs. No ICERs were calculated therefore. 
 
 
 Discounted costs (3%) 
cytology  245 
added HPV testing once  284 
only 3x cotesting  210 
 
health care costs per woman in US $  
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to 
test for HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Kitchener 
et al. 
2014 
UK [2] 
 
Goal: Analyze HPV based screening 
strategies for cervical cancer 
screening in England 
 
Screening started at 25 years. 
 
Strategies 
 (CP) current practice = LBC with 
HPV triage, 3-yearly from 25-49 
years, then 5-yearly 
 (S1) HPV with LBC triage 
 (S2) HPV with LBC triage 
(immediate) and HPV 16/18 
genotyping (after 24 months) for 
women who were HPV pos/ cyt 
neg 
 (S3) HPV with HPV 16/18 
genotyping 
(if HPV 16/18 positive refer to 
colposcopy, if positive for other 
hrHPV cytology triage) 
 (S4) Cotesting (with HPV 16/18 
genotyping after 24 months for 
women who were HPV pos/cyt 
neg) 
 
Frequency: for HPV based  strategies 
5 yearly or 6 yearly  or  
6 yearly for 25-49 year old women, 
then 10 yearly  
and follow up of positive results after 
either 24 or 12 months 
 
Perspective:  Health system 
In general 6-yearly HPV based testing strategies 
were as effective or more effective in terms of cancer 
incidence than current cytology based practice, 
especially  if follow up of HPV+/cyt- women was 
done after 12 months instead of 24 months  
The following strategies were more effective than 
current practice and on the cost effectiveness frontier 
or give information on screening start age with HPV 
Cotesting was always dominated in all scenarios. 
 
Strategy coded as follows: Strategy Code, months 
follow up after negative triage test, age of switch 
from cytology to HPV based strategy if strategy was 
not applied from 25 years on. All dominant HPV 
based strategies had a frequency of 6 yearly 
strategy code 
LY/ 
woman 
Increase of 
colposcopies vs CP 
S2 24m with 
10 yearly 
frequency for 
>50years) 
26.2306  
CP 26.2307   
S1 24m 30y 26.2308 1% 
S2 24m 26.2310 -4% 
S2 24m 30y 26.2310 10% 
S3 24m 26.2316 26% 
S1 12m 26.2317 10% 
S2 12m 26.2320 26% 
S3 12m 26.2323 50% 
 
Life-years were considered as the primary outcome 
of the analysis. In addition supplementary alternate 
QALY weights were considered and lifetime risk of 
cancer was taken as effectiveness measures. 
Recommendations were made based on the life-
In the base 
case all 
strategies are 
applied starting 
at age 25.  
 
In additional 
scenarios 
younger 
women 
received 
cytology and 
switched to 
HPV based 
testing at age 
30 or 35 
 
HPV testing 
with cytology 
triage starting 
at 25 years 
yielded more 
life years 
(26.2317LY) 
and increased 
colposcopy 
rates by 10% 
compared to 
current 
practice 
(26.2307LY). 
Switching at 30 
or 35 years 
was as 
ICERs were not calculated by the authors 
compared to current setup as HPV based 
strategies were more effective and cheaper.  
However ICERs were calculated for this thesis 
for the strategies on the cost effectiveness 
frontier.  
Switching from cytology screening to HPV 
based screening at age 30 was dominated, 
however is still more effective and cheaper 
than current practice. Switching at age 30 
dominated switching at age 35. 
Strategy 
code 
Lifetime 
cost/ 
woman 
ICER 
S2 24m with 
10 yearly 
frequency for 
>50years) 
131 baseline 
CP 159 Dominated 
S1 24m 30y 145 Dominated 
S1 24m 35y 150 Dominated 
S2 24m 35y 151 Dominated 
S2 24m 135 10’000  
(against baseline) 
S2 24m 30y 148 Dominated 
S3 24m 144 15’000 
S1 12m 147 30’000 
(dominated,  
but lower 
colposcopy rates) 
S2 12m 152 20’000  
(against S3 24m) 
S4 12m 167 Dominated 
S3 12m 161 30’000  
(against S2 12m) 
20’000  
(against base line) 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to 
test for HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Results reported in 2010 £ 
Costs and benefits discounted at 
3.5% 
Quality score: 0.86 
Transferability data score:0.93  
 
years saved by strategies, rather than based on 
QALYs, as “the diversity of the findings when 
different QALY weights are used emphasizes the 
uncertainty involved in the selection and application 
of these weightings”  
 
effective as 
current 
practice  
(26.2308LY) at 
1% increased 
colposcopy 
rate 
 
Switch at 35 
years had 
overall higher 
costs than a 
switch at 30 
years.  
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
What is the 
best age to 
start using 
HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Huh et al. 
2015 
USA 
[37] 
 
Goal: to evaluate the cost 
effectiveness of cervical cancer 
primary screening with a HPV-16/18 
genotyping test which simultaneously 
detects 12 other high-risk HPV types.  
 
A cohort of unvaccinated women of 
30-70 years was modelled 
 
Strategies 
 cytology + HPV triage,  
 HPV + cytology triage 
 cotesting 
 HPV + 16/18  genotyping 
In the latter strategy women positive 
for HPV 16 or 18 were directly 
referred to colposcopy. Women 
positive for other hrHPV strains were 
sent to cytology triage. 
 
Frequency: 3-yearly intervals for all 
strategies were chosen  
 
Perspective: US health payer  
Results reported in 2013 US$ 
Costs and benefits discounted at 3% 
Quality score: 0.93 
Transferability data score:  0.87 
HPV testing with HPV16/18 genotyping yielded the 
most undiscounted Life-years (LY), the most QALYs 
and the lowest mortality. 
Strategy LY QALY 
cytology + HPV triage =  37.978 22.856 
HPV + cytology triage =  37.981 22.866 
cotesting  =  37.982 22.868 
HPV + 16/18 genotyping =  37.984 22.874 
 
Burden of screening : 
HPV testing with genotyping increased colposcopies 
only slightly compared to cytology with HPV triage 
and less than HPV testing with cytology triage and 
cotesting 
Colposcopies (per 100’000 women annualized)   
cytology + HPV triage =  2.104 
HPV + cytology triage =  2.339 
cotesting  =  2.967  
HPV + 16/18 genotyping =  2.159 
 
HPV testing with genotyping had the lowest number 
of colposcopies per CIN3+. 
cytology + HPV triage =  4.76 
HPV + cytology triage =  3.95 
cotesting  =  4.79  
HPV + 16/18 genotyping =  3.06  
 
QALYs: Disutilities were assigned to CIN1,2,3 and 
cervical cancer, however not to screening itself, or 
being in triage after an initial positive screening test 
Not addressed 
 
All strategies 
were applied to 
women of 30 
years and 
older 
HPV testing with HPV16/18 genotyping had an 
ICER of 7667$ compared to cytology with HPV 
triage 
 
HPV testing with cytology triage and cotesting 
were dominated by HPV testing with 
genotyping 
 
 Discounted Costs ICER 
 US $ $/QALY 
cytology + HPV triage  = 1.230 
HPV + cytology triage  = 1.749 dominated 
cotesting = 2.014  dominated 
HPV + 16/18 genotyping =  1.367 7667 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
What is the 
best age to 
start using 
HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Arbyn et 
al. 
2015 
Belgium 
[28] 
 
Goal: The analysis of clinical and 
cost-effectiveness of primary HPV 
screening for cervical cancer in 
Belgium. 
 
A cohort of unvaccinated women of 
30 years until end of life was 
modelled 
 
Strategies 
 Cytology with HPV triage 3 yearly 
 HPV with cytology triage 5 yearly 
(starting with 30 years, in younger 
women cytology) 
 
Frequency: see above, start of 
screening at age 25 
 
Perspective: 3
rd
 party payer incl. 
patients out of pocket expenses for 
health care 
Results reported in 2014 € 
Costs discounted at 3% and benefits 
at 1.5  
Quality score: 0.91 
Transferability data score: 0.87 
 
 5-yearly HPV testing was more effective in 
preventing cervical cancer cases and gained more life 
years   
 
Different triage options were evaluated and HPV 
based testing with cytology triage was found to have 
the best balance between safety and referral rate to 
colposcopy. 
 
 
Cervical 
cancer 
cases 
Life years 
discounted 
cytology + HPV triage 462 3’658’751 
HPV + cytology triage 222 3’660’369  
 
 
 
Not 
addressed  
 
According to 
literature 
review and 
with special 
reference to 
the combined 
follow up by 
Ronco et al 
2013 from 4 
big European 
randomized 
controlled 
trials, no 
protective 
effect on the 
reduction of 
cervical 
cancer was 
observed in 
women 
younger than 
30 years. 
 
Therefore a 
switch to HPV 
testing at 30 
years was 
chosen. 
5-yearly HPV testing was more effective at a 
lower price than 3-yearly cytology based 
screening. 
 
Base case 
 
Total 
costs (€) 
Total costs (€) 
discounted  
cytology + 
HPV triage 83’066’833  51’786’706  
HPV + 
cytology triage 68’179’074  46’004’382  
 
In a scenario analysis a higher price was 
assumed for the HPV assay of 58 € instead of 
35 € 
 
In this case 5-yearly HPV testing was cost 
effective at a higher price than 3-yearly 
cytology based screening with an ICER of  
4319 €/LYG 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to 
start with HPV 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Accetta et 
al. 2010 
Italy 
[76] 
 
Goal: To evaluate the cost-
effectiveness of cytology based and 
HPV based screening algorithms in 
vaccinated and unvaccinated women 
in the Italian health system 
 
A cohort of unvaccinated women 
 
Strategies 
 Pap test only 3y 
 Pap with HPV triage 3y 
 HPV with Pap triage 3y 
 HPV with Pap triage 5y 
 HPV only 3y 
 HPV only 5y 
 
Frequency: 3-or 5- yearly  
All screening programs start at age 
25 and end at age 65  
 
Perspective: health system 
Results reported in 2006 €  
Costs and benefits discounted at 3% 
Quality score: 0.65 
Transferability data score: 0.60  
 
Follow up is not well described. I.e. 
unclear whether HPV only strategies 
involve direct referral to colposcopies. 
It is not described, how patients with 
HPV+/Cyt triage- and Cyt+ (ASC-
US)/ HPV triage are followed up. 
No sensitivity analysis for 
unvaccinated women. 
Compared to Pap test only or to 3-yearly Pap test with 
HPV triage (Swiss recommended strategy), HPV 
based testing with Pap triage was more effective in 
reducing life time risk of cancer. 
3-yearly HPV test only yielded less QALY than HPV 
with Pap triage while reducing the risk of cancer to the 
same level. 
 
Therefore HPV testing with Pap triage with a 3 yearly 
or 5 yearly frequency seems the best strategy. 
 
Strategies reduction  QALY 
 cancer risk (%) 
 compared to  
 no screening 
Pap with HPV triage 3y 49.5 29.42803 
Pap test only 3y 52.9 29.42822 
HPV only 5y 53.7 29.42958 
HPV with Pap triage 5y 55.0 29.42991 
HPV only 3y 56.0 29.43042 
HPV with Pap triage 3y 56.0 29.43048 
 
The burden of screening was not addressed. QALYs 
were used; however no disutilities were assigned to 
screening itself, being in triage or being treated for 
CIN. 
Not 
addressed 
 
All strategies 
are applied 
starting at 25 
years of age 
The cost effectiveness plane in the publication 
mixed strategies with and without vaccination, 
so the cost effectiveness was calculated for this 
thesis from the published costs and QALYs 
(which will introduce some inaccuracy due to 
taking only the rounded values from the cost 
and effectiveness tables) 
 
Strategies lifetime 
cost 
ICER 
€/QALY 
Pap with HPV triage 3y 149 dominated 
Pap test only 3y 160 dominated 
HPV only 5y 176 dominated 
HPV with Pap triage 5y 136 4’444 
HPV only 3y 228 dominated  
HPV with Pap triage 3y 175 68’421 
 
HPV with Pap triage every 5 years is more 
effective and less costly than Pap with HPV 
triage every 3 years. The ICER to the next less 
cost effective strategy (Pap test only every 5y) 
is only 4’444 €/QALY 
 
HPV with Pap triage every 3 years is also on 
the cost effectiveness frontier, however at a 
higher ICER of 68’421 €/QALY. 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical 
effectiveness at the lowest burden of follow up? 
Question 1b  
best age to 
start using 
HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness ratios 
Burger et 
al. 2012 
Norway 
[32] 
 
Goal: to inform cervical cancer 
prevention guidelines in Norway. 
 
A cohort of unvaccinated women 
was modelled 
 
Strategies start at 25 years with 
3-yearly cytology with cotesting 
triage for ASC-US and LSIL or 
cotesting triage for ASC-US only 
 
switch at 31 years to either 
1. No switch cytology 3y 
2. HPV with cotesting triage  
 
Frequency: 3/4/5 or 6 yearly (y) 
Time to rescreen of HPV+/cyt- 
women was 6 or 12 months. The 
number of additional HPV+/cyt- 
results before referral to 
colposcopy varied between 1 
and 3 (base case) 
 
Perspective: societal (direct 
medical costs, travel and time of 
women) 
Results reported in 2010US$ 
Costs and benefits discounted at 
4% 
Quality score: 0.80 
Transferability data score: 0.83 
Life Years and lifetime risk of cancer were 
taken as effectiveness measures.  
 
HPV testing of all frequencies reduced cancer 
cases more than 3-yearly cytology alone.  
HPV based screening yielded more discounted 
life years when performed at 5 yearly 
frequencies or more often 
Strategies coded by  
Primary screening test, yearly frequency, 
months to rescreen triage negative women 
 
Primary 
screening 
test, post-
switch 
Absolute 
reduction 
in cancer 
(%) 
Total 
discounted 
life years 
no screening — 32.9276 
HPV 6y, 12m  55.59 32.9500 
cytology 3y 55.45 32.9502 
HPV 5y, 12m  58.82 32.9510 
HPV 4y, 12m 63.44 32.9524 
HPV 4y, 6m  65.26 32.9529 
HPV 3y, 6m  70.22 32.9542 
HPV 3y, 6m, 
colposcopy 
after 1 
repeated 
HPV+/cyt- 
70.49 32.9543 
 
Women 
were 
switched to 
HPV 
based 
strategies 
at either 34 
years 
(base 
case) or 31 
years. 
 
Switching 
at age 31 
dominated 
switching 
at age 34. 
Cytology with cotesting triage was dominated, while most 
HPV with cytology triage strategies were on the cost 
effectiveness frontier, however some with high ICERs 
6-yearly HPV will cytology triage is almost as effective as 
3-yearly cytology with cotesting triage at a 25% lower 
price with an ICER against no screening of 29’000 $/LY.  
Other HPV based strategies were more effective than 
cytology based screening at ICERs > 50’000 $/LY  
 
Primary screening 
test, post-switch 
Total cost 
per woman 
($)a 
ICER ($/YLS) 
no screening 120 — 
HPV 6y, 12m time to 
rescreen 
760 29000 
cytology 3y 1001 Dominated 
HPV 5y, 12m time to 
rescreen 
822 57000 
HPV 4y, 12m time to 
rescreen 
922 76000 
HPV 4y, 6m time to 
rescreen 
971 98000 
HPV 3y, 6m time to 
rescreen 
1160 144000 
HPV 3y, 6m time to 
rescreen, 
colposcopy after 1 
repeated HPV+/cyt- 
1200 513000 
 
ICERs are generally higher than in many other studies, 
however in this Norwegian study some indirect medical 
and some societal costs such as women’s travel and time 
for screening, diagnostic follow up and treatment were 
taken into account. 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness at the 
lowest burden of follow up? 
Question 1b  
What is the 
best age to 
start using 
HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
Goldhaber-
Fiebert et 
al. 2008 
USA [35] 
 
Goal: to evaluate for women 
who are not vaccinated, 
what recommendations can 
be made regarding cervical 
cancer screening 
guidelines, taking into 
account new data on the 
performance of HPV DNA 
testing 
 
A cohort of unvaccinated 
women of 9 years until x 
was modelled 
 
Strategies 
 Cytology with HPV triage 
 HPV with cytology triage 
 cotesting 
 
Frequency: 1/2/3 and 5-
yearly, start age for 
screening was varied 
between 18/21 and 25 years 
 
Perspective: societal 
perspective including 
medical costs, staff time, 
patient time and transport 
cost for screening, 
diagnostic follow up and 
cancer treatment, however 
no indirect costs 
QALYs and lifetime risk of cancer were taken as 
effectiveness measures.  
 
Only strategies with ICER < 200’000$/QALY and are on the 
cost effectiveness frontier are shown.  
3-yearly cytology based testing was dominated, but is 
shown for clinical effects as reference. 
 
Strategies are coded as follows 
Start age with cytology, switch age, strategy after switch 
(“cyt” for cytology with HPV triage or “HPV” for HPV with 
cytology triage), frequency in years,   
 
Strategy  % reduction QALYs 
 cancer risk 
 compared to no screening 
no screening - 26.67212 
25, none, cyt, 5y 50.9% 26.71857 
Any, none, cyt, 3y 61.5% 26.72766 
25, 35, HPV, 5y 61.6% 26.72609 
25, 30, HPV, 5y 62.3% 26.72733 
25, 35, HPV, 3y 70.7% 26.73237 
25, 30, HPV, 3y 71.5% 26.73344 
21, 30, HPV, 3y 72.2% 26.73493 
21, 30, HPV, 2y 76.3% 26.73769 
 
The burden of screening was not directly addressed apart 
from time and travel cost of women for screening, diagnostic 
follow up and treatment. No numbers of colposcopies or 
women being in triage were compared between studies.  
QALYs had no disutilities assigned to screening, being in 
triage or being treated for CIN2/3. 
Screening 
was always 
started with 
cytology and 
switched to 
HPV based 
testing at 
ages 25, 30 
or 35, with 
the exception 
of one 
scenario with 
HPV testing 
starting at 
age 18 
 
The authors 
recommend 
starting HPV 
based testing 
at 30 years 
from an 
overall cost 
effectiveness 
analysis  
 
(no burden of 
individual 
strategies 
were 
compared) 
3-yearly cytology based testing was dominated; its 
cost is shown as reference. 
 
 
Strategy  cost $ ICER $/QALY 
 
 
no screening 153 
25, none, cyt, 5y 471 7’000 
Any, none, cyt, 3y 655-848 dominated 
25, 35, HPV, 5y 562 12’000 
25, 30, HPV, 5y 598 29’000 
25, 35, HPV, 3y 787 37’000 
25, 30, HPV, 3y 844 53’000 
21, 30, HPV, 3y 960 78’000 
21, 30, HPV, 2y 1297 122’000 
 
Based on these data 3-yearly HPV with cytology 
triage testing is cost effective at an ICER of 53’000 
$/QALY starting with cytology based testing at age 
25 and switching to HPV based testing at age 30 
 
Cotesting was only on the cost efficiency frontier 
with a strategy costing > 3Mio$/QALY, all other 
cotesting strategies were dominated 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness at the 
lowest burden of follow up? 
Question 1b  
What is the 
best age to 
start using 
HPV? 
Research Question 1c  
comparison of (Incremental) cost effectiveness 
ratios 
 
Results reported in 2004 
US$  
Costs and benefits 
discounted at 3% 
Quality score: 0.80 
Transferability data score: 
0.90  
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness at 
the lowest burden of follow up? 
Question 1b  
best age to 
start HPV 
Research Question 1c  
comparison of (Incremental) cost effectiveness ratios 
MSAC 
2014 
Australia 
[29] 
 
Goal: to evaluate 
strategies for policy 
renewal in the Australian 
cervical cancer screening 
program.  
 
A cohort of unvaccinated 
women was modelled 
(in addition a vaccinated 
cohort was modelled) 
 
Strategies 
1. Current practice  
2- yearly cytology at 
18-69 years, with HSIL 
referred to colposcopy.  
For LSIL either 
colposcopy or retesting 
after 6 months 
2. conventional cytology-
based screening 3-
yearly for age 25-49 
and 5-yearly for age 
50-64 (IARC intervals) 
3. LBC instead of Pap 
test (IARC intervals) 
4. Cytology with HPV 
triage 
5. HPV with cytology 
triage 5-yearly 
6. HPV with partial 
genotyping. HPV 16/18 
goes directly to 
colposcopy, other 
No comparator was analyzed that equals the Swiss 
recommended screening of 3-yearly cytology with HPV 
triage after 3 annual tests in younger women. Current 
practice in Australia is 2-yearly Pap test with Pap retest. 
The closest comparator to Swiss screening is cytology 
with HPV triage with 3 yearly testing from 25 to 49 and 
5-yearly testing from 50-65 and an exit test at age 69. 
 
Results of the best selected strategies show that HPV 
with cytology triage is more effective in reducing cancer 
incidence that cytology only or cytology with HPV triage 
at higher frequency at 25-49 years. Cotesting has the 
same effect as HPV with cytology triage. HPV16/18 
genotyping yielded the best result 
 
Strategies cancer incidence  discounted 
 ASR/100’000 life years 
1. Current practice 2y 6.9 not shown 
2. Cytology only IARC 7.6 21.62678 
3. Pap +HPV triage IARC 6.2 21.62760 
4. LBC + HPV triage IARC 6.1 21.62764 
5. HPV + cyt triage 5y 5.8 21.62779 
6. HPV16/18 genotyping 5y 5.7 21.62792 
7. Cotesting 5y 5.8 21.62783 
 
Burden of screening:  
Strategies number of colposcopies   
1. Current practice 2y reference 
2. Cytology only IARC -12% 
3. Pap +HPV triage IARC +13% 
4. LBC + HPV triage IARC +16% 
5. HPV + cyt triage 5y +20% 
6. HPV16/18 genotyping 5y +37% 
7. Cotesting 5y +33% 
Not 
addressed 
 
HPV testing 
was applied 
starting at 
age 25 
HPV based strategies are at the efficiency frontier and 
dominated cytology based strategies 
 
Cotesting has similar effectiveness as HPV only as the 
primary test at a higher cost (dominated) 
 
HPV with genotyping is more effective regarding LYG at a 
higher cost than HPV without genotyping 
 
Strategies total cost cost per ICER 
 Australian Mio $woman $ $/LY 
1. Current practice 2y 214.7 not shown dominated 
2. Cytology only IARC 162.3 277 reference 
3. Pap +HPV triage IARC 193.1 337  dominated 
4. LBC + HPV triage IARC203.5 358  dominated 
5. HPV + cyt triage 5y 175.5 310  33’000 
6. HPV16/18 genotyping 5y181 323 100’000 
7. Cotesting 5y 217.1 378  dominated 
 
If QALYs are compared, with QALY set 1 HPV with 
genotyping has similar effectiveness that HPV without 
genotyping, with QALY set 2 HPV without genotyping is 
more effective.  
QALY Weight Set 1 utilized a new set of weights from a 
study recently conducted in metropolitan Sydney, which 
was specifically designed to obtain weights relevant to 
cervical screening and HPV vaccination in an age-
representative sample of women invited for screening. 
This set of weights assigned some disutility to the 
experience of being screened, even if the test result was 
negative. 
 
The MSCA recommends switching to 5-yearly HPV testing 
with HPV16/18 genotyping in women of 25-69 years. 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness at 
the lowest burden of follow up? 
Question 1b  
best age to 
start HPV 
Research Question 1c  
comparison of (Incremental) cost effectiveness ratios 
hrHPV to cytology 
triage 5-yearly 
7. Cotesting, 5yearly 
Frequency:  as above 
 
Perspective: health 
system 
Results reported in 2013 
Australian $ 
Costs and benefits 
discounted at 5 % 
Quality score: 0.89 
Transferability data score 
0.83 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical 
effectiveness at the lowest burden of follow up? 
Question 1b  
best age to 
start HPV 
Research Question 1c  
comparison of (Incremental) cost effectiveness ratios 
Vijayara-
ghavan et 
al. 
2010 
Canada 
[33] 
 
Goal: to determine the potential 
cost-effectiveness of including 
HPV tests for cervical cancer 
screening for Quebec, Canada.  
 
A cohort of unvaccinated 
women of 13 years until end of 
life was modelled. Screening in 
younger women was done with 
Pap tests, at age 30 strategies 
switched as follows: 
 
 No screening;  
 Cytology  only (1/2/3 yearly)  
 Cytology with HPV triage 
ASC-US (1/2/3 yearly)  
 HPV with cytology triage (3 
yearly) 
 Co- testing (3 yearly)  
 HPV only (direct referral to 
colposcopy if HPV-positive 
(3yearly) 
Perspective:  Health System 
Results reported in 2007 
Canadian $  
Costs and benefits discounted 
at 5% 
The quality score was only 0.73 
and transferability data score 
0.77, as some data are only 
available in supplements and 
until June 09, those 
supplements could not be 
obtained from the author yet. 
Cancer cases and QALYs were taken as 
effectiveness measures. Disutilities were assigned 
to CIN and Cancer stages. Burden was briefly 
discussed as number of expected colposcopies. 
 
Screening strategies with 3-yearly HPV as primary 
screening test were more effective in reducing 
cervical cancer incidence than annual cytology 
based testing 
 
Screening 
Strategy*  
Annual 
Cervical 
Cancer 
Incidence 
QALY 
No screening 1’282 17.7817  
Cytology only 3y 339 17.8196  
Cytology+HPV 
triage 3y 
291 17.8215  
Cytology only 1y 191 17.8259  
HPV+cytology 
triage 3y 
163 17.8263  
Co- testing 3 y 163 17.8263  
Cytology+HPV 
triage 1y 
147 17.8270  
HPV only 3y 145 17.8272  
 
The HPV only strategy had the highest 
colposcopy rates of 2’000 per 100’000 women, 
while HPV with cytology triage or cotesting had 
55-59% fewer colposcopy rates (830) compared 
to cytology based strategies with 160-700 
colposcopies 
 
Not 
addressed  
Screening 
strategies 
started at 30 
years 
“All strategies incorporating HPV testing as a primary 
screening test were more effective and less expensive 
than annual cytology alone, while HPV testing to triage 
equivocal Pap smears annually was very cost-effective 
($2,991 per QALY gained compared to annual cytology 
alone). When compared to cytology every three years, 
HPV-based strategies cost an additional $8,200 to 
$13,400 per QALY gained.” 
 
Screening Strategy*  
Average  
Lifetime  
Costs ($) 
ICER 
$/QALY 
No screening 368  
Cytology only 3y 753 dominated 
Cytology+HPV triage 3y 750 9’’600 
Cytology only 1y 926 dominated 
HPV+cytology triage 3y 809 
12’300* 
(dominated) 
Co- testing 3 y 843 Dominated 
Cytology+HPV triage 1y 930 Dominated 
HPV only 3y 815 11’400* 
 
* ICERs for HPV with cytology triage and the HPV only 
strategy were calculated against 3 yearly cytology with 
HPV triage.  
HPV only dominated HPV with cytology triage. However 
this strategy may not be acceptable due to the more than 
two times higher colposcopy rates.  
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Vijayara-
ghavan et 
al. 
2010 
USA [36] 
 
Goal: to evaluate the cost-
effectiveness of HPV 16/18 genotype 
triage in the US health care setting.  
 
A cohort of unvaccinated women of 30 
years until end of life was modelled 
 
Strategies 
 LBC 2 – yearly 
 LBC with HPV triage, 2-yearly 
 HPV with LBC triage, 3-yearly 
 cotesting, 3-yearly 
 cotesting with HPV 16/18 
genotyping 3-yearly 
 HPV with 16/18 genotyping 
 
In the strategies with HPV genotyping 
women being HPV 16/18 positive were 
referred to colposcopy, those positive 
for other hrHPV types were referred to 
cytology triage 
 
Frequency: as described above 
Perspective: health care payer 
Results reported in 2007 US $ 
Costs and benefits discount rates no 
discounting described 
Quality score: 0.86 
Transferability data score: 0.90 
2-yearly LBC with or without HPV triage was less 
clinically effective than all HPV based screening 
methods with 3-yearly intervals 
 
The most clinically effective strategy in terms of 
cancer incidence was co-testing with HPV 16/18 
genotyping, followed by co-testing, followed by HPV 
with HPV16/18 genotyping. 
 
In terms of QALYs the most effective strategy was 
cotesting with HPV 16/18 genotyping, followed by 
HPV with HPV16/18 genotyping, followed by co-
testing. This is due to lower mortality. 
 
Strategies cancer  QALYs 
 incidence 
LBC  9.17 28.6623 
LBC with HPV triage 8.56 28.6651 
HPV with LBC triage 7.86 28.6670 
cotesting 7.49 28.6714 
cotesting. + genotyping  6.62 28.6745 
HPV with genotyping 7.57 28.6725 
 
The burden of screening was not addressed, 
QALYs assigned disutilities to CIN and cancer not to 
being screened per se or to being in triage after 
positive test result 
Not addressed  
 
The model 
chose 2-yearly 
cytology for all 
women until a 
switchover age 
of 30 
 
No comparator was used that was 
equivalent to the Swiss recommended 
screening of 3-yearly cytology with HPV 
triage 
 
2-yearly LBC with HPV triage was 
dominated by 3-yearly HPV testing with 
LBC triage 
ICERs are shown compared to next less 
effective strategy 
 
Strategies ICER /$/QALY) 
LBC  - 
LBC with HPV triage dominated 
HPV with LBC triage 13’617 
cotesting 17’204 
cotesting. + genotyping  33’807 
HPV with genotyping 34’074 
 
All HPV based strategies were cost 
effective with ICERs ranging from 13’617  
$ /QALY for HPV with LBC triage to  
HPV with 16/18 genotyping and cotesting 
with 16/18 genotyping with ICERs around 
34’000$/QALY 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Diaz et al.  
2010 
Spain 
[77] 
 
Goal: the primary goal of the study is 
to assess the health and economic 
impact of adding HPV vaccination to 
cervical cancer screening.  
In addition the study compares 
different screening strategies for 
vaccinated and unvaccinated women. 
 
A cohort of women of 9 years until 
end of life was modelled 
 
Strategies 
1. Cytology alone 
2. Cytology with HPV triage 
3. Cotesting 
 
Frequency: 1/2/3/4/5-yearly starting at 
25 years 
 
Perspective: direct medical cost plus 
cost of patient time and transport for 
screening and diagnostic follow up. 
Results reported in 2005 € 
Costs and benefits discounted at 3% 
Quality score: 0.76 
Transferability data score: 0.70 
 
Reporting on effectiveness of alternatives was not in 
a level of detail that allowed comparison of effects, 
harms and costs of the current Swiss screening 
algorithm (3-yearly cytology only or cytology with 
HPV triage). This strategy was dominated and no 
details were reported on it. 
 
In general the graphs show that cotesting every 5 
years is as effective as cytology only or cytology with 
HPV triage every 3 years. 
 
Not addressed  
 
HPV testing 
was added to 
cytology in the 
cotesting 
cohort at 35 or 
40 years 
 
Reporting on effectiveness of alternatives 
was not in a level of detail that allowed 
comparison of effects, harms and costs of 
the current Swiss screening algorithm (3-
yearly cytology only or cytology with HPV 
triage). This strategy was dominated and 
no details were reported on it. 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Kulasingam et 
al. 2009 
Canada [34] 
 
Goal: To determine the potential cost-
effectiveness of including HPV tests 
for cervical cancer screening for 
Canada and three provinces: Alberta, 
Newfoundland and Ontario 
 
A cohort of unvaccinated women was 
modelled 
 
Strategies 
 Pap test, yearly at age 18-21 
thereafter 3-yearly  (current 
practice) 
 Pap test only 1 or 2 yearly 
 LBC 
 HPV only (direct referral to 
colposcopy), 3 or 5-yearly 
 Cotesting, 2/3/5-yearly (in this 
case either HPV or Pap positive is 
directly referred to colposcopy) 
 Pap with HPV triage (1-yearly) 
 HPV with Pap triage (3 or 5 
yearly) (it is not clearly described, 
after how much time HPV+/Pap- 
women are rescreened) 
 
Perspective: health system 
Results reported in 2006 Canadian $ 
Costs and benefits discounted at 3% 
Quality score: 0.78 
Transferability data score:0.80  
 
The study did not have a comparator of cytology with 
HPV triage with 3-yearly frequency.  
The closest comparator to the Swiss strategy is 3-
yearly Pap testing. 
 
Concerning the burden of screening the number of 
false positive test results (Pap or HPV) was 
reported. 
 
HPV based methods with Pap triage starting at age 
25 yielded fewer cancer cases  than current practice 
with Pap testing (which starts screening at the age of 
18)  
 Cancer false  
 cases positives 
Pap test only  809 20’529 
HPV + Pap triage 5y 736 2’871 
HPV + Pap triage 3y 467 5’585 
Cotesting 2y 229 82’340 
 
 
HPV only (with direct referral to colposcopy) and 
cotesting of cytology and HPV (with direct referral to 
colposcopy if either test was positive) led to 
disproportionately high numbers of false positive 
tests  
 
The study 
modelled HPV 
with Pap triage 
starting at 
either 18 or 25 
years  
 
With 3 yearly 
screening 
cancer cases 
were reduced  
by 6% when 
starting at 18 
years with HPV 
testing but 
increased false 
positive results 
by a factor of 
1.8 vs starting 
at 25 years 
and increased 
the ICER 
twofold to 
47’319 $ 
 
With 5 yearly 
screening only 
25 years was 
on the cost 
effectiveness 
frontier as the 
switch age 
Numbers for false positives and cancer 
cases and ICERs for dominant strategies 
were reported in numbers; however LY 
and cost are only presented graphically.  
 
The current screening strategy with Pap 
test, yearly at age 18-21 thereafter 3-
yearly, was dominated in being less 
effective and more costly than HPV based 
testing with Pap triage starting at age 25. 
 
The ICER of 5-yearly HPV with Pap triage 
against no intervention was 6’720 
Canadian $.  
3-yearly HPV with Pap triage starting at 
25 years was the next most cost effective 
strategy and had an ICER of 24’257 
Canadian $. 
 
2 yearly cotesting was on the cost 
effectiveness frontier, however at a very 
high ICER of 432’751 Canadian $ 
 
HPV only with direct referral to 
colposcopy was not on the cost 
effectiveness frontier 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Chuck  
2010 
Alberta, Canada 
[78] 
 
Goal: To evaluate screening 
strategies for Alberta, Canada 
 
A cohort of unvaccinated women of 
12 years until 80 was modelled 
 
Strategies 
 Pap test 
 LBC 
 Pap with HPV triage 
 HPV with LBC triage all ages 
 HPV with LBC triage ≥ 30 years 
 
Frequency: 1/2/3/4/5 yearly 
 
Perspective: health system 
Results reported in 2007 Canadian $ 
Costs discounted at 5% 
and  benefits at 3% 
Quality score: not calculated 
Transferability data score: not 
calculated 
 
QALYs were taken as effectiveness measures. 
Disutilities were assigned to CIN and Cancer stages, 
not to screening itself. However effectiveness data 
were only presented graphically and highly 
aggregated, so no detailed analysis of the results 
was possible.  
This was considered a knock-out criterion for the 
study and a quality score and transferability data 
score was not calculated. 
 
Still it is curious from the graphical representation 
that in this study HPV based strategies seem to be 
less effective than cytology based strategies, which 
is different than findings from another study for 
Alberta, Canada ([34] and practically all other 
models. 
 
3-yearly Pap testing with HPV triage is 
recommended 
 
No detailed analysis was possible for the cause of 
this finding due to the missing details in the results 
presentation 
 
Cannot be 
derived from 
this study 
Cannot be derived from this study 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Mühlberger 
2008  
Germany  
 
[74] 
 
Goal: Systematic Review of Health 
Economic Evidence for HPV based 
screening vs Pap test 
Commissioned by the 
DAHTA@DIMDI, a subsidiary of the 
German Federal Ministry of Health 
 
12 decision-analytic cost-
effectiveness models up to March 
2006 were analyzed. 
 
Quality score and Transferability data 
score of the EURONHEED checklist 
was not applied as this is a 
systematic review of health economic 
studies not a health economic study 
itself 
Not addressed, focus was on cost effectiveness Not addressed The authors conclude that “the 
introduction of HPV-based screening 
programs is cost-effective if the screening 
interval of the established Pap program 
exceeds 2 years.  
 
In settings with biennial Pap screening, 
introduction of HPV-based screening is 
unlikely to be cost-effective, as clinical 
effectiveness of both test methods is 
comparable with HPV testing being more 
costly. 
 
Results also suggest cost-effectiveness of 
HPV-based screening in settings with 
annual Pap screening, where clinical 
effectiveness of HPV based screening at 
frequencies ≥ 2 years is comparable while 
costing less. This finding is based on the 
assumption of 100% screening 
attendance in the annual Pap screening, 
which is much higher than annual 
attendance rates in Germany (about 
50%). 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Berkhof et al. 
2010 
Netherlands [79] 
 
Goal:  
 
A cohort of unvaccinated women 
modelled 
 
Strategies 
 Cytology only 
 Cytology with HPV triage 
 HPV with cytology triage 
 cotesting 
 
Frequency: 5-10 years 
 
Perspective: societal (including travel 
time and productivity loss) 
Results reported in 2007 € 
Costs discounted at 4% and benefits 
at 1.5% 
The motivation of this study is the analysis of cost-
effectiveness of primary HPV screening for cervical 
cancer in the Netherlands.  
 
For transferability of this study on the Swiss context, 
a calculation of screening frequency higher than 5-
yearly as currently applied in the Swiss setting is 
missing. Therefore this study cannot be directly used 
for the transferability analysis and was not further 
analyzed. 
 
In short: “In comparison to 5-yearly cytology, 5-
yearly HPV testing with cytology triage gave a 
reduction in the number of cancer cases of 23% 
(range, 9–27%). The reduction was 26% (range, 10–
29%) for combination testing and 3% (range, 21 to 
8%) for cytology with HPV triage. For strategies with 
primary HPV testing, the model also estimated a 
reduction in cancer cases when the screening 
interval was extended to 7.5 years. 5-yearly cytology 
with HPV triage and 5 to 7.5-yearly HPV testing with 
cytology triage were cost effective (ICER below 
Dutch willingness-to-pay threshold of 
€20,000/QALY).” 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
van Rosmalen et 
al. 2012 
Netherlands [31] 
 
Goal: the analysis of cost-
effectiveness of primary HPV 
screening for cervical cancer in the 
Netherlands. 
 
A cohort of 8 Mio unvaccinated 
women born from 1939 to 1992 was 
modelled with the new simulated 
screening strategies starting at 2011 
(as described by [80]) 
 
Strategies 
 Cytology only 
 Cytology with HPV triage 
 HPV with cytology triage 
 
Frequency: comparator 5 yearly  
 
Perspective: society (In addition to 
medical costs, costs for an invitational 
system, registration, quality 
assurance, and time and travel cost 
of women was calculated) 
 
Results reported in 2010 € 
Costs and benefits discounted at 3% 
Quality score: 0.86 
Transferability data score: 0.90  
 
For transferability of this study on the Swiss context, 
a calculation of screening frequency of 3-yearly as 
currently applied in the Swiss setting is missing. 
Therefore this study cannot be directly used for the 
transferability analysis and will not be described in 
detail 
 
In short: cytology only based testing was dominated  
and the authors come to the conclusion that primary 
HPV testing with cytology triage is the most cost-
effective strategy  
 
With a cost effectiveness threshold of 20’000 or 
50’000 €/QALY gained only 3 screening rounds (10-
yearly, less effective than current practice) or 7 
screening rounds (6-yearly, more effective than 
current practice)  would be applied  
For women 
aged 32 and 
younger 
primary 
cytology 
screening is 
more cost-
effective than 
primary HPV 
testing 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
de Kok et 
al. 2012 
Netherlands 
[80] 
 
Goal: “To investigate, using a Dutch 
model, whether and under what variables 
framed for other European countries 
screening for human papillomavirus (HPV) 
is preferred over cytology screening for 
cervical cancer, and to calculate the 
preferred number of examinations over a 
woman’s lifetime.” 
 
A cohort of 8 Mio unvaccinated women 
born from 1939 to 1992 was modelled with 
the new simulated screening strategies 
starting at 2011. 
For the six scenarios that reflect differing 
background risks and test performances 
for cervical cancer screening in Europe, 
the predicted costs and QALYs gained 
were determined. 
 
Strategies 
1. Cytology only 
2. Cytology with HPV triage 
3. HPV with cytology triage 
 
 
Frequency: 3-10 yearly 
 
Perspective: societal including women’s 
travel and time 
Results reported in 2009 € 
Costs and benefits discounted at 3% 
Quality score: 0.88 
Transferability data score: 0.91  
Primary HPV screening was superior to cytology screening in most of the scenarios that were simulated in the 
model 
 
Scenarios were varied by  
 background cancer risk without screening (mortality of 5, 7.5 or 10 / 100’000 life years) 
 Prevalence of HPV “low” or “High” (based on background cancer risk) 
 Sensitivity of cytology (60 or 75%) 
 Cost of HPV testing (21 or 33 €) 
 Sensitivity of HPV (90 or 95%) 
 
According to the definitions of deKok Switzerland might potentially fall into the following categories based on data or 
conservative estimates  
 Average background cancer risk without screening (based on ASR of cervical cancer mortality of 8 in 1970-74 
when cervical cancer screening had just begun, source:  Federal Office of Statistics 
(www.bfs.admin.ch/bfs/portal/de/index/.../14/.../02.Document.110237.xls, last accessed 8 March 2016) 
 Prevalence of HPV “High” (conservative estimate based on prevalence graphs in [62]) 
 Sensitivity of cytology “high” (conservative assumption of high performance of the status quo) 
 Cost of HPV testing “high” (based on the cost structure in Switzerland and no fixed price yet for HPV as a 
screening test) 
 Sensitivity of HPV “high” (based on internationally clinically confirmed data of HPV test performance) 
 
Under these assumptions cytology based screening is the most cost effective strategy with 5, 6 or 8 screening 
events between the ages 30-55 or 65  with ICERs under 20’000 , 30’000 and 50’000 €/QALY. 
 
As all of these strategies have 5 yearly cytology screening and thus fewer screening events than current screening 
in Switzerland, these strategies will be less effective than current screening in Switzerland. No numbers for clinical 
benefits or burden of screening were shown. Thus no quantitative results for 3-yearly cytology are available from 
this study. 
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Publication 
Year 
Country 
Study Description Research Question 1 
What test results in the highest clinical effectiveness 
at the lowest burden of follow up? 
Question 1b  
best age to start 
with HPV? 
Research Question 1c  
comparison of (Incremental) cost 
effectiveness ratios 
Dillner 
2013 
Country 
independent 
[81] 
Review of existing health economic 
studies , however not systematic (Methods 
of systematic review not described) 
 
This study is discussing results from a 
HTA published in Italian [108] and of the 
study of de Kok. [80], which is separately 
analyzed in this thesis. Therefore no 
repetition of the results in this table is 
done. 
 
The study reports rather general thoughts 
and conclusions than quantitative results, 
however content for research question 2 
on the feasibility of HPV based screening 
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17 Appendix 5: “Research question 2 – Excerpt of answers” 
17.1 Excerpt of Answers to Research Question 2 from systematic reviews and meta-analyses  
 
Table 11: Excerpt of information on research question 2 from the clinical systematic reviews and meta-analyses 
Systematic Review 
/ Meta-analysis 
Research Question 2 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implementing screening 
based on HPV testing identified? If yes, which barriers are these?  
Are they relevant for the Swiss health care setting? 
Concern category 
Huh, 2015, USA 
[64] 
 
“To achieve the maximum benefit of screening we need to continue to identify women who are either unscreened or under-
screened.” 
“As with all new advances that enter clinical practice, the introduction of primary hrHPV screening raises a number of questions 
and concerns. Despite the improved sensitivity associated with primary hrHPV testing compared to cytology, clinicians should be 
aware that false negative results will continue to occur. Specimen adequacy, appropriate internal controls, and the impact of 
potential interfering substances (e.g., lubricants) are also important considerations when applying primary hrHPV testing to a 
screening population. Assay internal controls may not always reflect adequate sampling and do not completely obviate the risk of 
false negatives without the added morphologic control offered by cotesting. Data in this area are limited and further research is 
necessary.” 
“The 2011 ACS/ASCCP/ASCP Cervical Cancer Screening Guidelines stressed the importance of using FDA-approved tests that 
also met specific criteria for clinical performance. At present, there are four FDA approved hrHPV assays that are commercially 
available, but only one of these assays is now FDA-approved specifically for primary screening. Since the performance 
characteristics vary somewhat among these four FDA-approved assays, assumptions of comparability should not be made. As 
such, clinicians should not use an FDA-approved test without a specific primary hrHPV screening indication. Clinicians who wish 
to offer primary hrHPV screening to their patients are advised to inquire with their respective testing laboratories as to which 
hrHPV test is currently used and whether it is FDA-approved for primary screening.” 
“Concerns regarding harmonizing primary hrHPV screening algorithms with published screening, management, and treatment 
guidelines and the inherent confusion this alternate strategy might create for both patients and providers exist. Further 
investigation is also needed on understanding how women might transition in and out of different algorithms of cytology, cotesting, 
and primary hrHPV screening. Finally, there remain a number of questions with regard to adoption, implementation, and 
acceptance.” 
1 underscreened 
 
2 false negatives 
 
 
 
 
 
 
3 clinically validated 
HPV tests 
 
 
 
 
 
 
4 alternate policies 
 
5 change of policy 
IQWiG 2011, 2014 
Germany [46, 65] 
 
 
„Deshalb sind im Fall einer Änderung der Screeningstrategie des Zervixkarzinomscreenings im Rahmen der jährlichen 
gynäkologischen Vorsorgeuntersuchung in Deutschland mögliche Konsequenzen hinsichtlich anderer gynäkologischer 
Erkrankungen zu berücksichtigen.“ 
 
„Die aktuellen europäischen Leitlinien halten sich mit Empfehlungen zu einem primären Screening auf hrHPV-Infektionen zurück. 
6 side effects of 
longer screening 
intervals 
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Systematic Review 
/ Meta-analysis 
Research Question 2 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implementing screening 
based on HPV testing identified? If yes, which barriers are these?  
Are they relevant for the Swiss health care setting? 
Concern category 
Ein primäres hrHPV-Screening ohne die Definition der Altersgruppe, des Screeningintervalls und der wesentlichen Elemente einer 
Qualitäts-sicherung bei der Programmimplementierung wird nicht empfohlen [47,50]. Im Rahmen eines opportunistischen 
Screenings wird ein hrHPV-Screening ebenfalls nicht empfohlen, weil unter solchen Bedingungen das Einhalten der empfohlenen 
Screeningintervalle und die erforderliche Qualitätskontrolle nicht gewährleistet werden können. Stattdessen werden Pilotstudien 
mit einem validierten HPV-Test empfohlen, wenn sie im Rahmen eines organisierten Screeningprogramms mit sorgfältigem 
Monitoring und systematischer Evaluation der gewünschten Zielgrößen, Nebenwirkungen und Kosten stattfinden. Eine 
Ausweitung auf das gesamte Land solle erst dann erfolgen, wenn sich das Pilotprojekt als erfolgreich in Bezug auf die Effektivität 
und Kosteneffektivität erwiesen habe und wenn zentrale organisatorische Probleme adäquat gelöst worden seien.“ 
 
 
7 organized 
screening program 
8 Quality Control 
9 Adherence to 
screening protocols 
10 Monitoring of 
effects 
11 Pilotproject 
Pileggi, 2014, [47] Not addressed - 
Arbyn 2012, [44] “The possible advantages offered by HPV-based screening require a well-organized program with good compliance with 
screening and triage policies.” 
7 organized 
screening program 
9 Adherence to 
screening protocols 
Patanwala, 2013, 
[66] 
Not addressed - 
Saslow 2012, 
USA, [67] 
“Approximately half of the cervical cancers diagnosed in the United States are in women never screened, and an additional 10 
percent of cancers occur among women not screened within the past five years.  
Technologic improvements in screening are unlikely to have a substantial impact on mortality if they do not reach this population.”  
However: “HPV testing provides longer-term safety following a negative test than cytology, a useful characteristic for the 
infrequently screened.” 
“The most important research priority involves identifying strategies to increase screening coverage in unscreened or under-
screened women, in whom a significant proportion of invasive cancers occur. Novel strategies utilizing HPV testing and other 
molecular approaches should be examined. Specifically, self-collection of cervico-vaginal specimens coupled with HPV testing 
can achieve sensitivity that is comparable to or better than that of cytology-based screening.” 
“While cotesting is preferred to cytology alone based on risks and harms assessment, such a strategy might not be feasible in all 
clinical settings in the U.S. due to a lack of payment for cotesting or due to local policies “ 
 
“Implications, such as cost effectiveness of and adherence to implementing such a major change in the current US opportunistic 
screening setting, require further evaluation and planning.” 
“   potential stigmatization from the diagnosis of a sexually transmitted Infection…” 
1 underscreened 
 
 
 
 
12 self-testing 
 
 
 
13 reimbursement 
policy 
 
9 Adherence to 
screening protocols 
14 STI connotation 
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Systematic Review 
/ Meta-analysis 
Research Question 2 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implementing screening 
based on HPV testing identified? If yes, which barriers are these?  
Are they relevant for the Swiss health care setting? 
Concern category 
[54], Massad 2013, 
USA 
It is important that only validated tests for HPV with sound evidence from clinical studies are used in screening as other HPV tests 
may differ in their sensitivity and specificity and do not achieve the same results as in the studies on which the screening 
strategies are based. 
3 clinically validated 
HPV tests 
[56], ACOG, 2012, 
USA 
KPIs should be measured to monitor adherence to recommendations, e.g.: Percentage of women tested at shorter intervals than 
recommended 
“In addition, the anxiety and stigmatization associated with HPV infection are significant concerns for women participating in 
cervical cancer screening programs.” 
10 monitoring 
 
14 STI connotation 
[43], Bouchard-
Fortier, 2014 
Not addressed - 
[51], Moyer, 2012, 
USA 
“Efforts to further reduce cervical cancer morbidity and mortality need to focus also on women who have not been adequately 
screened.” 
“Maintaining the comparability of the benefits and harms of cotesting and cytology alone demands that patients, clinicians and 
health care organizations adhere to currently recommended screening intervals, protocols for repeat testing, thresholds for 
colposcopy and extended surveillance” 
1 Underscreened 
 
9 Adherence 
[48], Rebolj, 2012 Not addressed - 
[45], Murphy, 2012 “Whatever the triage method, it must be implemented within an organized screening program with an information system to 
facilitate invitations, recalls, and communication and follow-up of abnormal results. Such systems are essential, as intensified 
follow-up of positive results and longer screening intervals for HPV-negative women will likely be features of programs that 
implement HPV testing for primary screening.” 
 7 organized program 
 15 call – recall 
 16 communication  
17 triage follow up 
[68], Whitlock, 
2011, USA 
“Besides safety, feasibility or acceptability may affect adoption of a risk-stratified policy on cervical cancer screening because 
primary care physicians may not currently be extending the screening interval to 3 years after negative cotesting results” 
“To evaluate the potential psychological effects of HPV testing, we found 4 fair-quality observational studies (54–57) that used 
mailed questionnaires to examine the immediate and short-term effects of HPV testing in 4104 women in the United Kingdom or 
Australia. Levels of immediate anxiety and distress were increased in women who tested positive for HPV compared with those 
who tested negative. These differences, however, were resolved by 6-month follow-up. Data on other psychosocial outcomes and 
longer-term follow-up were sparse.” 
 9 adherence to 
protocols 
 21 Quality of Life 
[49], Cuzick, 2008 “HPV infections are very common, especially in young women, and usually clear spontaneously, so that over-reaction to the 
detection of HPV DNA carries a risk of unnecessary colposcopies, psychological distress and the possibility of overtreatment. 
Thus, it is essential that HPV testing-based screening is introduced within an organized program with ongoing process and 
outcome evaluation rather than in an opportunistic setting.” 
“The fact that HPV is a sexually transmitted infection may lead to anxiety and concerns about sexual relationships. These 
psychosocial aspects and the need for more information and educational programs…” 
“Women want their health providers to be well-informed about the disease in order to answer their questions without giving 
 7 organized 
screening 
 10 monitoring 
  
14 STI connotation 
 
18 education of 
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Systematic Review 
/ Meta-analysis 
Research Question 2 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implementing screening 
based on HPV testing identified? If yes, which barriers are these?  
Are they relevant for the Swiss health care setting? 
Concern category 
confusing and inconsistent information. Health professionals’ knowledge of HPV has not received much attention, but the 
experience of women with positive test results suggests that many have limited knowledge about HPV. Education of health 
professionals should be a priority. Women’s reactions to hearing about the test include confusion and anxiety about the 
association with STIs as well as issues of fidelity and trust in relationships. Anhang et al. identified confusion about the 
relationship between Pap testing and HPVDNA testing, and uncertainty about the level of risk. “ 
“Women from some ethnic and religious backgrounds express fears that community leaders could be less supportive of cervical 
screening if they were aware of the link with sexual transmission.” 
health care 
professionals 
 
14 STI connotation 
[52], Schiffman, 
2011, USA 
“Of note, in the United States, cervical cancer screening is often viewed as a clinician–“patient” decision, not as a public program 
as it is in some other countries. Clinicians and patients may view a particular level of risk and cost differently from public health 
planners who are faced with limited resources.” 
“In any case, the introduction of new HPV tests with varying test performances, new biomarkers, and the HPV vaccine will 
eventually make clinical algorithms regarding cervical screening and management of screening abnormalities untenably complex 
(…) and quickly out of date. Each round of revised algorithms will need to account for past virological, cytological, and histological 
test histories (…), as well as the results of any novel tests that emerge. Compared with branching algorithms, a properly 
constructed and validated risk assessment tool would be more powerful and easier to update and use for clinical decision making, 
even for clinician–patient discussions (…). The estimated risk of CIN3+ (e.g., if colposcopy were performed that day, or in 1 year, 
or at a 3-year follow-up) is the relatively objective, quantifiable outcome that scientists can provide as the basis for cost-effective 
clinical and public health decisions.” 
“However, such a change is not likely to happen soon in the United States, where cancer prevention policies are only partly 
dictated by evidence regarding optimal practice. It is notable that current evidence-based guidelines for cervical cancer screening 
and management are being widely ignored in the United States (…). Each interest group with input into policy, including various 
government agencies, has its own mandates and constraints. Much of screening practice is dictated by clinical groups; in 
considering clinical recommendations, we should not ignore that the economic threat to practicing gynecologists and cytopa-
thologists inherent in reducing the amount of screening is real.” 
 9 adherence to 
protocols 
 
18 education 
19 complexity 
 
 
 
 
 
9 adherence 
 
 
 
20 economic threats  
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17.2 Excerpt of Answers to Research Question 2 from Health Economic studies 
Table 12: Excerpt of answers to research question 2 from health economic studies 
Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
[37], Huh, 2015, 
USA 
No specific barriers were identified towards implementation, however it is interesting to note, that the recommended strategy in the US 
for cotesting is 5-yearly, while the authors say “American Congress of Obstetricians and Gynecologists and other clinical experts have 
contended that 3-yearly cotesting is the more likely scenario in the community as patients are unlikely to feel comfortable with 
extended screening intervals”.  
This implies that patients’ preferences need to be taken into account when defining the recommended screening strategy, otherwise it 
may not be implemented as recommended and thus miss its projected clinical and cost effectiveness. 
9 adherence  
24 patient 
preferences 
[30, 60], 
Sroczynski, 
2010, 2011, 
Germany 
The authors warn that prior to encouraging an extension of the screening interval, the effect of longer screening intervals on screening 
adherence and attendance at gynecological checkups should be carefully considered. 
 
In addition the authors recommend the implementation of an organized screening program for quality-controlled introduction of HPV 
screening with continued systematic outcomes evaluation.  
“The implementation of an organized screening programme for quality-controlled introduction of HPV screening and -vaccination with 
continued systematic outcomes evaluation is recommended. Future research is needed to acquire evidence-based information on 
adherence patterns and the impact of screening results on quality-of-life.  
On the limitation that no QALYs are available: Since screening results in a relatively small average gain in life expectancy, changes in 
quality-of-life due to psychological distress associated with the communication of screening results or adverse events of pre-cancer 
treatment may significantly affect the estimated cost-effectiveness ratios.” „Gerade aber im Screening können relativ kleine und 
vorübergehende Lebensqualitätsverluste durch zum Beispiel falsch-positive Testergebnisse einen grossen Einfluss auf der 
Populationsebene haben. Es ist anzunehmen, dass diese Lebensqualitätsverluste in Screeningsettings mit kürzeren 
Screeningintervallen oder hohen Teilnahmeraten stärker sind als in Settings mit längeren Screeningintervallen oder niedrigeren 
Teilnahmeraten.“ 
 
“ Europäische Leitlinien: Die Autoren der Leitlinien kommen zum Schluss, dass primäres HPV-Screening nicht empfohlen werden 
sollte, ohne die Altersgruppe, das Screeningintervall und die wesentliche Elemente für eine Qualitätssicherung bei der 
Programmimplementierung zu benennen. Im Rahmen eines opportunistischen Screenings wird ein HPV-Screening nicht empfohlen, 
weil unter solchen Bedingungen ein Einhalten der empfohlenen Screeningintervalle und die erforderliche Qualitätskontrolle nicht 
gewährleistet werden könne. Pilotstudien mit validierten HPV-DNA-Tests werden empfohlen, wenn sie im Rahmen eines organisierten 
Screeningprogramms mit sorgfältigem Monitoring und systematischer Evaluation der gewünschten Zielgrössen, Nebenwirkungen und 
Kosten stattfinden. (…) Unter einem organisierten Screening wird nach der Empfehlung des Europäischen Rats zur 
Krebsfrüherkennung die systematische Implementation eines Screeningprogramms verstanden, das die gesamte Zielpopulation 
erfasst und in dem Praxisleitlinien befolgt werden. Zur systematischen Implementation gehören ein Einladungssystem (call/recall 
6 side effects of 
longer screening 
intervals 
 
7 organized setting 
8 Quality control 
10 Monitoring and 
Evaluation 
21 Quality of Life 
 
 
 
 
9 adherence 
11 pilot project 
3 validated Tests 
 
 
 
15 call/ recall 
 
22 central database 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
system), die Qualitätssicherung auf allen Ebenen sowie effektive und angemessene evidenzbasierte diagnostische und 
therapeutische Massnahmen. Um ein organisiertes Screeningprogramm durchzuführen, werden zentrale Datensysteme für notwendig 
erachtet, die eine Liste aller Personen der Zielbevölkerung und Daten über alle Screeningtests sowie diagnostischen Abklärungstests 
und die endgültigen Diagnosen erhalten sollen. Ein Qualitätsmonitoring des Screenings beinhaltet eine Analyse des Prozesses und 
der Ergebnisse des Screenings und einen zeitnahen Bericht der Ergebnisse an die Bevölkerung und derjenigen, die das Screening 
anbieten und durchführen. Eine solche Analyse würde erleichtert, wenn die Screeningdatenbank mit Krebsregistern und 
Sterblichkeitsdatenbanken verbunden werden könnte.“ 
„Die Empfehlung zur Einschränkung des Zervixkrebsscreenings durch die neuen Altersgrenzen und eine Verlängerung des Intervalls 
auf 2 Jahre sind in der US-amerikanischen Öffentlichkeit zum Teil als reine Sparmassnahmen im Zusammenhang mit der 
Gesundheitsreform des Präsidenten Obama interpretiert worden. Zusätzlich wurde bezweifelt, dass Ärzte und Patienten den neuen 
Leitlinien folgen würden. Argumente von ärztlicher Seite waren, (…) dass generell bei einem Aufruf an die Öffentlichkeit, weniger zu 
tun, gerade Hochrisikogruppen diese Botschaft aufnähmen und dann gar nicht zum Screening gingen. Von Patientenseite wird das 
Gefühl grösserer Unsicherheit angeführt, wenn man jährliches Screening gewöhnt sei. Den möglichen negativen Folgen eines 
Screenings ( Überdiagnostik und –behandlung, ggf. Lebensqualitätseinschränkungen) wurde jedoch wenig Beachtung geschenkt. 
Während die Maximierung des Nutzens durch frühes und wiederholtes Screening erreicht werden kann, wird eine Minimierung des 
Schadens eher durch eine stärkere Fokussierung des Screenings erzielt. Das Spannungsverhältnis zwischen diesen beiden Zielen 
führt oft zu Kontroversen im Hinblick auf das Alter für Screeningstart und –ende und der Screeningintervalle. Leitlinien, die empfehlen 
weniger zu tun werden häufig mit Misstrauen betrachtet. Der US-Regierung wird ein primär wirtschaftliches Interesse an einer 
Reduktion von Screeninguntersuchungen unterstellt, ein wirtschaftliches Interesse ärztlicher Berufsgruppen an kurzen 
Screeningintervallen bleibt hingegen unerwähnt.“ 
 
„Opportunistisches Screening ist gekennzeichnet durch zu häufige Tests, niedrige Teilnahmeraten bei älteren Frauen, 
sozioökonomisch benachteiligten und Hochrisikogruppen, eine heterogene Qualität und unkontrollierte Einführung neuer Technologien 
und einem geringen Grad an Monitoring“ 
 
 
 
23 trust in policy 
makers 
 
6 side effects of 
longer screening 
intervals 
 
24 patient 
preferences 
 
20 economic 
threats 
[75], Bistoletti, 
2008, Sweden 
No barriers were discussed  
[2],Kitchener, 
2014, UK 
“Compliance with surveillance and optimal management of HPV-positive/cytology-negative women after primary HPV screening is of 
key importance”.  
A less well-understood area relates to the response of women to being told they are HPV positive/cytology negative in terms of 
understanding the need for follow-up and at the same time avoiding anxiety and uncertainty.” 
 
“Compliance with surveillance and optimal management of HPV-positive/cytology-negative women after primary HPV screening is of 
key importance. High compliance with early recall is predicted to be critical and careful attention should be paid to this aspect.” 
“Because triage testing with cytology has imperfect sensitivity, some women in this group will be at risk of progression. Delay in follow-
up in this group would result in a higher proportion of women with disease progression. Furthermore, compliance with follow-up in this 
9 adherence 
 
21 Quality of Life  
 
 
17 triage follow up 
of abnormal results 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
group is extremely important. 
 
“This study and economic evaluation lend support to convert from cytology to HPV-based screening, piloting of which commenced in 
the English programme in the second quarter of 2013.” 
 
 
11 Pilot project 
 
[28],Arbyn, 
2015, Belgium 
The authors state that implementation of such a new screening algorithm should have measures to drive adherence to screening 
guidelines in place as well as quality control over screening tests.  
The background is that currently in Belgium screening guidelines are not followed. Screening tests on cervical smears are taken much 
more often than every three years and colposcopies are performed on about 50% of the screened women, often at the same time as 
the smear was taken and not as a follow up of an abnormal primary cytological test. The frequencies of overscreening has declined 
since reimbursement is more strictly handled, so that only screening tests are reimbursed that occur within the recommended 
schedule. 
The need for quality control is inferred from the observation that there seems to be high heterogeneity between cytological 
laboratories. Heterogeneity of HPV testing should be lower than that of cytology, as the HPV test involves more automation than 
cytology testing. Quality control should be also implemented for colposcopy 
 
“Results of HPV testing are greatly impacted by the assay and therefore, all steps of HPV detection and typing used by a global 
network need careful standardization.” 
 
“External quality control, HPV reference laboratory that develops standards that can be used for Quality control by laboratories 
An additional task is the development of international standard materials which facilitate inter-laboratory comparisons and improves 
laboratory performance.  
Laboratories identifying correctly 50 international units (IU) of HPV16 and HPV18 and 500 IU of other high-risk HPV genotypes are 
considered proficient. Successive proficiency studies have demonstrated improved proficiency among participating laboratories  
The following European countries have a national HPV reference laboratory: Czech Republic, Denmark, England, France, Germany, 
Italy, Norway, Scotland, Slovenia, Switzerland, Sweden. “ 
 
“The clinicians are informed on the test results and are responsible to inform the screened woman and to organize the aftercare 
(secondary examinations and treatments). However, since the letter is directly send to the eligible women, the GPs are often unaware 
about the frequency of screening tests of their patients. This situation hampers the central role of the GP in sensitizing the woman 
about prevention of (cervical) cancer. The organization of a uniform sensitization program of the eligible women is in progress, but 
currently different organizations and sensitizations programs still exist, which could increase the risk to disseminate different 
messages. An evidence-based, objective and comprehensible patient leaflet which contains the advantages and disadvantages of 
cervical cancer screening, could facilitate the informed decision making by the woman.”  
 
“A key issue in the adherence to the recommended European, national or regional guidelines is the reimbursement policy. In Belgium, 
9 adherence 
 
 
 
 
 
 
8 Quality Control 
 
 
 
3 clinically validated 
HPV assays 
 
8 Quality Control 
25 external 
reference 
laboratory 
 
 
 
 
26 central role of 
the GP 
 
 
 
 
16 communication 
 
13 reimbursement 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
for instance, adaptation of the EU policy (screening every three years) in Flemish guidelines was hardly followed, since the 
reimbursement was not conditioned by the respect of the recommended screening interval4. However, the adoption of a new rule of 
reimbursement (restricted to one cytological screening examination once every two years) resulted in a 41% reduction in the total 
annual volume of examined Pap smears. It is expected that further restriction of reimbursement (once every three years) will further 
reduce the amount of over-screening” 
 
“However, loss to follow-up should be taken into account when triage involves more visits. Avoiding the necessity for repeat testing 
reduces the risk of loss to follow-up. In the two Dutch trials, the compliance with follow-up after six and twelve months was ~60% and 
~75%, repectivey28, 112. Other studies have also demonstrated considerable loss to follow-up at repeat testing, particularly after 
normal cytology. Therefore more sensitive one step reflex-triage scenarios are interesting as well, such as T1: ASCUS+ combined with 
HPV1618 genotyping, which results always in a good PPV (≥10%) in low- and intermediate risk situation and an acceptable NPV in 
low- risk situation. “ 
 
Currently the following HPV DNA tests can be considered as clinically validated according the Meijer guideline: Abbott RT hrHPV test, 
COBAS-4800, Papillocheck, and two PCR assays targeting (E6/E7) of separate high-risk HPV types. However, the list is changing 
rapidly and an updated list should be consulted. 
policy  
 
 
 
 
 
17 triage follow up 
 
 
 
 
 
 
3 clinically validated 
tests 
[76],Accetta, 
2010, Italy 
No barriers were identified towards implementation 
Instead the authors argue that the money saved from switching to HPV based screening and a 5 year interval from 3 year can be used 
for measures to improve attendance at and compliance with screening. 
No barrier, but 
favorable for the  
1 underscreened 
[32],Burger, 
2012, Norway 
The authors warn that loss to follow up may occur and “Norwegian women are more likely to ignore recommendations to follow-up 
equivocal and low-grade results compared to those indicating a high-grade lesion (Nygard et al 2006). If the importance of continuing 
to follow up an HPV+/Cyt – negative result is not communicated adequately to women, the additional sensitivity of HPV testing could 
be eroded”. Indeed a later study by Burger [109] on failures of screening systems cited the 2008 annual report population-based 
screening against cervical cancer (Oslo: Cancer Registry of Norway, 2009) saying that only 65% of eligible women attend cytology-
based screening every 3 years, but the rest either never attend or less frequently than recommended. In addition at least 35% of 
women with abnormal results fail to return within 1 year for follow-up testing. 
“The optimal strategies identified by this analysis will require a comprehensive and dynamic system, which can alert women according 
to their individual screening needs. More complex and tailored screening algorithms will be more difficult to understand, not only for 
women, but also for clinicians, who are responsible for explaining and implementing strategies. Extensive monitoring of the coverage, 
compliance, resource use, and outcome variables is also crucial in order to allow the public health officials to identify caveats and 
areas that are in need of improvement. “ 
 
Burger [109] showed that increasing compliance with screening reduces cancer risk considerably, however switching to HPV based 
screening without changes in compliance is expected to reduce cancer risk by 12% compared to cytology based screening and any 
increased compliance has a stronger beneficial effect with HPV based screening than with cytology based screening. 
17 triage follow up 
 
 
 
 
 
 
19 complexity 
 
10 Monitoring 
 
 
 
1 underscreened, 
however favorable 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
[35] Goldhaber-
Fiebert, 2008, 
USA 
The authors argue that the full potential of the new screening strategies require that age-based guidelines will be followed.  
 
In addition efforts should be targeted to recruit and screen women with historically poor access to cervical cancer prevention 
9 adherence 
 
1 underscreened 
[29],MSAC, 
2014, Australia 
The authors recommend strengthening adherence to screening with a “call-recall” system.  
The authors calculated that a call-recall system instead of only a reminder system will reduce cervical cancer incidence by 1% with an 
associated 2-3% relative increase in screening program cost.  
This system can only be implemented in an organized screening setting where all women are registered and receive an invitation to 
screening (“call”), where the attendance to and the result of the screening test is registered and in the absence of attendance a 
reminder (“recall”) is issued. 
“A systematic appraisal of evidence for invitation and recall systems was not undertaken in the evidence review, however a brief 
overview was provided. A number of studies (including RCTs, clustered RCTs and meta-analyses) supported the hypothesis that 
invitation systems would improve the uptake of screening (…). The meta-analyses found women who received invitations letters to 
attend screening had a significantly higher uptake of screening than women who received usual care or no invitation (relative rate 1.44 
95%CI 1.24-1.52) (…).” 
 
The modelled analyses included a reduction in general practitioner (GP) consultations, recognizing that freeing these resources would 
allow them to be redeployed to relieve some capacity pressure through making available appointments for other services. 
 
A recent review by Dijkstra et al (2014) suggested the Meijer et al guidelines could be used to assess the clinical performance of a 
candidate test, relative to either HC2 or GP5+/6+ PCR by cross sectional clinical equivalence analysis in a screening setting. They 
reported that Roche cobas® 4800 and Abbott Real Time PCR have fulfilled the criteria provided in the guidelines with sensitivities 
ranging from between 100% and 95.8% and specificities from 96.7% to 92.3%. They suggested these assays have been clinically 
validated for primary HPV cervical screening. 
 
Quality Assurance System for Laboratories 
15 call/recall 
 
 
7 organized setting 
22 central database 
 
 
 
 
 
 
 
27 more free 
resources of GPs 
(favorable) 
3 clinically validated 
tests 
 
 
 
 
8 Quality Control 
[33] 
Vijayaraghavan, 
2010, Canada 
Potential implementation problems could involve the available resources for colposcopy and biopsy, if a strategy is adopted that leads 
to increased colposcopy rates (e.g. HPV only) 
 
28 colposcopy 
resources 
[36], 
Vijayaraghavan, 
2010, USA 
No barriers were discussed - 
[77] Diaz, 2010, 
Spain 
No barriers were discussed - 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
[34], 
Kulasingam, 
2009, Canada 
No barriers were discussed  - 
[78],Chuck, 
2010, Alberta, 
Canada 
Adherence to recommended screening strategies was mentioned as the most critical risk 9 adherence 
[74] 
Mühlberger, 
2008, Germany 
No barriers to implementation were discussed, however auditing of screening programs is highly recommended by the authors to 
evaluate the history of women who develop cervical cancer to find out whether the failure of the screening program is due to non-
attendance or other methodological weaknesses 
10 monitoring and 
evaluation 
[81] Dillner  “However, there are logistical challenges to implement HPV-based screening, such as the need to ensure that HPV tests are used at 
increased screening intervals and in the correct age groups, … the limited international standardization and quality assurance, and the 
need to optimize and evaluate the method switch in the real-life setting.“ 
 
“The necessary infrastructure to exploit the potential of HPV-based screening for improved cost-efficiency exists within organized, 
invitational screening programs.  
Piloting of HPV screening can be implemented by such programs, preferably as randomized healthcare policies.” 
 
The authors raise the concern that 148 different HPV tests are available on the market (plus 44 variants). A method needs to be found 
to evaluate HPV assays with appropriate performance for screening 
 
Success factors: 
1. Use standard and quality-assured HPV test 
2. Tendered pricing 
3. Do not invite too young women 
4. Avoid unnecessary referrals of low-risk women with recently acquired HPV infections 
5. Perform a pilot 
6. Establish quality assurance system 
9 adherence 
8 Quality Control 
10 monitoring and 
evaluation 
7 organized setting 
11 Pilot project 
 
 
3 clinically validated 
tests 
 
30 economy of 
scale 
[79] Berkhof, 
2010, 
Netherlands 
Any potential strategy should be evaluated on detected number of high-grade lesions, costs and colposcopy rate computed from large 
cohort studies before implementation can take place. 
11 Pilot Project 
[31] van 
Rosmalen, 
2012, 
Netherlands 
One interesting feasibility aspect is the potential loss of women in follow up after a positive HPV test. This loss can be reduced by 
always taking the cervical smear in a way that both HPV test and cytology can be performed in the laboratory if the HPV test should be 
positive.  
Taking samples for both HPV and cytology will slightly increase the cost of initial sampling, so van Rosmalen et al simulated both 
options. The authors found that collecting the material for the first triage test during the visit for the primary test is more cost-effective 
than letting women return for a triage test after 2 weeks.  
17 triage follow up 
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Publication, 
Country 
In case that HPV testing is found to be clinically effective and cost effective: Are any potential barriers to implement screening based 
on HPV testing identified? If yes, which barriers are these? 
Concern category 
It was not completely clear what the effect of dropouts in triage tests was. According to van Rosmalen if 10% of the women with a 
positive primary HPV test did not attend the triage tests primary cytology screening became the most cost-effective option, whereas 
according to De Kok with 90% attendance of triage HPV testing was still the most cost-effective option. 
 
Sampling for both the primary test and the triage test during the first screening visit should be taken into account if setting up a 
screening organization 
 
[80] de Kok, 
2012, 
Netherlands 
HPV based screening must, however, only be implemented in situations where screening is well controlled. 
“Implementing HPV screening in situations where screening is not well controlled carries risks that may be unacceptable. Frequent 
screening at a young age decreases the programme’s specificity given that every screening round adds to false positive test results 
(that is, the detection of non-progressive HPV infections or cervical intraepithelial neoplasia lesions), and screening at a young age 
detects many transient infections and abnormalities. “ 
 
In addition, HPV screening should be organized in such a way that the procedures are carried out in large centers to monitor the 
quality of the screening and to benefit from economies of scale. This is especially the case for HPV testing, which can be automated to 
a large extent, and where economies of scale will make a considerable difference to costs. 
7 organized 
screening setting 
 
9 adherence 
 
 
29 large centers 
30 economy of 
scale 
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18 Appendix 6: “EURONHEED checklists for the health economic 
studies” 
Table 13: EURONHEED checklist for health economic studies 
Page 1 of this table contains the questions of the EURONHEED checklist; pages 2 and 3 contain the 
ratings per publications. Questions in bold formatting and light blue background are relevant for the 
calculation of the transferability data score. 
 
Question  
Q1. Is the study question clearly stated? 
Q2. Are the alternative technologies justified by the author(s)? 
HT1. Is the intervention described in sufficient detail? 
HT2. Is(are) the comparator(s) described in sufficient details? 
SE1. Did the authors correctly specify the setting in which the study took place (e.g. primary care, community)? 
SE2. Is(are) the country(ies) in which the economic study took place clearly specified? 
P1. Did the authors correctly state which perspective they adopted for the economic analysis? 
SP1. Is the target population of the health technology clearly stated by the authors, or when it is not done 
can it be inferred by reading the article? 
SP2. Are the population characteristics described? (e.g. age, sex, health status, socioeconomic status, inclusion/ 
exclusion criteria) 
SP3. Does the article provide sufficient detail about the study sample(s)? 
SP4. Does the paper provide sufficient information to assess the representativeness of the study sample with 
respect to the target population? 
M1. If a model is used is it described in detail? 
M2. Are the origins of the parameters used in the model given? 
E1. If a single study is used is the study design described (sample selection, study design, allocation, follow-up)? 
E2. If a single study is used are the methods of data analysis described (intention to treat/per protocol or 
observational data)? 
E3. If based on a review/synthesis of previous published studies, are review methods described (search strategy, 
inclusion criteria, sources, judgment criteria, combination, investigation of differences)? 
E4. If based on opinion, are the methods used to derive estimates described? 
E5. Have the principal estimates of effectiveness measures been reported?/ Is the level of reporting of 
the effectiveness results adequate 
E6. Are the side-effects or adverse effects addressed in the analysis? 
E7. Does the article provide the results of a statistical analysis of the effectiveness results? 
B1. Do the authors specify any summary benefit measure(s) used in the economic analysis? 
B2. Do the authors report the basic method of valuation of health states or interventions? 
B3. Do the authors specify the source(s) of health states (e.g. specific patient population or the general public)? 
B4. Do the authors specify the valuation tool used? 
B5. Is the level of reporting of benefit data adequate (incremental analysis, statistical analyses)? 
C1. Are the cost components/items used in the economic analysis presented? 
C2. Are the methods used to measure costs components/items provided? 
C3. Are the sources of resource consumption data provided? 
C4. Are the sources of unit price data provided? 
C5. Are unit prices for resources given? 
C6. Are costs and quantities reported separately? 
C7. Is the price year given? 
C8. Is the time horizon given for each element of the cost analysis? 
C9. Is the currency unit reported? 
C10. Is a currency conversion rate given? 
C11. Does the article provide the results of a statistical analysis of cost results? 
D1. Was the summary benefit measure(s) discounted? 
D2. Were the cost data discounted? 
D3. Do the authors specify the rate(s) used in discounting costs and benefits? 
D4. Were discounted and not discounted results reported? 
S1. Are quantitative and/or descriptive analysis conducted to explore variability from place to place? 
O1. Did the authors discuss caveats regarding the generalizability of their results? 
 
Quality Data Score 
Transferability Data Score  
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Study 
USA  
Huh 
Belgium 
Arbyn 
Australia 
MRCA 
NL 
deKok 
Germany 
Sroczynski 
NL van 
Rosmalen 
UK 
Kitchener 
US Vijaya-
raghavan 
Q1 yes yes yes yes Yes yes yes yes 
Q2 yes yes yes yes yes yes yes yes 
HT1 yes yes yes yes yes yes yes yes 
HT2 yes yes yes yes yes yes yes yes 
SE1 yes yes yes yes yes yes yes yes 
SE2 yes yes yes yes yes yes yes yes 
P1 yes yes yes yes yes yes yes yes 
SP1 yes yes yes yes yes yes yes yes 
SP2 yes yes yes yes yes yes yes yes 
SP3 N/A N/A N/A N/A N/A N/A N/A N/A 
SP4 yes yes N/A yes P yes N/A N/A 
M1 yes yes P yes yes P P yes 
M2 yes yes yes yes yes yes P yes 
E1 N/A N/A N/A N/A N/A N/A N/A N/A 
E2 N/A N/A N/A N/A N/A N/A N/A N/A 
E3 N/A P N/A N/A P N/A N/A N/A 
E4 N/A yes N/A N/A P N/A N/A N/A 
E5 yes yes yes partially yes yes yes yes 
E6 yes yes yes partially No/NI P yes No/NI 
E7 yes yes yes yes yes yes yes yes 
B1 yes yes yes yes yes yes yes yes 
B2 yes N/A yes yes N/A yes No/NI yes 
B3 yes N/A yes partially N/A P P yes 
B4 yes N/A yes partially N/A P P yes 
B5 yes yes P yes yes yes P yes 
C1 P yes yes yes yes yes yes yes 
C2 yes yes yes partially yes yes yes yes 
C3 yes yes yes partially yes P yes yes 
C4 yes yes yes partially yes P yes yes 
C5 yes yes yes yes yes yes yes yes 
C6 P P P partially P P P P 
C7 yes yes yes yes yes yes yes yes 
C8 yes P P partially P P P yes 
C9 yes yes yes yes yes yes yes yes 
C10 N/A N/A N/A N/A N/A N/A N/A N/A 
C11 yes yes yes yes yes yes yes yes 
D1 yes yes yes yes yes yes yes No/NI 
D2 yes yes yes yes Yes yes yes No/NI 
D3 yes yes yes yes yes yes yes N/A 
D4 P yes P yes yes yes P N/A 
S1 P No/NI No/NI yes P No/NI yes P 
O1 P P P yes P yes yes P 
 
         
Q Score 0.93 0.91 0.89 88% 0.87 0.86 0.86 0.86 
T Score 0.87 0.87 0.83 91% 0.90 0.90 0.93 0.90 
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Study 
Sweden 
Bistoletti 
Norway 
Burger 
USA 
Goldha-
ber-
Fiebert 
Canada 
Kulasingam 
Canada 
Chuck 
Spain 
Diaz 
Canada 
Vijayara-
ghavan 
Italy 
Accetta 
Q1 yes yes yes yes yes yes yes yes 
Q2 yes yes P yes P yes P P 
HT1 no/NI yes yes P yes yes P no/NI 
HT2 no/NI yes yes yes yes yes P no/NI 
SE1 yes P yes P P yes yes P 
SE2 yes yes yes yes yes yes yes yes 
P1 yes yes yes yes yes yes yes P 
SP1 yes yes yes yes yes yes yes yes 
SP2 yes yes yes P yes yes P yes 
SP3 N/A N/A N/A N/A N/A N/A N/A N/A 
SP4 yes P N/A yes P P P N/A 
M1 yes P P P yes P P yes 
M2 yes yes yes yes yes yes yes yes 
E1 N/A N/A N/A N/A N/A N/A N/A N/A 
E2 N/A N/A N/A N/A N/A N/A N/A N/A 
E3 N/A N/A N/A N/A N/A N/A N/A N/A 
E4 N/A No/NI N/A N/A N/A N/A No/NI P 
E5 yes P yes P No/NI No/NI yes yes 
E6 No/NI P No/NI P P P P No/NI 
E7 yes P yes P P No/NI P No/NI 
B1 yes yes yes yes yes yes yes yes 
B2 N/A N/A P yes yes N/A P P 
B3 N/A N/A No/NI yes yes N/A P No/NI 
B4 N/A N/A No/NI yes yes N/A P No/NI 
B5 P P yes P No/NI P P yes 
C1 yes yes yes yes yes yes yes yes 
C2 yes yes yes yes yes yes P yes 
C3 yes yes yes yes yes yes P yes 
C4 yes yes yes yes yes yes yes yes 
C5 yes yes yes yes No/NI yes yes yes 
C6 P P P P P P P P 
C7 yes yes yes yes yes yes yes yes 
C8 yes P P P yes P yes P 
C9 yes yes yes yes yes yes yes yes 
C10 No/NI yes N/A N/A N/A N/A N/A N/A 
C11 P P yes yes yes No/NI yes No/NI 
D1 yes yes yes yes yes yes yes yes 
D2 yes yes yes yes yes yes yes yes 
D3 yes yes yes yes yes yes yes yes 
D4 yes P P P No/NI P P P 
S1 P P P yes No/NI No/NI No/NI No/NI 
O1 yes yes P P yes P yes No/NI 
         
Q Score 0.82 0.80 0.80 0.78 0.78 0.76 0.73 0.65 
T Score 0.77 0.83 0.90 0.80 0.67 0.70 0.77 0.60 
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19 Appendix 7: “Transferability Analysis for the health economic studies” 
Table 14: Transferability analysis of health economic studies to the Swiss health system  
Study Transferability Summary 
[35] 
Goldhaber-Fieber, 
2008, USA 
Transferability is potentially possible. A comparator was used that reflects Swiss screening recommendations. Follow up 
of CIN1 may be slightly different in that in the US CIN1 will be followed up by surveillance until negative, while in 
Switzerland CIN1 is recommended for treatment if persistent. HPV prevalence seems to be slightly lower than in 
Switzerland, which may slightly favor HPV based testing (with lower prevalence a more sensitive test is of advantage).  
Transferability question Analysis of the study 
Was a comparator used 
that is relevant for the 
Swiss setting? 
Yes, 3-yearly cytology with HPV triage was modelled. 
Sensitivity of cytology  70% for CIN1 and 80% for CIN2+, this was varied in the sensitivity analysis between 18.6-99% 
If the sensitivity of the cytological evaluation was reduced by more than 15% (e.g., below 70% for CIN2,3), then HPV DNA testing with cytology  
triage became increasingly attractive (see the Supplementary Appendix, pp. 21,120, available online). 
Sensitivity of HPV 83% for CIN2+, this was varied in the sensitivity analysis between 70 -85% 
Changes in the specificity of HPV DNA testing were more influential than changes in test sensitivity. For example, compared with cytology-based 
strategies, HPV DNA testing with cytology triage every 5 years remained an efficient strategy even when the sensitivity for CIN2, 3 was as low as 
70%. In contrast, when the specificity of HPV DNA testing was less than 85%, cytology-based screening with HPV DNA testing when ASC-US was 
detected was preferred (see the Supplementary Appendix, pp. 23,125,126, available online). 
Viewpoint of the analysis Health Care Payer perspective plus some societal costs were included ( direct medical costs, patient time and transport cost for screening, 
diagnostic follow up and cancer treatment) 
Do treatment options 
compare to current clinical 
practice in Switzerland? 
Women with histologically confirmed CIN1 are not treated but are monitored every 6 – 12 months until they have three negative screening test 
results. In comparison in Switzerland CIN1 is recommended for treatment if persistent 
 
Is there any hint for a 
different base line risk of 
the populations? 
hrHPV prevalence in this model seems to be slightly lower than in Switzerland (compared to de Vuyst), while cervical cancer incidence in the US 
has been reported slightly higher (2007–2011 US age-adjusted incidence of 7.8 per 100,000 reported by the SEER (acc. to Huh 2015) compared 
to 5.4 in Switzerland 
Do the screening setting or 
attendance rates influence 
the result?? 
US screening is opportunistic with different ethnic groups having or using different access to health care resources. Adherence rates were varied 
to reflect observations from different ethnic groups.  
All groups will have an incremental benefit of switching to the recommended HPV based testing. The effect being higher with increasing adherence 
levels to new recommendations 
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Study Transferability Summary 
[32] 
Burger, 2012, Norway 
Transferability is potentially possible.  
The screening strategy is similar as in Switzerland with the exception that LSIL is only followed up with colposcopy in 
Norway, if persistent and that ASC-US and LSIL are followed up with HPV and cytology cotesting. However the strategies 
are still comparatively close. 
In this model women were switched to HPV testing at 31 years and HPV positive results were followed with cotesting 
triage. 
Transferability question Analysis of the study 
Was a comparator used 
that is relevant for the 
Swiss setting? 
The current Norwegian screening strategy is 3 yearly cytology with cotesting triage for ASC-US or LSIL after 6 months. Women with HSIL are 
referred directly to colposcopy/ biopsy. This strategy is similar to the current Swiss recommendations with the exception that in Switzerland with 
LSIL immediate colposcopy is recommended  
Theoretically due to the stricter follow up the Swiss cytology strategy could be more sensitive than the Norwegian strategy. On the other hand 
comparatively high sensitivities of cytology based testing to detect CIN2+ were assumed in the model. Therefore the differences in the strategy 
seem negligible. 
Sensitivity of cytology  Sensitivity of cytology was 70% to detect CIN1 and 80% to detect CIN2+ 
Assuming lower sensitivities of 50% or 40% made an HPV based strategy with 5-yearly testing the optimal strategy with colposcopy after only 1 
repeated HPV+/Cyt- result after 6 months (instead of 4-yearly with 12 months before colposcopy) 
Sensitivity of HPV Sensitivity and specificity of the HPV test for the presence or absence of HPV was assumed 100% 
Viewpoint of the analysis In addition to direct medical costs indirect medical costs (patients’ transport costs) and some social costs (patient time translated into cost for 
productivity loss) for screening, diagnostic follow up and treatment was calculated. 
Do treatment options 
compare to current clinical 
practice in Switzerland? 
Treatment options are not described in detail; however costs for CIN1 treatment were shown indicating that this stage is eligible for treatment in the 
Norwegian context. In comparison in Switzerland CIN1 is recommended for treatment if persistent. On the other hand in Norway LSIL is not 
immediately followed up with colposcopy, but only if persistent. If in this case CIN1 is detected, this may also be a persistent histological finding. 
Is there any hint for a 
different base line risk of 
the populations? 
No data were available for the prevalence of hrHPV. Incidence and mortality rates are 9.5 and 1.7 per 100 000 women-years, respectively (Cancer 
Registry of Norway, 2011) compared to 5.4 and 1.4 in Switzerland 
Do the screening setting or 
attendance rates influence 
the result?? 
Norway has an invitational system. 
In the base case 100% compliance with all recommendations was assumed to compare maximum possible benefits of each strategy 
In addition in the sensitivity analysis 2 scenarios were included in which 15 or 20% never attend and 70% comply with recommendations and the 
rest screens less frequently (1 year later) than recommended. Potentially scenario 2 is closest to the Swiss situation. The strategy with HPV testing 
every 4 years remained to be the best case 
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Study Transferability Summary 
[30, 60] Sroczynski, 
2010, 2011, Germany 
Despite the differences between the German and the Swiss screening approaches (details see below) the results may be 
transferable to the Swiss setting. As a conservative assumption the base case with higher sensitivities for cytology testing 
would be taken as transferable. 
Transferability question Analysis of the studies 
Was a comparator used 
that is relevant for the 
Swiss setting? 
3-yearly Pap test was modelled; however follow up of positive Pap tests was slightly different. While Swiss recommendations indicate colposcopy 
for LSIL and HSIL, in the German model more than 50% of the HSIL was followed by retest with either cytology or HPV or a combination of both. 
For LSIL retesting was done for more than 76% of the women instead of colposcopy. 63% of ASC-US results receive repeat Pap testing and 26% 
HPV or cotesting, the rest is referred to colposcopy. 
In the “HPV” strategy, a positive HPV test was followed up with Pap triage in 43% of the cases, 23% were referred to colposcopy, the rest retested 
with HPV or cotesting.  
As in Switzerland some variability in adherence to recommendations will probably exist, this strategy may still be a close comparator to the Swiss 
health system. 
In the HPV with Pap triage or cotesting strategies a finding of HPV and Pap positivity was not always followed up with colposcopy, but depending 
on the severity of the Pap finding. With HSIL referral to colposcopy or immediate treatment was done in 63% of the cases, with LSIL in 44% and 
ASC-US 20%. This is a less stringent follow up of positive test results than in other models in other countries and less stringent than recommended 
for Switzerland. Potentially therefore both the comparator strategy in Germany as well as the modelled HPV based strategy may be less sensitive 
than possible. As this may affect both the comparator and the HPV based strategy, the result of this study is still relevant. 
Sensitivity of cytology  Base case 47% for CIN1 and 72% for CIN3+, “German case” 42%  for CIN1 and 46% for CIN3+ 
Sensitivity of HPV Base case 81% for CIN1 and 98% for CIN3+, “German case” 81%  for CIN1 and 97% for CIN3+ 
Viewpoint of the analysis Third party payer, direct medical costs in the context of diagnosis, therapy and follow-up care of cervical cancer and its precursor states 
Do treatment options 
compare to current clinical 
practice in Switzerland? 
Treatment recommendations in Germany and Switzerland are similar in that the age of affected women is taken into account to take a decision for 
immediate treatment of precancerous lesions or surveillance. From the discussion in the German publication it is indicated that CIN2 is less often 
treated but more often referred to surveillance, than e.g. in US studies where treatment was always indicated, however the recommendations 
involve judgment of the responsible physicians and actual treatment frequencies were not reported.  
Variation of treatment cost did not have a relevant impact on the results.  
Is there any hint for a 
different base line risk of 
the populations? 
No data were available in Germany for age related HPV prevalence.  
Incidence of cervical cancer is about 9-10/100’000 in Germany compared to 4.5 in Switzerland. This result may be due to differences in the 
screening strategies and not necessarily reflects different background risk. 
Do the screening setting or 
attendance rates influence 
the result?? 
What attendance rates were modelled? 
An average screening adherence of only 55% was assumed in the base case and in the sensitivity analysis varied between 0% and 100%. The 
relative effectiveness of the strategies did not change with different adherence rates 
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Study Transferability Summary 
[75] Bistoletti, 2008, 
Sweden 
It is unclear whether the findings of this study are transferable to the Swiss setting. The sensitivity of cytology testing in 
Sweden may be lower than in Switzerland, which would favor HPV testing in the study. The model started screening only 
at 32 years, leading to a higher background risk at the start of screening. Only the primary screening test is described, not 
the follow up after a positive primary screening test. 3 HPV based tests in a woman’s life were more effective and less 
expensive than 3 yearly cytology based screening between 32 and 50 years, afterwards 5 yearly cytology, however it is 
unclear how this strategy would compare to the Swiss 3-yearly cytology with HPV triage. 
Transferability question Analysis of the studies 
Was a comparator used 
that is relevant for the 
Swiss setting? 
Cytology screening at 32 to 50 in 3-yearly intervals, afterwards 5 yearly was the comparator, however as an important limitation only the primary 
screening test is described, not the follow up after positive results. 
Starting screening only at age 32 will lead to a higher background risk at start of screening 
Sensitivity of cytology  Invasive cancer if Cyt pos: p=0.0017, Invasive cancer if Cyt neg: p=0.0001, Normal if Cyt neg: p=0.9999  
Sensitivity and specificity of cytology may be lower in Sweden than in other countries incl. Switzerland as in Sweden more cytology samples were 
read as normal, which in other countries (UK, US) were read as ASC-US. This could point at a low sensitivity of cytology which would make HPV 
based screening more favorable in comparison. 
Sensitivity of HPV For cotesting the assumptions were: Invasive cancer if Cyt pos or HPV pos: p=0.0017, CIN2-3 if Cyt pos or HPV pos: 0.18, Invasive cancer if Cyt 
neg & HPV neg: p= 0.00008 
All data were based on Swedish data of the Swedescreen study or earlier publications 
Viewpoint of the analysis Provider/health service perspective 
Do treatment options 
compare to current clinical 
practice in Switzerland? 
Treatment was only indicated for CIN2 and 3, and CIN 1 is under surveillance with cytological screening, while in Switzerland also CIN1 will be 
treated if persistent.  
 
Is there any hint for a 
different base line risk of 
the populations? 
HPV prevalence in women between 32 and 38 years is 7.1% in Sweden (deVuyst 2009). Prevalence in that age group was found higher in a study 
in Switzerland (10- 15%) (deVuyst 2009).   
The ASR of cervical cancer incidence in Sweden is 7.4 vs 5.4 /100’000 women in Switzerland) 
Do the screening setting or 
attendance rates influence 
the result?? 
50% organized, 50% opportunistic screening was assumed with 75% attendance rate at each screening cycle and 100% adherence to follow up.  
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Study Transferability Summary 
[2] Kitchener, 2014, 
UK 
Transferability is limited as the closest comparator of cytology with HPV triage was only modelled slightly later with 
screening (25 years, compared to 21 in Switzerland) and women of 50-64 years are only tested every 5 years vs 3 yearly in 
Switzerland. In Switzerland screening is recommended until the age 70. Therefore the Swiss current screening may be 
more effective and more expensive than this comparator screening.  
Age specific incidence rates for cervical cancer in young women are much higher in the UK than in Switzerland.  
Transferability question Analysis of the study 
Was a comparator used 
that is relevant for the 
Swiss setting? 
The closest comparator is a 3-yearly cytology screening (LBC) with HPV triage (current screening practice) in women of 25-49 years and 5-yearly 
cytology screening for women 50-64 years 
Sensitivity of cytology  The LBC positivity rate for CIN2+ was estimated at 77% with ASC-US and 70% with LSIL result and for CIN3+ with 76% (ASC-US) and 70 % 
(LSIL) 
Sensitivity of HPV testing HPV was assumed to give positive results for 96% of CIN2 and 96% for CIN3+ 
Viewpoint of the analysis The economic evaluation of primary HPV screening in England took a health services perspective, taking into account the health services costs 
associated with population-based screening, management, diagnosis, and follow-up and treatment of CIN and invasive cancer. 
Cost for organized screening was added to the calculations. This is different from current screening in Switzerland, however, a scenario that may 
become relevant in Switzerland in the future. 
Do treatment options used 
in the model compare to 
current clinical practice in 
Switzerland? 
In the UK women with histologically confirmed CIN1 are not treated but are monitored every 6 – 12 months. The authors assume that a small part 
of CIN1 will be treated along with CIN2+. In comparison in Switzerland CIN1 is recommended for treatment if persistent  
 
Is there any hint for a 
different base line risk of 
the populations? 
hrHPV prevalence in the UK is higher than in Switzerland until the age of 40 and afterwards similar or slightly lower [62]. Data from the HART 
study were used as basis as they come from 5 cities. Here prevalence in the age group of 30-69 is 7.1% vs 9.4% in Switzerland. Differences have 
been reported between different areas in the UK ranging from 5% in South Wales to 10% in Manchester for the age group of 30 to 69 [62].  
Age specific cervical cancer incidence in the UK is much higher than in Switzerland at age 25-35 (around 17/100’000 in the UK versus less than 8 
in Switzerland in this age group).  
Does the screening setting 
influence the result? What 
attendance rates were 
modelled? 
England cervical cancer screening organized different to the Swiss system. Therefore in this model the cost of the screening organization is added 
to the calculation. 
Attendance at routine screening was assumed to be around 85% which may be higher than in Switzerland. 
Attendance rates of follow up tests was calculated more conservatively than in many other studies with 80-85% in the base case (and modelled in 
the sensitivity analysis between 60 and 100%). 
Attendance at follow up tests is important especially for HPV+/cyt- women 
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Study Transferability Summary 
[37] 
Huh, 2015, USA  
Transferability is limited in that all strategies started at 30 years which leads to higher baseline risk at start of screening.  
However under the assumption that a strategy in Switzerland may involve cytology screening for women up to the age of 
30 and only afterwards the strategy would switch, the comparison of strategies after the age of 30 is still of interest. 
Different to the recommendations in Switzerland no treatment cost for CIN1 and CIN2 was calculated in this study. 
Transferability question Analysis of the study 
Was a comparator used 
that is relevant for the 
Swiss setting? 
Yes, 3-yearly cytology testing with HPV triage, however all strategies start only at 30 years (leading to higher baseline risk at start of screening) 
Sensitivity of cytology  Sensitivity to detect CIN3+ cytology 56% 
Sensitivity of HPV HPV with cytology triage: 52%, HPV with 16/18 genotyping: 72%, cotesting 56% 
Viewpoint of the analysis US healthcare payers perspective 
 
Do treatment options 
compare to current clinical 
practice in Switzerland? 
No treatment cost for CIN1 and CIN2 were calculated. The authors argue that “Since approximately 90 % of CIN 1 and 88 % of CIN 2 cases 
regress within 1 year [31, 32], the model accounted only for sensitivity in detecting incident and persistent cases of CIN 3.”  
It was not discussed, how women with CIN1 and CIN2 should be followed up and it is unclear how the costs for this were taken into account in the 
model.  
In comparison in Switzerland CIN2 is recommended for treatment and CIN1 is treated if persistent.  
Since disutilities were assigned to CIN1 and CIN2 QALYs as effectiveness measure take increased detection of CIN1 and CIN2 into account  
Is there any hint for a 
different base line risk of 
the populations? 
hrHPV prevalence in women of 30-60 years in the US seems to be slightly lower but close being 8.5% vs 9.4% in Switzerland [37, 62]. 
Incidence of cervical cancer is 7.8/100’000 [37] compared to 5.4 in Switzerland 
Based on HPV prevalence the background risk may be similar 
Do the screening setting or 
attendance rates influence 
the result?? 
The model assumed “that all women complied with scheduled screening visits as well as recommendations for colposcopy and biopsy.” 
Thereby the model compares the maximum possible effect of all strategies.  
Other studies have varied the attendance rates in their sensitivity analyses and found that this did not change the relative effectiveness of 
strategies, however higher attendance rates led to higher effectiveness and higher ICERs 
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Study Transferability Summary 
[28] Arbyn, 2015, Belgium Transferability is likely. 
The study included a comparator that reflects Swiss screening recommendations. Like in Switzerland all CIN 
stages seem to be eligible for treatment. HPV prevalence and cervical cancer incidence are slightly higher in 
Belgium than in Switzerland. However according to [80] higher HPV prevalence favor cytology based 
screening, so the case could be even more favorable in the Swiss environment. 
Transferability question Analysis of the study 
Was a comparator used that is relevant for 
the Swiss setting? 
Yes, cytology screening with HPV triage was modelled, with an algorithm that reflects Swiss recommendations 
Assumed sensitivity of cytology  51% for CIN2 and 49% for CIN3+ (age group 35-49, higher sensitivities in older women of around 80%) 
Assumed sensitivity of HPV testing 95% for CIN2 and 95% for CIN3+ (age group 35-49, higher sensitivities in older women of around 99-100%) 
Viewpoint of the analysis The economic evaluation was undertaken from the perspective of the health care payer. Costs included were direct medical costs 
paid out of the health care budget and the patients’ out-of-pocket expenses for health care. Societal costs such as productivity 
losses and direct non-health care costs such as personal travel expenses were not accounted for.  
Do treatment options used in the model 
compare to current clinical practice in 
Switzerland? 
Exact treatment was not described. Cost data were included for CIN 1,2 and CIN3 indicating that all precancerous lesions have a 
planned treatment pathway 
Is there any hint for a different base line 
risk of the populations? 
hrHPV prevalence in women of 30-60 years in Belgium is 12.5 vs 9.4% in Switzerland [62]. The incidence of cervical cancer is 
9.7/100’000 (8.1 in 2012 acc. to [28]) 
Does the screening setting influence the 
result? What attendance rates were 
modelled? 
The base case assumed a 60% 3 year participation rate (40-80%) 
increasing the participation at cytology screening to 80% (instead of 60% in the base) decreases the incidence of cervical cancer 
and reduces the incremental number of LY saved by HPV screening by 20% (from 2878 to 2312 LY gained). Though slightly c 
reduced, HPV screening still results in net savings (€14.4 million instead of €14.8 in the base case), such that HPV screening 
remains a dominant option. 
The finding that HPV testing is more effective at a lower price was robust to participation rates. It is likely that in Switzerland too a 
participation rate between 60 and 80% can be reached. 
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Study Transferability Summary 
[76]  
Accetta, 2010, Italy 
The study did not describe in detail the follow up of triage tests. Under the assumption that the strategy 
cytology with HPV triage is similar to the current Swiss recommendations transferability of the results may be 
considered. 
Transferability question Analysis of the study 
Was a comparator used that is relevant for 
the Swiss setting? 
As a limitation of this study the follow up of triage tests is not described. It can be assumed that cytology with HPV triage from 25-
65 years represents a strategy that is similar to the current Swiss recommendation 
Assumed sensitivity of cytology  sensitivity for low grade lesions is assumed 70%, high grade lesions 80% and for cancer 100% 
Assumed sensitivity of HPV testing According to the publication a sensitivity of the HPV test for hrHPV was assumed 96%. However it looks inconsistent with data from 
other studies that the sensitivity of the HPV test for hrHPV is only as low as 96% (with reference to Ronco 2006 and 2008) and 
specificity only 94%. Arbyn (2015) assigns with reference to Ronco 2006 a sensitivity of the HPV test of 96% to detect CIN3+ (not 
just hrHPV) 
Viewpoint of the analysis Authors did not state the perspective taken, however from the costs taken into account the perspective seems to be that of the 
health system including direct medical costs 
Do treatment options used in the model 
compare to current clinical practice in 
Switzerland? 
Treatment is not described; however costs for CIN1 treatment were not shown indicating that this stage is not eligible for treatment 
in the model. In comparison, in Switzerland CIN1 is recommended for treatment if persistent. 
Is there any hint for a different base line 
risk of the populations? 
hrHPV prevalence is comparable. The incidence rate for cervical cancer is 9.5 per 100 000 women-years, (Cancer Registry of Italy, 
2011) compared to 5.4 in Switzerland. 
Does the screening setting influence the 
result? What attendance rates were 
modelled? 
Italy with invitational system, no further details 
Average compliance with the screening schedule was assumed 70.9% (based on Italian statistics of 2005). Three groups were 
defined: Women who never undergo screening (20%), women who always undergo screening (44%) and women for whom the 
compliance increases with age (36%) 
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Study Transferability Summary 
[29] MSAC, 2014, 
Australia 
Transferability is limited as the closest comparator of cytology with HPV triage was only modelled slightly later with 
screening (25 years, compared to 21 in Switzerland) and women of 50-64 years are only tested every 5 years vs 3 yearly in 
Switzerland. In Switzerland screening is recommended until the age 70. Therefore the Swiss current screening may be 
more effective and more expensive than this comparator screening. 
Transferability question Analysis of the study 
Was a comparator used 
that is relevant for the 
Swiss setting? 
The closest comparable strategy modelled was 3-yearly screening with LBC and HPV triage for women aged 25-49 and 5-yearly screening for 
women aged 50-64. 
Sensitivity of cytology  With LSIL taken as threshold the sensitivity was assumed 74% for CIN2+ and 76% for CIN3+ 
Sensitivity of HPV testing 96% sensitivity for CIN2+ and 98% sensitivity for CIN3+ 
Viewpoint of the analysis A health service perspective  was taken 
 
Do treatment options 
used in the model 
compare to current 
clinical practice in 
Switzerland? 
CIN2 and 3 are treated, CIN1 is put to surveillance, whereas in Switzerland CIN1 is treated if persistent 
 
Is there any hint for a 
different base line risk of 
the populations? 
Only graphical presentations could be compared. In these hrHPV prevalence in the Australian model seems to be slightly lower than in Switzerland 
(compared to de Vuyst), while cervical cancer incidence in Australia seems similar or slightly higher compared to Switzerland 
Does the screening 
setting influence the 
result? What attendance 
rates were modelled? 
Screening in Australia is organized 
The authors found that it makes a difference, whether reminder systems are used or call/recall set ups. A “Call / Recall” instead of “Reminder” 
system will improve adherence to recommended screening intervals and reduce cervical cancer incidence by 1% with an associated 2-3% relative 
increase in screening program cost. 
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Study Transferability Summary 
[33] Vijayaraghavan, 2010, Canada 3 yearly cytology testing with HPV triage was used as comparator. Young women were screening with 
Pap testing and were switched to different screening strategies at the age of 30 years, As a downside 
of this study it was impossible to retrieve from the study author the supplementary material which 
described treatment options and the sensitivity analysis. 
Transferability question Analysis of the study 
Was a comparator used that is relevant for the 
Swiss setting? 
3-yearly cytology testing with HPV triage was modelled 
 
Assumed sensitivity of cytology  33% sensitivity for CIN1+, 59% sensitivity for CIN2+ (CCCaST) 
Assumed sensitivity of HPV testing 71% for CIN1+, 98% for CIN2+ 
Viewpoint of the analysis We adopted a health care payer perspective and as such included direct medical costs 
 
Do treatment options used in the model compare to 
current clinical practice in Switzerland? 
Treatment options were only described in the supplement material, which was impossible to obtain up to now 
 
Is there any hint for a different base line risk of the 
populations? 
hrHPV prevalence was similar in women of 30-39 years and afterwards lower than in published values for Switzerland 
[62]. Cervical cancer incidence seems to be slightly higher than in Switzerland compared to Canadian incidence graphs 
presented in [34] 
Does the screening setting influence the result? 
What attendance rates were modelled? 
In the base case 100% adherence and compliance was assumed.  
Attendance rates were varied in sensitivity analyses, however did not change the rank order between strategies (e.g. 16% 
never screened, 70% as recommended, 18% missing follow-up colposcopies) 
More details on this sensitivity analysis were supposedly described in supplements, which were impossible to obtain up to 
now 
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Studies that don’t have a comparator relevant for the Swiss health care system 
 
Study Transferability Summary 
[36]  
Vijayaraghavan, 2010, USA 
Transferability analysis impossible – no comparator equivalent to Swiss cervical cancer screening used 
 
Transferability question Analysis of the study 
Was a comparator used that is relevant for the Swiss 
setting? 
Strategies compared included 2-yearly LBC, 2-yearly LBC with HPV triage, 3-yearly HPV with LBC triage, 3-yearly 
co-screening and 3-yearly co-screening with HPV genotyping and HPV with 16/18 genotyping 
As no comparator was used that was equivalent to the Swiss recommended screening of 3-yearly cytology with HPV 
triage, no detailed transferability analysis was done 
 
Study Transferability Summary 
[34] Kulasingam, 2009, Canada Transferability analysis impossible – no comparator equivalent to Swiss cervical cancer screening used 
 
Transferability question Analysis of the study 
Was a comparator used that is relevant for the Swiss 
setting? 
Unfortunately no comparator that directly reflects Swiss recommendations was used. 
Pap with HPV triage was only modelled with 1-yearly frequency  
3-yearly Pap testing was only modelled with Pap triage 
therefore no further transferability analysis was done 
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20 Appendix 8: “Costs and cost effectiveness values in CHF by adaptation to purchasing power parities” 
The following table shows the deduction of test costs and cost effectiveness results in CHF by adaptation to purchasing power parities according 
to the description in the methods chapter 5.4.7 
 
Table 15: Deduction of cost of testing and cost effectiveness values in CHF by adaptation of purchasing power parities 
Study Summary
12
 
[30, 60] Sroczynski, 2010, 2011, 
Germany 
In the base case with higher sensitivities for cytology testing, 3-yearly HPV based screening (where most of 
the HPV positive samples were followed up with cytology triage) at a cost of 101 CHF for HPV testing (thereof 
42 CHF for the HPV assay) resulted in an ICER of 17’450 CHF/LYG. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
 
Strategy ICER (CHF 2015/LYG) 
no screening - 
Pap 5y 5’041 
Pap 3y 13’766 
HPV 3y 17’450 
HPV 2y 55’064 
HPV + Pap-Triage, 2y 181’673 
HPV 1y 301’496 
 
In a scenario, where Pap test sensitivity was lower based on German studies all Pap test based strategies were dominated and  
5 yearly HPV based testing was cost effective at 6’786 CHF/LYG (against no screening) and  
3-yearly HPV based testing at 11’827 CHF/LYG (against 5 yearly HPV based testing) 
Assumed cost for cytology in 2015 CHF 71 CHF 
Assumed cost for HPV testing in 2015 CHF 101 CHF thereof 42 CHF for the HPV test 
 
  
                                                          
 
12 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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Study Summary 
[75] Bistoletti, 2008, Sweden It is unclear whether the findings of this study are transferable to the Swiss setting. Sensitivity of cytology 
testing in Sweden may be lower than in Switzerland, which would favor HPV testing in the study. The model 
started screening only at 32 years, leading to a higher background risk at the start of screening. Only the 
primary screening test is described, not the follow up after a positive primary screening test. 3 HPV based 
tests in a woman’s life were more effective and less expensive than 3 yearly cytology based screening 
between 32 and 50 years, afterwards 5 yearly cytology, however it is unclear how this strategy would 
compare to the Swiss 3-yearly cytology with HPV triage. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
Transferability is limited. Only the primary screening test is described, not the follow up after positive results. All screening started 
only at 32 years. Three HPV based tests in a woman’s life were more effective and less expensive than 3 yearly cytology based 
screening between 32 and 50 years, afterwards 5 yearly cytology. 
Assumed cost for cytology in 2015 CHF 45 CHF 
Assumed cost for HPV testing in 2015 CHF 90 CHF 
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13
 
[2] Kitchener, 2014, UK Under the assumption of the UK setting and with cytology test prices of 11 CHF if negative, 32 CHF if positive 
and an HPV test price of 20 CHF the costs for the different strategies translates into ICERs between  
32’171 CHF for HPV with genotyping for HPV16/18 and 24 months follow up of HPV+/cyt- women,  
42’895 for HPV with LBC triage and genotyping for HPV 16/18 for women initially HPV+/cyt- 
and 64’342 CHF for HPV with genotyping for HPV16/18 and 12 month follow up of HPV+/cyt- women. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
 
Strategy code ICER CHF/LYG 
CP=  Current practice  CP Dominated 
 
S1 24m 30y Dominated 
 
S1 24m 35y Dominated 
 
S2 24m 35y Dominated 
 
S2 24m 25y 21’447 
 
S2 24m 30y Dominated 
S3=  HPV with HPV 16/18 genotyping 
  (if HPV 16/18 positive refer to colposcopy, 
   if positive for other hrHPV cytology triage) 
 
S3 24m 25y 32’171 
S1=  HPV with LBC triage 
 
S1 12m 25y 64’342 (dominated,  
but lower colposcopy rates) 
S2=  HPV with LBC triage (immediate) and  
  HPV 16/18 genotyping (after 12 months)  
 for women who were HPV pos/ cyt neg 
 
S2 12m 25y 42’895 (against S3 24m 25y) 
S4=  Cotesting  
 (with HPV 16/18 genotyping after 24 months 
 for women who were HPV pos/cyt neg) 
 
S4 12m 25y dominated 
S3=  HPV with HPV 16/18 genotyping 
  (if HPV 16/18 positive refer to colposcopy, 
   if positive for other hrHPV cytology triage) 
 
S3 12m 25y 64’342 (against S2 12m 25y) 
 
Assumed cost for cytology in 2015 CHF 11 CHF if negative, 32 CHF if positive 
Assumed cost for HPV testing in 2015 
CHF 
20 CHF 
                                                          
 
13 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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Study Summary
14
 
[37] 
Huh, 2015, USA  
With a price of cytology testing of 37 CHF and 62 CHF for HPV testing (including genotyping for HPV 16/18)  
3-yearly screening with HPV 16/18 genotyping had an ICER of 10’000 CHF /QALY. The authors calculated that 
this strategy would still be the most cost effective one, up to a price of 193 CHF, resulting in an ICER of 
62’193 CHF/QALY. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
 ICER 
 CHF 2015$/QALY 
cytology + HPV triage =   baseline 
cytology + HPV cotest  =   dominated 
HPV + cytology triage =   dominated 
HPV + 16/18 genotyping =   10’001 
Assumed cost for cytology in 2015 CHF 37 CHF 
Assumed cost for HPV testing in 2015 
CHF 
62 CHF including HPV genotyping for HPV 16/18 in the base case  
(however the HPV16/18 genotyping strategy was cost effective with an ICER below 65’222 CHF up to an HPV test price of 193 
CHF) 
 
Study Summary
15
 
[28] Arbyn, 2015, Belgium At the assumptions taken in the study and at a price of 35 CHF for cytology (52 CHF if a second reading is 
necessary) and 56 CHF for the HPV assay, 5 yearly HPV testing dominated 3 yearly cytology. If an HPV test 
price of 92 CHF was assumed the strategy HPV with cytology triage had an ICER of 6’862 CHF /LYG 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
In the base case with 57 CHF for the HPV test, 5 yearly HPV testing dominated 3 yearly cytology. At 94 CHF HPV based testing 
was more expensive but cost effective at an ICER converted into CHF 2015 = 6’862 CHF/LYG (compared to 3 yearly cytology with 
HPV triage) 
Assumed cost for cytology in 2015 CHF 35 CHF for normal test, 52 CHF  if second reading is necessary 
Assumed cost for HPV testing in 2015 CHF 56 CHF in the base case, varied from 32 to 92 CHF 
 
  
                                                          
 
14 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
 
15 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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[76]  
Accetta, 2010, Italy 
With a price for the cytology test of 57 CHF and for the HPV test of 63 CHF, 5 yearly HPV testing with cytology 
triage had an ICER of 8’990 CHF /QALY while 3 yearly HPV testing with cytology triage was above an 
acceptable cost effectiveness threshold with an ICER of almost 140’000 CHF/QALY. 
The study had a sensitivity of the HPV assay for HPV presence of only 96% potentially favoring cytology 
based screening. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
Strategies ICER CHF/QALY 
 Pap test only 5y Baseline 
 Pap with HPV triage 3y dominated 
 Pap test only 3y dominated 
 HPV only 5y dominated 
 HPV with Pap triage 5y 8’990 
 HPV only 3y dominated 
 HPV with Pap triage 3y 138’413 
 
Assumed cost for cytology in 2015 CHF 57 CHF 
Assumed cost for HPV testing in 2015 CHF 63 CHF 
  
                                                          
 
16 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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[35] 
Goldhaber-Fieber, 2008, USA 
At a cost for cytology testing of 55 CHF and of HPV testing of 100 CHF cytology based testing was dominated. 
Interestingly all strategies that started testing below 25 years had ICERs of more than 100’000 CHF/QALY. 
Strategies starting testing at 25 years and older had ICERs below 100’000 CHF/QALY. 
Switching from cytology to HPV testing with cytology triage at 30 years was always clinically more effective 
but more expensive than switching at 35 years.  
At a switch age of 30 years 5 yearly HPV testing had an ICER of 52’634 CHF/QALY and 3 yearly HPV testing of 
96’192 CHF/QALY 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
Strategies 
Start age with cytology, switch age, strategy after switch (“cyt” for cytology with HPV 
triage or “HPV” for HPV with cytology triage), frequency in years 
ICER CHF/QALY 
1.no screening 
 2.25, none, cyt, 5y 12’705 
3.25, 35, HPV, 5y 21’779 
4.Any, none, cyt, 3y dominated 
5.25, 30, HPV, 5y 52’634 
6.25, 35, HPV, 3y 67’153 
7.25, 30, HPV, 3y 96’192 
8.21, 30, HPV, 3y 141’566 
9.21, 30, HPV, 2y 221’424 
 
Assumed cost for cytology in 2015 CHF 55 CHF  
Assumed cost for HPV testing in 2015 CHF 100 CHF  
 
  
                                                          
 
17 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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[32] 
Burger, 2012, Norway 
With a price of 50 CHF for cytology testing and 62 CHF for HPV testing, cytology based testing was dominated. 
Three yearly HPV testing (6 month follow up time of HPV+/cyt- women) had an ICER of more than 100’000 
CHF/LYG. Four yearly HPV testing with 6 months follow up time had an ICER of 97’523 CHF/LYG. With 12 
months follow up the ICER went down to 75’630 CHF/LYG. Five yearly HPV testing with 12 months follow up 
had an ICER of 56’723 CHF/LYG and 6 yearly HPV testing was less effective than 3 yearly cytology with an 
ICER of 28’859 CHF/LYG 
Deduction of costs and ICERs into CHF 
by adaption to purchasing power parities 
and inflation to 2015 
Primary screening test, post-switch (at 31 years) ICER (CHF 2015/LYG) 
no screening — 
HPV with cotesting triage 6y, 12m time to rescreen 28’859 
cytology 3y Dominated 
HPV with cotesting triage 5y, 12m time to rescreen 56’723 
HPV with cotesting triage 4y, 12m time to rescreen 75’630 
HPV with cotesting triage 4y, 6m time to rescreen 97’523 
HPV with cotesting triage 3y, 6m time to rescreen 143’299 
HPV with cotesting triage 3y, 6m time to rescreen, colposcopy after 1 repeated 
HPV+/cyt- 
510’504 
 
Assumed cost for cytology in 2015 CHF 50 CHF 2015 
Assumed cost for HPV testing in 2015 
CHF 
62 CHF 2015 
 
  
                                                          
 
18 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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[29] MSAC, 2014, Australia Under the assumptions of the Australian model and with cytology test prices of 54 CHF and HPV test prices 
of 64 CHF, cytology with HPV triage was dominated and 5 yearly HPV testing with cytology triage had an 
ICER of 29’687 CHF/LYG. 
A screening strategy with 5 yearly HPV16/18 genotyping as primary screening test had an ICER of 89’961 
CHF/LYG. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
Strategies ICER CHF/LYG 
1.Current practice Cytology 2y dominated 
2. Cytology only IARC intervals baseline 
3.Pap +HPV triage IARC dominated 
4.LBC + HPV triage IARC dominated 
5.HPV + cyt triage 5y 29687 
6. HPV16/18 genotyping 5y 89961 
7. Cotesting 5y dominated 
 
Assumed cost for cytology in 2015 CHF 54 CHF for Pap, 64 CHF (manually read) or 69 CHF (automatically read) if LBC was the primary screening test  
Assumed cost for HPV testing in 2015 CHF 64 CHF Australian$ for primary HPV testing and 95 if HPV was used as a triage test 
96 CHF for cotesting with LBC 
 
  
                                                          
 
19 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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[33] Vijayaraghavan, 2010, Canada With the data available for this model and with cytology cost of 21 CHF and HPV costs of 33 CHF 3 yearly 
cytology with HPV triage had an ICER of 12’783 CHF/QALY and 3 yearly HPV with cytology triage had an 
ICER of 16’378 CHF. This strategy was dominated by 3 yearly HPV only with direct referral to colposcopy 
after a positive HPV result with an ICER of 15’180 CHF/QALY. This strategy involves higher colposcopy 
rates, the burden of which may be only partially reflected in the QALYs as only CIN and Cancer stages had 
disutilities assigned. 
Deduction of costs and ICERs into CHF by 
adaption to purchasing power parities and 
inflation to 2015 
Screening Strategy*  ICER CHF/QALY 
No screening baseline 
Cytology only 3y dominated 
Cytology+HPV triage 3y 12’783 
Cytology only 1y dominated 
HPV+cytology triage 3y 16’378 
Co-screening 3 y dominated 
Cytology+HPV triage 1y dominated 
HPV only 3y 15’180 
 
Assumed cost for cytology in 2015 CHF 21 CHF 
Assumed cost for HPV testing in 2015 CHF 33 CHF 
                                                          
 
20 Strategies are shown in order of their effectiveness. ICERs were always calculated against the next less effective strategy on the cost effectiveness frontier of the same study. 
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21 Kritische Würdigung / Methodenkritik 
21.1 Persönliches Fazit 
 
Die Arbeit an diesem Thema hat mir viel Freude gemacht hat. Nach vielen Jahren im 
Berufsleben, in dem ich viel mit operativen und strategischen Managementaufgaben betraut 
war, war es eine grosse Befriedigung wieder einmal tief in eine Forschungsarbeit eintauchen 
zu können. 
 
Ohne Erfahrung mit systematischen Reviews war mir allerdings vor Beginn der Arbeit der 
Umfang derselben nicht klar. Die Materialfülle und Komplexität der Fragestellungen war 
enorm. 
Während ich erwartet hatte, dass ein Review von Systematischen Reviews und 
Metaanalysen die geeigneten Kennzahlen zu Benefits und Harms des Screenings und das 
Vorgehen für den Vergleich verschiedener Screeningstrategien bereits einfach verdaubar 
beinhalten würden, musste ich lernen, dass dies nicht der Fall war. Besonders die 
Metaanalysen zielten auf verschiedene, zum Teil überschneidende, aber nicht immer direkt 
vergleichbare Subaspekte des Themas ab. Daten aus denselben klinischen Studien wurden 
mehrfach etwas unterschiedlich zusammengefasst, z.T. nach Altersgruppen getrennt, z.T. 
unter Ein- oder Ausschluss einzelner Studien. Um die Aussagen zu den verschiedenen 
klinischen Studien nachvollziehen und einordnen zu können, musste ich schliesslich 
zusätzlich in die Primärliteratur einsteigen und die wichtigsten Publikationen zu den 
klinischen Studien selbst lesen. Ein alternativer Ansatz für diese Masterarbeit wäre daher 
gewesen, gleich einen systematischen Review der Primärliteratur zu machen. Obwohl eine 
Einarbeitung in diese notwendig war, um die Sekundärliteratur zu verstehen, komme ich 
zum Schluss, dass ein systematischer Review der gesamten Primärliteratur trotzdem 
wesentlich zu aufwändig gewesen wäre, und dass ein Review der bestehenden 
systematischen Reviews und Metaanalysen die bessere Methodenwahl war, um im Rahmen 
einer Masterthesis zu Antworten zu kommen. 
 
Mit fortschreitender Arbeit hat mich die Evidenz zum Thema HPV basiertes Screening 
zunehmend überzeugt. Sollten die Lesenden dieser Arbeit nicht zu denselben Schlüssen wie 
ich kommen, so stellt diese Arbeit hoffentlich trotzdem allen Interessierten am Thema einen 
reichen Datenschatz zur Verfügung, der als Nachschlagewerk dienen kann und als Einstieg 
in die verschiedenen HTAs und gesundheitsökonomischen Studien für weitere 
Nachforschungen. 
 
Bei der gesundheitsökonomischen Evidenz stellt diese Arbeit meines Wissens aktuell die 
umfangreichste Sammlung von gesundheitsökonomischen Daten zum Thema dar. 
In diesem Zusammenhang betrachte ich den Appendix 4: “Research question 1a-c – Excerpt 
of answers from HTAs and Health Economic Studies” als wichtiges Kernstück der Arbeit. Auf 
wenigen Seiten ist hier eine Übersicht über alle aktuellen gesundheitsökonomischen Studien 
mit den wichtigsten kosteneffektiven modellierten Screening Strategien zusammengefasst. 
Ersichtlich sind die wichtigsten Eckdaten aller Studien, die Effektivitätsmessergebnisse 
sowie die ICERs. 
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21.2 Methodische Limitationen und nächste Schritte 
 
Ein 4-Augenprinzip wäre für alle Schritte dieses systematischen Reviews ideal gewesen. Bei 
der Literaturauswahl konnte ich eine zweite Person für ein 4-Augenprinzip gewinnen. Die 
Übereinstimmung nach der ersten unabhängigen Auswahl der Literatur war hoch und 
erzielte 100% nach kurzer Diskussion der Gründe für den Ein- oder Ausschluss einzelner 
Publikationen. Hingegen wurden alle anderen Extraktionen von Informationen und alle 
Auswertungen aus den Publikationen von mir allein durchgeführt. Bei einer Masterarbeit 
wäre es mit einem 4-Augenprinzip für alle Aspekte schwieriger gewesen, den Beitrag der 
verschiedenen Mitwirkenden an der Arbeit voneinander abzugrenzen. In der Durchführung 
habe ich mich darum bemüht, alle Ausschlüsse von Studien zu beschreiben, sowie 
Diskrepanzen transparent darzustellen und Interpretationen als solche kenntlich zu machen. 
 
Bei der Transferanalyse habe ich die von Prof. Michael Drummond21 empfohlenen Fragen 
gewählt, wie in den Methoden beschrieben. Hier musste ich feststellen, dass nicht alle diese 
Fragen tatsächlich zu Ein- oder Ausschlusskriterien von Studien führten: 
 
Bei der Frage „Is the viewpoint of the analysis relevant to the Swiss setting“ stellte ich fest, 
dass grundsätzlich jede eingenommene Perspektive der verschiedenen Studien relevant für 
das Schweizer Gesundheitssystem sein konnte. Ob nur direkte medizinische Kosten 
eingeschlossen wurden oder auch indirekte (z.B. Fahrtkosten zu den 
Screeninguntersuchungen, oder Produktivitätskosten wie die Zeit der Frauen für Screening, 
Diagnose und Behandlungen), machte in meinen Augen keinen Unterschied für die 
Relevanz in der Schweiz. Wichtig war hier vor allem die Transparenz über die Art der 
eingeschlossenen Kosten, da diese die Höhe der ICERs beeinflussen konnten. 
Selbst Gesundheitssysteme mit organisiertem Screening wurden von mir als relevante 
Vergleichssysteme für ein zukünftiges Screening in der Schweiz akzeptiert. Aufgrund der 
Argumente zu Erfolgsfaktoren für die Umsetzung von HPV basiertem Screening 
(Forschungsfrage 2) komme ich zum Schluss, dass eine Einführung eines organisierten 
Screenings auch in der Schweiz sinnvoll wäre. In diesem Fall ist es interessant zu wissen, in 
welcher Höhe die ICERs von organisierten Screenings liegen. Dieser Punkt ist in der 
Transferanalyse kenntlich gemacht. 
 
Die möglichen Kosten für den Aufbau eines organisierten Screenings in der Schweiz wurden 
für diese Masterarbeit nicht eruiert. Dies müsste im Rahmen eines HTAs separat beleuchtet 
werden, damit die Gesamtkosten über eine längere Zeit inclusive nötiger Investitionen in der 
Aufbauphase transparent gemacht würden. 
 
Während es bereits einige systematische Reviews zur klinischen Effektivität von HPV 
basiertem Screening gibt, ist ein vertiefter Review der gesundheitsökonomischen Evidenz 
mit einer Transferanalyse auf das Schweizer Gesundheitssystem neu.  
Aus diesem Grund und angesichts der Materialfülle habe ich mich bei der systematischen 
Anwendung von Checklisten zur Bewertung der Literatur auf die gesundheitsökonomischen 
Studien beschränkt. 
                                                          
 
21
 Prof. Dr. Michael Drummond ist Professor der Gesundheitsökonomie an der Universität von York, UK,  
Author des Buches “Methods for the economic evaluation of health care programmes” und hat in verschiedenen Funktioinen 
massgeblich zur Entwicklung von Methoden für die Evaluation von Gesundheitsleistungen beigetragen. 
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In der ursprünglichen Projektskizze war der Einsatz der Prisma Checkliste vorgesehen. 
Nachdem ich mich etwas zum Thema Transferanalysen eingelesen hatte [57], erschien mir 
jedoch eine Checkliste, die spezifisch für gesundheitsökonomischen Studien und 
Transferanalysen erstellt wurde, besser geeignet. Aus diesem Grunde habe ich bei den 
gesundheitsökonomischen Studien die EURONHEED Checkliste angewandt.  
Diese Checkliste erlaubte nicht nur die Ermittlung eines Qualitätsdatenscores, sondern 
erleichterte auch die systematische Extraktion von Daten, die ich für die 
Studienbeschreibung brauchte (Populationen, Interventionen und Vergleichsstrategien, 
Diskontierungsraten, Währungen und Kostenjahre etc.). 
Hingegen habe ich auf die Anwendung einer Checkliste bei den systematischen Reviews 
und Metaanalysen verzichtet. Stattdessen wurde ein informeller Check durchgeführt, der 
sicherstellte, dass die eingeschlossenen Publikationen grundlegende 
Qualitätsanforderungen erfüllten, wie in den Limitationen dieser Arbeit beschrieben.  
 
Bei der Transferanalyse war es methodisch besonders herausfordernd, die Referenzdaten 
für das Schweizer Gesundheitssystem zu ermitteln.  
 
In der Analyse habe ich mich für die aktuelle Praxis des Screenings in der Schweiz 
vollständig auf die Empfehlungen der Schweizerischen Gesellschaft für Gynäkologie und 
Geburtshilfe abgestützt. Tatsächlich ist es wahrscheinlich, dass diese Empfehlungen in der 
Praxis nicht 1:1 umgesetzt werden. Die Ergebnisse der Umfrage des BAG von 2014 zeigen 
zumindest auf, dass viele Ärzte wesentlich öfter zum Screening einladen als empfohlen [96]. 
Hingegen scheinen andere Aspekte der Empfehlungen wie z.B. der Einsatz von HPV Tests 
in der Abklärung pathologischer Befunde im Pap-Test gut akzeptiert zu sein. Gemäss einer 
Umfrage unter Schweizer Gynäkologen von Altermatt sehen von 283 teilnehmenden 
Gynäkologen 92% eine Bedeutung des HPV-Tests in der Abklärung pathologischer Befunde 
im Pap-Test [98]. 
Interessant wäre es in einem nächsten Schritt, Interviews mit Vertretern der Fachärzte zum 
Thema zu führen und zu erfahren, wie nah die tatsächliche Praxis an den Empfehlungen ist. 
 
Für die Sensitivität des zytologischen Testens in der Schweiz habe ich keine publizierten 
Daten gefunden. Es ist jedoch wahrscheinlich, dass diese Frage von Fachpersonen in der 
Schweiz untersucht wurde, und dass auch die durchführenden pathologischen Labore hierzu 
Daten erheben. Angaben zur tatsächlichen Sensitivität des zytologischen Screenings sollten 
in einem nächsten Schritt eruiert werden. Auch hier wäre eine Kontaktaufnahme zu 
Spezialisten möglicherweise zielführend.  
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Interessante weitere Aspekte sind sämtliche nötigen Implementierungsschritte, damit HPV 
basiertes Screening in der Schweiz umgesetzt werden kann. Die Antworten zur 
Forschungsfrage 2 geben zahlreiche Hinweise, welche Voraussetzungen geschaffen werden 
sollten, damit eine Umsetzung erfolgreich gelingen kann.  
 
Einige mögliche Forschungsthemen in diesem Zusammenhang sind die folgenden Fragen: 
 Wie sollte die Kommunikation zum HPV basierten Screening erfolgen, um 
Stigmatisierung und Verunsicherung der Frauen zu vermeiden und die bestmögliche 
Teilnahme am Screening und Folgeuntersuchungen zu gewährleisten? 
 Welche Massnahmen müssen getroffen werden, um die grösstmögliche Einhaltung 
der Screeningempfehlungen auf Seiten der Ärzte zu erzielen? 
 
Wichtigste Voraussetzung für die Einführung von HPV basiertem Screening ist die 
Durchführung eines Health Technology Assessments in der Schweiz. Dies könnte im 
Rahmen des HTA-Programm des Bundes zur Re-Evaluation von Leistungen der 
obligatorischen Krankenpflegeversicherung eingeleitet werden.  
 
Ich würde mich freuen, wenn diese Masterarbeit Input zu diesem HTA leisten könnte.  
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22 Public Health Relevanz 
 
Public Health beschäftigt sich mit der Erhaltung und Förderung von Gesundheit der 
Bevölkerung oder von Bevölkerungsgruppen, der Vermeidung von Krankheit und Invalidität, 
sowie der Versorgung der Bevölkerung mit präventiven, kurativen und rehabilitiven Diensten 
[110].  
Sie ist geprägt durch einen interdisziplinären Forschungs- und Handlungsansatz, der 
gesundheitswissenschaftliche, sozialwissenschaftliche, wirtschaftliche und politische 
Aspekte einbezieht. 
 
Diese Arbeit ist stark relevant für die Anliegen von Public Health in der Schweiz, da sie sich 
mit dem Thema Krebsvorsorge für Gebärmutterhalskrebs beschäftigt. Hier geht es um ein 
Thema, welches die Vermeidung einer Krankheit in der Bevölkerungsgruppe der Frauen 
zum Ziel hat. 
Diese Arbeit vergleicht die Wirksamkeit und Wirtschaftlichkeit des aktuellen Vorgehens mit 
dem aktuellen Wissensstand der Forschung, bewertet diesen für die Relevanz in der 
Schweiz und versucht eine Empfehlung abzugeben, wie diese für das weitere Vorgehen in 
der Schweiz genutzt werden sollten. 
Hierbei werden schwerpunktmässig gesundheitswissenschaftliche Aspekte (Wirksamkeit 
des Gebärmutterhalskrebsscreenings sowie mögliche daraus resultierende Belastungen), 
und wirtschaftliche Aspekte (Kosteneffektivität des Screenings), aber auch 
sozialwissenschaftliche Aspekte (Auswirkungen auf die Lebensqualität der betroffenen 
Frauen, Sicherstellung der Teilnahme von Frauen aus allen gesellschaftlichen Schichten), 
sowie politische Aspekte (Umsetzungsschritte bei einer möglichen Umstellung des 
Screenings) beleuchtet. 
 
Das Thema ist aktuell. Im Moment werden in einer zunehmenden Anzahl Ländern 
Änderungen im Gebärmutterhalskrebsscreening umgesetzt oder empfohlen (z.B. in den 
Niederlanden, Australien, Belgien, UK, USA). In der Schweiz ist die Einführung eines 
organisierten Screeningprogramms für Gebärmutterhalskrebs im nationalen Krebsprogramm 
vorgesehen [61], und eine mögliche Umstellung auf HPV-basiertes Screening in der 
Schweiz wird diskutiert [1].  
 
Das Thema ist wichtig: Das aktuelle Screening für Gebärmutterhalskrebs in der Schweiz 
stellt möglicherweise nicht die klinisch wirksamste Methode dar, und ist gleichzeitig 
möglicherweise in seiner Durchführung teurer als nötig.  
 
Berechnungen des Bundesamts für Gesundheit (BAG) von 2006 zeigten, dass zu diesem 
Zeitpunkt in der Schweiz jährlich eine Million Pap-Abstriche gemacht wurden, mit denen 
70% der Zielgruppe gescreent wurden. Die Hälfte der Abstriche wäre jedoch ausreichend 
gewesen, um 100% der Zielgruppe zu screenen. Dies ist ein klares Signal, dass einige 
Frauen zu oft getestet werden, während andere Frauen nie oder zu selten getestet werden. 
[1] In einer Umfrage des BAG von 2014 stellte sich heraus, dass trotz der Empfehlungen der 
Fachgesellschaft für Gynäkologie von 2012 für ein dreijährliches Screeningintervall 
Ärztinnen und Ärzte den Pap-Test bei 78 Prozent der 18- bis 24jährigen Frauen jedes Jahr 
durchführen, und bei zwei Dritteln der 25- bis 49-jährigen ebenfalls [96]. Zu häufiges 
Screening erhöht die Kosten, ohne einen Mehrwert für den Schutz vor Krebs zu bringen. Im 
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Gegenteil erhöht sich dadurch sogar das Risiko von falsch positiven Resultaten und 
unnötigen Folgeuntersuchungen oder Überbehandlungen [67].  
Andere Frauen werden hingegen zu selten getestet. Gemäss der Gesundheitsbefragung von 
2007 gaben 79.6% der Frauen (im Alter von mehr als 20 Jahren) an mindestens einmal in 
ihrem Leben eine Krebsvorsorgeuntersuchung für Gebärmutterhalskrebs gemacht zu haben. 
Hieraus kann man im Umkehrschluss schliessen, dass 20% der Frauen nie in ihrem Leben 
gescreent worden sind. Für ausländische Frauen in der Schweiz sowie Frauen, die nur die 
obligatorische Schule besucht, haben ist dieser Anteil sogar noch höher (ca. 30%)  
Eine Unterrepräsentation von Personen mit niedrigem sozioökonomischen Status und die 
mangelhafte Befolgung von Behandlungsempfehlungen sind typische Merkmale von 
opportunistischen Screeningmodellen [30]. 
 
Hauptaugenmerk dieser Arbeit ist die Technologie der Krebsvorsorge in der Schweiz: das 
zytologiebasierte Screening mittels Pap-test und Dünnschichtzytologie. Da für die 
Entwicklung von Gebärmutterhalskrebs eine Infektion mit sogenannten hrHPV Viren die 
Voraussetzung ist, stellt sich die Frage, ob ein HPV-test nicht besser für ein Screening 
geeignet wäre. Studien zeigten, dass zytologische Tests gegenüber einem HPV Test eine 
bis zu 40% niedrigere Sensitivität besitzen, um Frauen zu identifizieren, welche bereits eine 
Krebsvorstufe entwickelt haben [28]. So hatten in einer US Studie 32% aller Frauen mit 
invasivem Gebärmutterhalskrebs in den 3 Jahren zuvor ein negatives Ergebnis im Pap-test 
[23]. Eine Umstellung auf HPV basiertes Screening könnte den daran teilnehmenden Frauen 
daher eine wesentlich höhere Sicherheit geben, dass keine Krebsvorstufen übersehen 
wurden, und sie durch das Screening tatsächlich vor Gebärmutterhalskrebs geschützt sind.  
 
Gemäss den Vorgaben des Bundesgesetz über die Krankenversicherung (KVG) müssen die 
Leistungen, die von der obligatorischen Krankenversicherung vergütet werden, wirksam, 
zweckmässig und wirtschaftlich sein. Sie müssen periodisch überprüft werden, ob sie diese 
Merkmale (noch) erfüllen.  
 
Zu diesem Zweck versucht diese Arbeit Fragen zur Wirksamkeit (klinische Effektivität bei 
möglichst niedrigster Belastung für die betroffenen Frauen) sowie die Wirtschaftlichkeit des 
aktuellen Screenings mit zytologischen Tests gegenüber einem möglichen Screening mit 
HPV Tests zu beantworten. Die gewählte Methode war die eines systematischen Reviews 
klinischer systematischer Reviews und Metaanalysen sowie von HTAs und 
gesundheitsökonomischen Studien. Es wurde ausserdem versucht zu beurteilen, in wieweit 
sich die Befunde aus anderen Ländern auf die aktuelle Situation in der Schweiz übertragen  
lassen.  
 
Die Ergebnisse dieser Arbeit zeigen, dass die Evidenz für die klinische Wirksamkeit eines 
HPV basierten Screenings gut genug ist, um die ausreichende Wirksamkeit des aktuellen 
Screenings in der Schweiz in Frage zu stellen. In grosser Übereinstimmung kommen 
Studien aus verschiedenen europäischen Ländern, den USA, Canada und Australien 
ausserdem zum Schluss, dass HPV basiertes Screening auch wirtschaftlich ist. Im Vergleich 
mit 3-jährigem zytologischem Screening zeigten HPV basierte Screeningstrategien häufig 
sogar eine bessere klinische Wirksamkeit bei niedrigeren Kosten. Auch aus 
gesundheitsökonomischen Gründen ist das HPV basierte Screening daher interessant. 
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Für die Implementierung wurden in dieser Arbeit einige wichtige Aspekte genannt, die zum 
Erfolg eines HPV basierten Screenings beitragen. Allen anderen voran, ist die Sicherstellung 
der Einhaltung der Screeningempfehlungen identifiziert worden. Hierbei ist die Einführung 
eines organisierten Screenings die am häufigsten genannte Empfehlung, jedoch 
möglicherweise nicht die einzig denkbare Lösung. Bis zur Umsetzung der nötigen 
Massnahmen kann allenfalls die Zweckmässigkeit des HPV basierten Screenings in Frage 
gestellt werden.  
 
Es sollte jedoch in der Diskussion nicht vergessen werden, dass auch das aktuelle 
Screening mit zytologischen Tests Schwachstellen hat. Auch eine zu häufige Durchführung 
der zytologischen Tests kann zu falsch positiven Resultaten und zur unnötigen Entdeckung 
von regressiven präkanzerösen Läsionen führen. Die Qualität von zytologischen Tests ist 
ausserdem stärker von den durchführenden Personen abhängig als die Qualität von HPV 
Tests, die mit Hilfe von automatisierten Laboranalysesystemen durchgeführt werden.  
Die Einführung eines organisierten Screenings sollte aufgrund der besseren systematischen 
Qualitätskontrolle und des möglichen besseren Einbezugs der Frauen aus allen 
Bevölkerungsschichten deshalb auch unabhängig von der Einführung einer neuen 
Technologie diskutiert werden. 
 
Aus Public Health Sicht ist klar, dass die wissenschaftliche Evidenz allein für eine 
erfolgreiche Umsetzung einer gesundheitspolitische Massnahme nicht ausreicht. 
 
Sehr wichtig für die erfolgreiche Umsetzung eines neuen Screeningprogramms ist z.B. die 
Einbindung der wichtigsten Interessen- und Anspruchsgruppen. Diese sind in diesem 
Zusammenhang die Kantone, die Ärzte, die Frauen, die Krankenkassen, sowie die 
Pathologen und Diagnostiklabors [98]. Hierbei spielen sowohl monetäre Interessen als auch 
persönliche und politische Einstellungen eine Rolle. 
 
Monetäre Interessen könnten die Kantone haben, die im Falle der Einführung eines 
organisierten Screenings Infrastruktur aufbauen müssten. Die Gynäkologen könnten 
finanzielle Einbussen erleiden, wenn längere Intervalle für das Screening umgesetzt werden. 
Die Krankenkassen könnten ein monetäres Interesse am neuen Screening haben, wenn es 
kostengünstiger als das aktuelle ist. Die Frauen könnten profitieren, wenn sie weniger häufig 
zum Screening gehen müssten und weniger Tests im Rahmen ihrer 
Krankenkassenfranchise selbst zahlen müssten. Die Pathologen würden mit einem HPV 
basierten Screening weniger zytologische Tests durchführen, die Diagnostiklabors hingegen 
mehr.  
 
Die Einstellungen der Gynäkologen zum aktuellen Screening scheint positiv zu sein [98]. 
Eine Änderung zum Status Quo kann auch als Bevormundung durch den Gesetzgeber 
angesehen werden.  
Auch die Frauen sind an das aktuelle Screening gewöhnt. Die Einführung einer neuen 
Technologie und längerer Screeningintervalle kann verunsichern [98]. Die Kommunikation 
der Gründe und der Evidenz für das neue Vorgehen müssen daher gut vorbereitet und 
begleitet werden. In den USA haben Frauen die Wahl zwischen 3-jährigem zytologischen 
Screening und 5-jährlichem Cotesting. Auch in Deutschland ist vorgesehen im Rahmen der 
Einführung eines organisierten Screenings den Frauen in den ersten Jahren der Einführung 
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die Wahl zwischen jährlichem zytologischem und 5 jährlichem HPV basierten Screening zu 
geben. Anschliessend ist eine vergleichende Evaluation beider Strategien vorgesehen [111]. 
Diese Beispiele zeigen, dass die Umsetzung einer neuen Screeningstrategie den 
Präferenzen der Betroffenen Rechnung tragen kann. 
 
Die Umsetzung eines neuen Screeningmodells für die Vorsorge des Gebärmutterhalskrebs 
beschäftigt sich mit der Gesundheitsvorsorge der Bevölkerungsgruppe der Frauen. Sie 
berührt mit all seinen Facetten gesundheitswissenschaftliche, sozialwissenschaftliche, 
wirtschaftliche und politische Aspekte und ist ein daher Public Health Thema von hoher 
aktueller Relevanz.  
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